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Insulin-like growth factor 1 (IGF-1) plays central roles in neuromuscular junction (NMJ) development, 
skeletal muscle and motor neurons growth. The NMJ is the interface between the nerve and muscle 
fibre, and thus they may receive (patho) physiological input from both the muscle and the motor neuron. 
Several conditions including ageing, disuse, neurodegenerative diseases, diabetes, and cancer are 
associated with NMJ dysfunctions which lead to profound muscle wasting and impaired NMJ function. 
Recent attention has focused on the use of anabolic growth factors such as IGF-1 in preventing muscle 
atrophy associated with NMJ dysfunction, however, difficulties in isolating and extracting functional 
NMJs, low bioavailability and potential side effects such as hypoglycaemia appear to limit the 
usefulness of IGF-1 for clinical treatment of muscle wasting conditions linked with NMJs degeneration. 
Therefore, there is a need for a simplified and reproducible system of engineered in vitro NMJs to 
facilitate the investigation of sustained slow release of IGF-1 on NMJs function. The aim of this thesis 
was to fabricate mesoporous silica nanoparticles (MSNPs) loaded with IGF-1 to manipulate the 
function of NMJ using physiologically relevant human in vitro NMJ model. MSNPs were generated 
using the Stöber method and fully characterised using different techniques (dynamic light scattering, 
scanning electron microscopy, powder X-ray diffraction and nitrogen adsorption) and then loaded with 
IGF-1. Human in vitro co-culture model of NMJ was engineered using human immortalised myoblast 
and human embryonic stem cells (hESCs)-derived neural progenitor cells (NPCs). In the co-culture, 
myoblasts differentiated into aligned myotubes and NPCs differentiated spontaneously into cholinergic 
motor neurons sprouted axons that branched to form multiple NMJ innervation sites along myotubes, 
which showed extensive spontaneous contractile activity. The NMJ model was characterised using pre- 
and postsynaptic markers and functional assessment was verified using agonist and antagonist to NMJ. 
Finally, the NMJ platform was treated with IGF-1 loaded MSNPs for 7 days. The data showed that the 
slow IGF-1 release enhanced the formation and the functions of NMJs significantly compared with 
exogenous IGF-1. Furthermore, the slow release of IGF-1 enhanced the bi-directional communications 
between motor neurons and muscle cells through the elevation of endogenously secreted essential 
neural growth factors providing regenerative niche for NMJ formation and function. The outcome of 
this project may provide a breakthrough approach to enable research in designing new therapeutic 
treatments using IGF-1 for muscle wasting linked with NMJ deterioration.
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Chapter 1: Introduction  
 
1.1 Skeletal muscle 
  
The body mass of a healthy adult constitutes of between 40% and 50% skeletal muscle. This muscle 
is extremely metabolic in nature and is important for the stability and movement of the body. The 
muscle provides storage for around 80% of glycogen found in the body; making it an important 
reservoir for protein. This is in addition to being a primary provider of the requirements of metabolism 
and in the process, making a contribution to thermoregulation (Yin et al., 2013). According to 
Pedersen and Toft (2000), skeletal muscle responds strongly to stimuli, a good example is the way it 
responds to a workout or inactivity, which could lead to synthesis or degradation, respectively. 
Muscle contraction increases the risk of injury or muscle tissue damage due to its mechanical forces 
and its anatomical superficial location; furthermore, the danger of muscle tissue damage increases 
over periods of deconditioning associated with disease and in elderly people, with reduced 
regenerative ability (Price et al., 2015). 
In contemporary times, the muscle wasting is a current public health problem, originating from 
numerous life threatening disorders like heart disease and cancer cachexia. Ageing is linked to 
decreased muscle mass; individuals aged between 40 and 70 years lose 10 to 25% of their body mass 
and the elderly over 80 years lose 40% of their mass (McPhee et al., 2013). It is estimated that after 
the age of 50, healthy persons lose around 1% of their skeletal muscle mass per annum (Marzetti et 
al., 2010). Added to the comparatively slow advanced degeneration arising due to natural ageing, a 
varied range of chronic diseases that are seen in elderly people regularly result in secondary muscle 
wasting, which happens at a moderately rapid level (Aoyagi et al., 2015). This results in the 
dysfunction of the muscle, which can be seen through the typical process of ageing, referred to as 
sarcopenia (Dodds et al., 2015). It is for this reason why it is important to discover the reasons behind 
muscle wasting with the aim of determining what could be done to mitigate the challenge so that 
people could maintain a healthy muscle mass through ageing and disease.  
Discoveries from recent studies suggest that as people age, the ability for their systems to restore 
skeletal muscle becomes reduced. The moderated capability of muscle reparation and revival with 
ageing is caused by drop in skeletal muscle stem cells (satellite cells), a definite population of muscle 
precursor cells. Equally, in ageing, there is a noticeable failure in immune function. For example, in 
the case of an injury, immune cells donate to the local situation that can impact on the reformative 
procedure of skeletal muscle cells. Muscle injury is supplemented by the encouragement of precursor 
satellite cells by the infiltration of immune cells, which in turn discharge cytokines that affect muscle 
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restoration and regeneration (Tidball, 2005). This is the reason why a reduced capacity among older 
people is linked to a reduction in immune reaction (Dumke & Lees, 2011).   
Human and animals depend on skeletal muscle to do almost everything. It is common for people to 
take everyday tasks such as dressing, getting up from bed, chewing food, and managing personal 
hygiene for granted. However, a close analysis shows that it is these seemingly easy exercises that 
necessitate institutional care for many people. Even though there are certain cases where a precise 
reason behind weakness can be identified, like a neurological disease, one of the factors that are 
inevitable is the process of ageing. Hence, it is with old age that the biggest loss of ability to do things 
is observed (Mitchell et al., 2012; Moore, 1965). This leads to a loss of independence for around 25 
percent of people over the age of 90 in the UK; often sending them to nursing, residential, or hospital 
care  (Bajekal et al., 2006;  Office of Fair Trading, 2005). Mitchell et al. (2012) report that a 
compromised muscle function has been observed to be a way that can be used for predicting whether 
an individual ends up with a disability or hospitalization. 
Muscle wasting is characterised by a slowing down of rehabilitation after a person has been 
immobilised due to fractures or undergoing surgery. When mobilising the elderly is delayed after 
surgery, the result could be a rapid loss of muscle. This could eventually degenerate into a spiral 
leading to pneumonia which can end in death. According to Argiles et al (2003), muscle wasting can 
accompany a number of other diseases such as cancer cachexia, arthritis, diabetes, and cardiovascular 
disease. Lynch et al (2007) note that the problem of muscle wasting is usually associated with ageing 
and loss of the ability to function independently. This could lead to a reduced quality of life especially 
when one considers the statistics made available by the Office of National Statistics (Office for 
National Statistics) which reports that in the last 30 years, there has been an increase of 3 percent in 
the proportion of people above the age of 65 and this is estimated to increase by another 7 percent by 
2031. 
The decline of the neuromuscular system, linked to age, has been identified as the basis of the loss of 
independence among the elderly that results from a weakening in physical performance (Baumgartner 
et al., 1999). Several studies, especially within the last ten years, have placed their attention on causal 






1.1.0 The structure of the skeletal muscle 
 
According to Yin et al. (2013), skeletal muscle (SkM) is responsible for around half of the total mass 
of a healthy human being. The same author notes that there could be around 650 designated muscles 
in the human body; making it the biggest metabolically active muscle in the body of a human being. 
SkM is different from the other main types of muscle (smooth and cardiac) in that its regulation 
happens through the somatic nervous system. This is the reason why its function can be managed by 
humans. This is a view also noted by Biswal et al. (1995) who report that the processes of  Preparation, 
regulation, and implementation of voluntary locomotion of the body is regulated in the motor cortex 
region of the brain. The motor neurons of the upper side deliver information from the brain’s motor 
cortex via the spinal cord to the lower motor neurons. Notwithstanding the fact that the main job of 
the SkM is to facilitate movement, another vital job done by SKM is the regulation of metabolism 
through the macronutrient storage, with substrate oxidation replenishing the adenosine triphosphate 
stores (ATP) (Leto & Saltiel, 2012) which keep depleting. Added to this, Pedersen and Febbraio 
(2008) report that the SkM also performs important roles in respiration and endocrine functions. The 
body's systematic and local environments are also subject to the influence of growth factors, 
cytokines, and myokines discharged into the ECM by SKM fibres (Pedersen, 2011).  
The SkM development is a process that includes the synthesis of myoblasts to create multinucleated 
fibres which are referred to as myotubes, which will later mature into myofibers. A motor neuron is 
responsible for triggering these SkM singular contractile cells. According to Sherrington (1925), the 
name given to this organisation of MN and the other muscle fibres, which that same neuron 
innervates, is called the functional motor unit. The endomysium draws the separate myofibers unto 
bundles, referred to as muscle fascicle. They are kept together by a perimysium. This is followed by 
the wrapping and encapsulation of the fascicles by a connecting tissue called epimysium. This is how 
the whole tissue is produced, as is represented in Figure 1.0. There are several motor units located 








Figure 1.0: Gross anatomy of a skeletal muscle belly. The separate skeletal muscle fibres are 
enclosed inside the dedicated cell membrane known as the sarcolemma. A fine coating of connective 
tissue, known as the endomysium, plays the role of binding the fibres together. The same tissue also 
plays the role of delivering nerve axons, oxygen, and other nutrients through the lymphatic vessels 
and the blood. These bound muscle fibres are held together by a perimysium. This is a thin fibrous 
layer of connected tissue that splits the muscle belly into fascicles. The epimysium then forms an 
envelope on top of the thick fibrous epimysium and in the process builds the complete SkM (Image 
“1007_Muscle_Fibes_ (large).jpg” available for free public reuse at OpenStax CNX 
(https://cnx.org/contents/FPtK1zmh@12.8:bfiqsxdB@6/Skeletal-Muscle), licenced under 















1.1.1 Fibres in the skeletal muscle 
  
Mature myofibres are comprised of structures of myofibrils, which include among them thin filaments 
protein actin and thick filaments protein myosin (Rayment et al., 1993), with titin providing support. 
The term sarcomeres is used to denote the iterative organisation of such proteins within the myofibrils 
(Figure 1.1), expressing as striations on the myofibres. The actin molecules, found on the edges of a 
sarcomere, are attached to a place known as Z-discs, which form the distinct boundaries between the 
sarcomeres. The actin, which is attached to the Z-disc on one end, projects in the direction of the M-
line in the middle. The Myosin filaments interfacing with the actin filaments that are static is found 
in the centre of the M-line, with the end of the myosin filament are carefully attached by titin to the 
Z-disks. If nervous input prompts them, the result is a creation of a cross-bridge while the actin 
filaments are also triggered and move along the myosin filaments, a process that results in the 
sarcomere becoming shorter and triggering a myofiber contraction (Denoth et al., 2002).  
 
 
      
Figure 1.1: Structures of a myofibril.  Myofibrils fill a myofiber, composed of distinct 
sarcomeres connected in a sequence. A distinct sarcomere is found between a set of Z-disks, creating a 
distinctive contractile unit, which is made up of a dense (myosin) filament and thin (actin) filament. The 
sarcomere’s I-band is the zone where the myosin is not overlapping the actin, providing the muscle fibre with 
its lightened appearance. Since it has anisotropic myosin protein, the A-band has a darker appearance on the 
muscle fibre. The different banding provides muscle fibres with the ridges appearance. Structural stability is 
provided by the M-line which is located at the centre inside the H-zone. (Image “1022_Muscle_Fibers_ 
(small).jpg” available for free public reuse at OpenStax CNX 
(https://cnx.org/contents/FPtK1zmh@12.8:bfiqsxdB@6/Skeletal-Muscle), licenced under Attribution 4.0 
International (CC BY 4.0) (https://creativecommons.org/licenses/by/4.0/.  
6 
 
1.1.2 Myogenesis and satellite cells  
 
With the exclusion of muscle cells in the head, skeletal muscle cells are initiated from forthcoming 
mesodermal precursor cells, created from somites. Within the vertebrate embryo that is still in a state 
of change, the somites develop into three practical cellular categories which would eventually turn 
into vertebrae (sclerotome), dermis (dermatome), and skeletal muscle (myotome) (Parker et al., 2003; 
Buckingham, 2006). The construction of the skeletal muscle starts in the embryonic myogenesis and 
is finally concluded in the utero (Bentzinger et al., 2012). The myogenic precursors, developed in the 
mesoderm, appear within the somite and turn into embryonic satellite cells (muscle stem cells) which 
later develop into myoblasts (Chen & Goldhamer, 2003). The embryonic satellite cells are reproduce 
significantly in the embryonic myogenesis primary stages until the maximum for myofibrils protein 
synthesis is obtained (Bentzinger et al., 2012). Once the satellite cells arrive at the myoblasts, they 
depart from the cell lining and sequence to create multinucleated cells which are called myotubes. 
Eventually, the myotubes will turn into myofibres, the skeletal muscles’ distinct contractile unit 
(LeGrand & Rudnicki, 2007). The distribution of the satellite cells created within the embryonic 
myogenesis move to a state where they are inactive; remaining inactive until they are triggered at a 
time when muscle repair or growth is needed. After that, the terminally distinct microfibers are unable 
to proliferate because of embryonic myogenesis. This is the reason why the quantity of microfibers 
an individual has at birth and afterwards is likely to diminish as old age and disease degrade muscle 
fibres (Carosio et al., 2011).  
A rationally consistent procedure is skeletal muscle renewal after birth.  Myofibre damage results in 
the inflammatory response, which can be seen through the interruption of muscle tissue by 
populations of inflammatory cells which follows (Tidball, 2005; Carosio et al., 2011). This response 
is attained through a renewal platform whose origins are in the inactive satellite cell stimulation. 
Skeletal muscle renewal can happen if there is a stimulation of the mitotically inactive satellite cells 
so that they turn into myoblasts (Siegel et al., 2011; Turner & Badylak, 2012). Once stimulated, the 
satellite cells quickly permeate the cell system once more and begin the reproduction process (Sousa-
Victor et al., 2015). Once the propagation limit has been reached, a group of satellite cells will 
undergo a process of renewal and then become dormant so that they can join the muscle renewal 
process when required (Relaix & Zammit, 2012). The myoblasts, waiting to be used, move near the 
area that is damaged and start coming together to create myotubes. As the myotubes expand, they 
interface with the existing central myofibres, repairing the damage caused to the muscle (Simionescu 
& Pavlath, 2011). Research has also concluded that a decline in the quality, processes, and stimulation 
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of satellite cells is associated with the dilapidation of muscle mass which can be observed among the 
elderly (Shefer et al., 2006; Brack et al., 2007; Brack et al., 2005; Tajbakhsh, 2013). 
 
 
Figure 1.2: Myogenesis. The development of embryonic progenitors into mature muscle fibres 














1.2 Motor Neurons  
 
Motor neurons (MNs) can be defined as neuronal cells which emanate from the central nervous 
system (CNS) and then assign the axons into the margins to create synapses with the tissue that is 
targeted. Whether one is thinking about people or other vertebrates, a system which transmits signals 
is important for such important tasks as locomotion and breathing. Even though the MNs are often 
described as homogenous cells, these cells have great diversity with regards to the expression of 
genes, molecular profiles, and target muscles which are also varied. Their diverse character permits 
for separated innervation of the many separate SkM groups in the body of the vertebrate (Kanning et 
al., 2010). For instance, in humans there are over 600 SkM throughout the body with most muscles 
making up one part of an identical bilateral pair found on both sides, resulting in approximately 300 
pairs of muscles (Frontera & Ochala, 2015). This is the reason why the transmission of CNS signals 
in the direction of the MN and MN outputs to the SkM targeted should be strictly regulated. This 
strict regulation seeks to organise and refine motor control, as is seen in advanced motor behaviours. 
Results from several studies show that the MNs innervation sequence and the link to the target SkM 
are regulated by the MN subtype identity (Landmesser, 2001; Milner & Landmesser, 1999). It is for 
this reason that MN subtype diversity requires further exploration so that the role of MNs and their 
motor units are fully understood.  
 
                                       
Figure 1.3: Diagram of a spinal motor neuron, showing both the cell body and synapse to a muscle 
(Kandel et al., 2000). 
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1.3 The Neuromuscular Junction  
The neuromuscular junction (NMJ) is a dedicated site that connects a motor neuron’s axon’s terminal 
to skeletal muscle. As the structure that makes it possible for a neuron to transmit a chemical or 
electrical signal to another neuron, the integrity of the NMJ is vital for moving the motor neuron 
signals which trigger the contraction of the skeletal muscle. The majority of diseases and the ageing 
of the skeletal muscle can be connected to the impairment in NMJ function and the connected wasting 
of the muscle (Liu & Chakkalakal, 2018).  
The NMJ constitutes the ultimate element in the process of control of skeletal muscle contraction. 
Hence, the NMJ plays the role of being the access for back and forth communication between the 
muscle fibres and motoneurons. An important feature of neuromotor control is the practical match 
existing between the characteristics of the motoneuron and the muscle fibres it innervates. 
The NMJ forms the structure responsible for the transmission of the nerve impulse to the muscle, 
which triggers muscle contraction. On its way to the muscle, the axon splits into a linkage of terminal 
branches. Every one of the muscle fibres has one neuromuscular junction, providing a way through 
which the neuron’s axon connects to the fibre. The end where the axon terminates is located adjacent 
to the endplate of the motor, an area of the muscle cell membrane or sarcolemma. A space known as 
the synaptic cleft separates the plate and the nerve, which are not in direct contact. Chemical 
transmission is, therefore, the method through which muscle activation takes place. In the axon, is 
located the transmitter acetylcholine, which binds to the motor endplates’ receptors as soon as it is 
released (Rodger Laurent, 2010). This is an action that leads to the depolarization of the sarcolemma 
and the action potential is dispersed through the sarcolemma and travels through the transverse 
tubules, making its way to the triads inside the cell. The discharge of the calcium and the muscle 
contraction that follows is triggered by the potential stimulus. The acetylcholine effect does not last 
long because this zone has a lot of enzyme acetylcholinesterase, which quickly leads to the destruction 
of the acetylcholine. At the NMJ, certain drugs can have the effect of facilitating such processes. An 
example of such drugs is curare which races against acetylcholine for access to endplate receptors.  A 






Figure 1.4: Neuromuscular junction. It is possible that action leads to the release of 
Neurotransmitters over the synaptic left, resulting in muscle contraction (Scicurious, 2010). 
 
Motor neurons are responsible for transporting signals for the SkM to contract; making the voluntary 
movement in humans possible. Each skeletal muscle fibre is innervated by a single motor neuron, so 
it is vital that the nerve-muscle connection is maintained to avoid muscle fibre degeneration and 
movement impairment. Neuromuscular Junctions also play the role of being a platform for the skeletal 
muscle and nerves to interact. The NMJ contains a presynaptic motor neuron terminal, a postsynaptic 
motor endplate, and a synaptic cleft. The structure for the formation and maintenance of NMJs relies 
on the back and forth molecular interface between the motor neuron and muscle (Zahavi et al., 2015). 
In the event that there is a disruption in communication, the consequence is a degradation of the NMJ, 
including the degeneration of the axon, disruption of the synapse, a reduction in NMJ transmission, 
and degradation of the muscle fibre (Gonzalez-Freire et al., 2014). All this leads to the proliferation 
of chances for other conditions such as muscle wasting, neuromuscular diseases myopathy peripheral 





Even though most of the investigations into NMJ function make use of animals, its function and 
structure have been well characterised, although the vast majority of investigations utilised animal 
models (reviewed in Wu, Xiong, & Mei (2010). Which do not sufficiently reflect disease progression 
in humans (Van der Worp et al. 2010). To date, some progress has been achieved through 
development of in vitro co-culture models employing human (Thomson et al.,2012 & Berry et 
al.,2015];  cross-species models (Vilmont et al.,2016; Arnold, Christe, & Handschin 2012); mouse 
(Umbach et al., 2012);  human embryonic stem cells (hESC) (Happe et al.,2017; Guo et al.,2014); 
human primary myoblasts (Guo et al.,2017; Demestre et al., 2015); or rats (Smith et al.,2013). 
Available in vitro skeletal muscle and motor neuron arrangements often need complicated neural 
growth media which consists of cocktails and serum of about 15 neural growth factors (of which 
some originate from animals). This is a factor that makes the discovery of drugs and the ability to 
conduct toxicology studies challenging because of the potential novel compound cross-
communication with the factors existing in the media which is added; providing a possible 
explanation as to why most of the promising therapies never make their way into clinics. The other 
challenge with models that currently exist is that contraction is triggered by applied chemical or 
electrical stimulation, which fails to duplicate the innate physiological stimulation needed for the 
muscle to contract (Guo et al., 2011; Umbach et al., 2012; Guo et al., 2010).  
From the discussion above, it is a clear that there is a requirement for NMJ models that use human 
nerve and muscle cells types for which the contraction of the skeletal muscle does not need external 
input (chemical or electrical). Inventions introduced in recent times connected to the employment of 
iPSCs delivers possibilities for deriving of motor neurons and myoblasts for developing an NMJ 
model in vitro. Nonetheless, iPSCs-derived cells could show genetic modification and inconsistency, 
which could make their use limited (Chin et al., 2009). Primary cells such as surgical samples or 
muscle biopsy can be used for obtaining human skeletal myoblasts, but that challenge is that their 
lifespan is limited, which hampers effective experimentation because of the need for a repeated supply 
of such cells (Webster & Blau 1990; Mouly et al.,2005). Another challenge is that primary cells tend 
to be inconstant when it comes to purity. Also, when such cells expand, they go through phenotypic 
changes; making primary myoblasts a challenging choice when one wants a reliable co-culture system 





1.4 Insulin-Like Growth Factor-1 (IGF-1)  
 
Insulin-Like Growth Factor-1 (IGF-1), which is originally referred to as somatomedin C, can be 
defined as a 70-amino acid polypeptide hormone programmed by a chromosome 12q22–23 localised 
gene. It has a molecular weight of 7.6 K Daltons. IGF1 is the primary moderator of both the prenatal 
and postnatal growth. It is mainly manufactured in the liver and takes the role of the endocrine (also 
an autocrine and paracrine) hormone which moderates the GH action in marginal tissues such as 
muscle, lungs, cartilage, skin, bone, nerves, kidney, and the liver itself. Within the circulation system, 
the IGF1 is present together with an acid-labile subunit (ALS) and IGF binding protein 3 (IGFBP3) 
(Alan Lap-Yin Pang, 2009).  
The IGF-1 is also a key moderator of the effects of growth hormone (GH). Inside the pituitary gland 
is where the growth hormone is manufactured, before its release into the bloodstream, and then 
triggering the liver to start the process of making IGF-1. Organised blood growth is then stimulated 
by IGF-1. It also has the capacity to trigger growth in almost any body cell, particularly the cells in 
the skeletal muscle, lung, cartilage, hematopoietic, bone, skin, liver, nerve, and kidney cells. Apart 
from IGF1’s insulin-like effects, it also has the capability to the synthesis of cellular DNA (Yaker et 
al., 2002).  
When IGF-1 is absent, the result is the autosomal recessive mode of transmission. Currently, four 
IGF-1 transformations which lead to negative or extremely low IGF-1 expression have been defined 
(Pang & Chan, 2010). One of IGF-1’s features is that its pleiotropic growth factor has many characters 
that present in numerous properties of compulsive and standard differentiation and propagation. The 
IGF-1 receptor (IGF1R) is responsible for facilitating the IGF1’s natural activities. There is a 
structural and functional relationship between the insulin receptor and the cell-surface heterotetramer.  
The outcomes of IGF-1 are moderated by the intimate binding proteins (IGFBPs) that transmit the 
ligand in the motion and extracellular fluids. IGF-1 is widely expressed in the central nervous system 
(CNS) where it facilitates the propagation, presence, and differentiation of non-neuronal and neuronal 
cells. Also, IGF-1 is a potent neurotrophic factor which can save neurons from apoptosis and develop 
neuronal growth and myelination. Again, IGF-1’s signalling conduit plays an important role in the 
proliferation of cancer. Currently, attempts are being made to prompt this pathway for healing 
purposes.  
An appreciation of how the IGF-1 system functions and how it transmits instructions will be important 
for both clinical and basic application (Bentov & Werner, 2013). Added to this, comprehending the 
comparative roles of peptide hormones in the regulation of receptiveness to insulin comes with the 
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fact that the growth hormone IGF-1 in the insulin system is flexible. Variations in insulin and glucose 
discharge result in counter controlling reactions, and adjustments in growth hormone and IGF-1 
occupation modify insulin’s ability to maintain normal carbohydrate homeostasis (Clemmons, 2004).  
An autosomal recessive mode of transmission is followed by a deficiency of IGF-1. This can be a 
consequence of molecular defects which impact any of the GHRH-GH-IGF1 axis and the IGF-1’s 
upstream components. At the moment, there are only four IGF-1 mutations which have been 
described. The homozygous deletion of 181 nucleotides constitutes the first case. Included are IGF-
1’s Exons 4 and 5. IGF-1’s translated product is completely absent in patients with short stature. The 
other case was observed in a patient circulating IGF1 was low. At the 3’UTR of IGF1, a homozygous 
T→A trans-version was discovered. The consensus sequence of the mRNA polyadenylation is 
disrupted by the mutation, leading to the alteration of the IGF-1 precursor, which is vital for the 
maturation of the IGF.   The V44M mutant indicates an extremely lessened attraction to the IGF 
receptor. The other mutant that has a homozygous Arg-to-Gln substitution at the C domain shows 
only a limited loss of attracting for the receptor (Pang et al., 2009).  
IGF-1 binds to at least two cell surface receptor tyrosine kinases: the insulin receptor and the IGF-1 
receptor (IGF1R). The main action of the IGF-1 is regulated by the act of binding IGF-1 to IGF1R, 
its specific receptor. IGF1R can be found on the external walls of many types of cells within cell 
tissues. The process of intracellular signalling is initiated by the binding to the IGF1R. In the AKT 
transmission conduit, IGF-1 is one of the strongest natural activators. The AKT signalling pathway 
is a trigger for cell proliferation and growth, and a vital mechanism for stopping the involuntary death 
of cells (Peruzzi et al., 1999). 
It looks like the IGF-1 receptor seems to be the "physiologic" receptor because it binds IGF-1 with 
significantly higher affinity than insulin receptor does. Specifically, IGF-1 receptor binds at around 
0.1 times better than insulin. The IGF1R/Insulin receptor heterodimers may provide a conduit for part 
of the signalling. The reason why there is a certain level of confusion has to do with the fact that 
binding research indicates that IGF-1 binds the insulin receptor 100 times weaker than insulin when 
it binds. However, this is not consistent with the IGF-1’s actual potency in vivo with regards to the 
induction of the insulin receptor’s phosphorylation and hypoglycaemia. There are several pathways 
for signalling for the IGF-1R and the other tyrosine kinase growth factor receptors. The 
phosphatidylinositol-3 kinase (PI3K), working with its other downstream partner, the mammalian 
target of rapamycin (mTOR), regulate an important pathway: Rapamycins complex with FKBPP12 
to constrain the mTORC1 complex. The mTORC2 is not impacted on, and its response happens 
through the upregulation of Akt, moving the signals via the mTORC1, which is inhibited. The 4EBP’s 
capacity to inhibit if-4E and slow down metabolism is itself inhibited by the phosphorylation of 
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eukaryotic initiation factor 4e (eif-4E) [4EBP] by mTOR. It has been observed that the Insulin-like 
growth factor 1 binds and interfaces with all the seven IGF-1 binding proteins (IGFBPs): IGFBP1, 
IGFBP2, IGFBP3, IGFBP4, IGFBP5, IGFBP6, and IGFBP7. Certain IGFBPs have inhibiting 
characteristics. For instance, both IGFBP-5 and IGFBP-2 have the capacity to bind IGF-1 with a more 
robust attraction than what it has when binding its receptor. Hence, the reduction in IGF-1 activity 
corresponds with an escalation in levels of serum in these two IGFBPs (Peruzzi et al., 1999). IGF-1 
is unique growth factors which is the only factor induces proliferation and differentiation. At high 
concentrations (>20ng/ml), IGF-1 induces proliferation whereas at low concentration (<20ng/ml) in 





Figure 1.5: Diagram of a skeletal muscle hypertrophy and regeneration, showing interplay 





There is a close relationship between IGF-1 and a protein which also binds to the IGF receptor; known 
as "IGF-2". However, on its own IGF-2 binds a receptor known as “IGF-2 receptor" (Sometimes 
called mannose-6 phosphate receptor). The insulin-like growth factor-II receptor (IGF2R) does not 
have the signal transduction capacity. It has the primary task of being an IGF-2's sink; making lower 
quantities of IGF-2 available for binding with IGF-1R. As is denoted b the name “insulin-like growth 
factor 1”, there is a structural relationship between insulin and IGF-1, and even has the capacity to 
bind the insulin receptor, even though this happens at affinity levels that are lower than those of 
insulin (Peruzzi et al., 1999).  
  
    











1.4.0 IGF-1 and Neuromuscular Junction (NMJ) disorders 
 
According to Lewis et al. (1993), the Insulin-like growth factor-I (IGF-1) has a role to play in the 
development and preservation of neurons. It has also been noted that impaired IGF-1 signalling plays 
a role in numerous neurological conditions such as stroke. Disorders linked to motor neurons like the 
loss of motor neurons in the spinal cord in amyotrophic lateral sclerosis or the deterioration of spinal 
cord motor neuron axons in particular outlying neuropathies, present a distinctive opening for the use 
of neurotrophic proteins for therapeutic intervention. Typically, these kinds of proteins would not 
cross the brain-blood barrier. However, nerve terminals and neuron axons lie outside the barrier, 
which makes it possible for them to be the target of the general administration of protein growth 
factors (Lewis et al., 1993). Within the spinal cord, Insulin-like growth factor-I (IGFI) receptors can 
be found. Just like affiliates of the neurotrophin receptor clan, IGF-1 receptors intermediate the 
transduction of signals through a tyrosine kinase domain. It has been noted that IGF-1 inhibits the 
loss of choline acetyltransferase activity in embryonic spinal cord cultures and also leads to a 
reduction of the programmed cell death of motor neurons in vivo in the process of typical 
development or after axotomy or spinal transection.  
In line with prior reports, which indicate that IGF-1 boosts neuronal sprouting in vivo, focusing on 
subcutaneous administration of IGF-1 increases muscle endplate size in rats (Lewis et al., 1993; Chen 
et al., 2005), it can be noted that IGF-1 injections also result in an acceleration of functional recovery 
after sciatic nerve crush in mice. It has also been observed to weaken the marginal motor neuropathy 
triggered by the administration of chronic cancer chemotherapeutic agent vincristine in mice. IGF-1 
doses which make a recovery to happen faster after sciatic nerve crush in mice leads to raised serum 
levels of IGF-1; comparable to the ones attained after formulated recombinant human IGF-1 
(Myotrophin) injections in normal human subjects. Using such conclusions as a basis and the proof 
of safety in humans and animals, clinical trials of recombinant human IGF-1 are now being 
administered in patients who have peripheral neuropathies induced by chemotherapy (Lewis et al., 









1.4.1 Neuromuscular dysfunction in Type 2 Diabetes  
 
When compared to non-diabetic patients, diabetic patients have an increased risk of developing 
physical disabilities. In the majority of cases, these physical disabilities are related, even if partly, to 
a malfunction of the muscles (Orlando et al., 2016). A number of studies have come to the conclusion 
that lessened muscle strength under statistic or dynamic conditions happens in both the lower and 
upper limbs of patients with Type 2 Diabetes. Other effects associated with diabetes include reduced 
muscle  mass which is also accompanied by changes in the composition of muscle fibre. However, it 
needs to be noted that the data linked to these parameters are conflicting (Orlando et al., 2016). 
Diabetes’ impact on neuromuscular function has been linked to the presence of long-term 
complications. It has been observed that peripheral neuropathy affects muscles, damaging the nerve 
condition. The declining strength of the muscle may also be attributed to vascular complications. 
However, muscle dysfunction happens much earlier in the progression of diabetes and may also have 
an impact on the upper limbs. What this implies is that it could develop without the aid of micro and 
macrovascular disease (Orlando et al., 2016). Increasingly, evidence is indicating the possibility of 
hyperglycaemia causing changes in the muscle’s intrinsic properties with regards to the generation of 
force through the use of numerous mechanisms. In recent studies, it has been proved that resistance 
exercise can be an effective way of countering the dilapidation of muscle performance. It has also 
been noted that the greater the intensity of the exercise, the more the benefits. On the other hand, the 


















1.4.2 Amyotrophic Lateral Sclerosis (ALS) and Motor Neuron Disease 
 
There has been an extensive examination of the potential of IGF-1 to deal with neuronal loss and 
muscle weakness of ALS (Sullivan et al., 2008). This is because of the positive effects it has shown 
on both motor neurons and muscle. When it comes to human patients who either have motor neuron 
disease or not, the immunoreactivity is detected in Schwann cells, motor neurons, skeletal muscle, 
and astrocytes. In the same kinds of cells, IGF-II immunoreactivity is also identified to a lesser degree. 
Dore et al. report increased binding of the IGF-1 and –II in the spinal cords of all patients with ALS, 
implying increased IGF-1R expression. On the other hand the western blotting of post-mortem human 
spinal cervical spinal cord study showed no change in the total IGF-1 levels between healthy patients 
and ALS patients. Nonetheless, free IGF-1 was reduced by 53% in ALS patients (Sullivan et al., 
2008). The concept of free IGF-1 denotes the IGF-1 which is available for binding with IGF-1R, 
which is not complexed with IGFBPs. For this study, there was a significant up-regulation of IGFBP-
2 and -5, a situation which implies that there was a possible change in the bioavailability of IGF-
1(Sullivan et al., 2008 ; Sakowski & Feldman, 2012). However, in this study the levels of IGF-1 were 
















1.4.3 The need for IGF-1 in Central Nervous System Axonal Regeneration  
 
One of modern medicine’s biggest challenges is the functional repair of the adult central nervous 
system (CNS). Whether it is the traumatic injuries of the CNS or neurodegenerative diseases, it has 
been shown that the result is irreparable motor and cognitive functions, which are linked to permanent 
disability. The dendritic or axonal regeneration is a primary condition for functional recovery, for the 
neuronal connections to be re-establish so that the CNS can operate normally again. In the past, the 
thinking was that it was impossible for the axonal revival of the adult CNS (Goldberg & Barres, 
2000). However, Dupraz et al. (2013) note that prevailing knowledge of external and internal factors 
regulating axonal renewal and construction of new synapses has led to a shift in such a view. 
Proposals have been advanced to the effect that the processes which constitute an axonal renewal of 
adult CNS has several features which make them comparable to those that are vital in the development 
of the CNS (Cui Q, 2006). Nonetheless, a number of characteristics of axonal renewal are still not 
known, particularly the ones regarding directing the new axon sprouting by extracellular cues (Harel 
& Strittmatter, 2006). The majority of CNS neurons fail to regenerate after a lesion (Rossi, Gianola, 
& Corvetti, 2007).  
An understanding of how the axonal outgrowth and specification is regulated during the development 
of extracellular factors is beginning to be possible. The established model for the examination of such 
events in culture are the pyramidal cells acquired from the embryonic hippocampus. An important 
reflection is that a specifically early event in those neurons that are not yet showing obvious axon 
(perceived as the second stage of differentiation) (Sosa et al. 2006), involves the isolation of 
activatable IGF-1 receptors (IGF-1R) to one single neurite. This is followed by the accumulation of 
phosphatidylinositol-3 kinase (PI3K) and PIP3. This accumulation takes place in the growth cone and 
distal zone of that particular neurite, coupled with IGF-1R. These are important events with regards 
to the outgrowth of the future axon (Shi, Jan & Jan 2003). Definitely, the axon designation needs the 
IGF-1R to activate P13K (Sosa et al. 2006).  For the renewal of the adult peripheral nervous system, 
a similar arrangement is involved (Dupraz et al., 2013).  
On the other hand, no information can be found about the potential involvement of the IGF1R-PI3K 
pathway in the regeneration of CNS neurons in adult mammals. For purposes of dealing with this 
question, as a model for experimentation, they employed retinal ganglion cells (RGC). The reason 
why RGCs were used is that it has been observed that they have the ability to survive and rejuvenate 
neurites in vitro (Luo X et al., 2001). Also, both IGF-1R and IGF-1 exist extensively in various 
mammalian retinal cells, including humans (Lambooij et al., 2003; Cha et al, 2013). 
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From the results we obtained, it can be seen that IGF-1R expression is substantially higher in cultured 
adult RGC than it is in freshly disaggregated adult retina cells. The results also show that the variant 
of IGF-1R that contains bipolar cells is enriched at the third distal axon. Experiments dealing with 
the loss of function which employ a process of blocking the IGF-1R antibody or the use of shRNA 
directed against IGF-1R, and also the pharmacological inhibition of PI3K signalling, resulted in the 
repression of axonal renewal. The use of a constitutively active type of PI3K, used in the co-
transfection of cells suppressed with IGF-1R was observed to rescue the phenotype with the 
outgrowth of a single axon or more (Dupraz et al., 2013). 
 
Physical exercise’s neurobiological effects are many and include a broad array of interconnected 
effects on the cognition, and brain structure and function (Erickson, Hillman & Kramer, 2015). In 
part, these effects may be regulated by the discharging of peptides, referred to as myokines, from the 
muscles that are contracting. A huge amount of research using humans has shown that people 
involved in steady aerobic exercise of around half an hour every day, results in clear improvements 
in cognitive functions, healthy changes in the brain's gene expression, and other desirable types of 
behavioural plasticity and neuroplasticity. Other effects that will be observed in the long term include 
augmented growth of neurons, better intellectual regulation of behaviour, boosted  neurological 
activity, improvements with regards to coping with stress, improved spatial, declarative, and working 
memory, and functional and structural advances in brain pathways and structures linked to memory 
and cognitive control (Erickson, Hillman, & Kramer, 2015).  
The impact of exercise on cognition has vital implications with regards to boosting academic 
performance in both children and students in college, boosting productivity for adults, maintaining 
cognitive function in old age, averting or treating particular neurological disorders, and leading to 
improvements in the overall quality of life (Erickson, Hillman, & Kramer, 2015). When it comes to 
adults who are healthy, it has been observed that aerobic exercise leads to temporary effects with 
regards to cognition after one session of exercise. However, for regular exercise, results from studies 
show lingering effects over a period of several months (Cox et al., 2016). It has also been concluded 
that individuals who are regularly involved in aerobic exercise such as running, cycling, walking fast, 
jogging, and swimming, tend to have higher scores neuropsychological function and performance 
tests measuring particular cognitive functions. Examples of such tests include declarative memory, 
attentional control, speed of information processing, inhibitory control, spatial memory, working 
memory capacity, and updating (Cox et al., 2016).  
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The temporary effect of exercise on cognition include enhancements in the majority of executive 
functions such as attention, making decisions, working memory, solving problems, cognitive 
flexibility, and inhibitory control. It has also been observed that there are improvements in the speed 
of information processing for a period of about 120 minutes following an exercise session (Erickson, 
Hillman, & Kramer, 2015).   
Both short and long-term effects on emotional states and mood can be induced by aerobic exercise. 
This has the impact of promoting long and short-term positive effect, preventing negative effect, and 
lessening the biological response to severe psychological stress. In the short-term aerobic exercise 
can play the role of both a euphoriant and antidepressant, while physical exercise done on an ongoing 
basis has the effect of boosting self-esteem and mood (Basso & Suzuki, 2017).  
When done on a regular basis, aerobic exercise results in improvements in symptoms linked to several 
disorders linked to the central nervous system and could play the role of being an adjunct therapy for 
such conditions. Evidence of exercise treatment effectiveness is available when it comes to the 
attention deficit hyperactivity disorder and other major depressive orders (Schuch et al., 2016). The 
American Academy of Neurology's clinical practice guideline for mild cognitive impairment advises 
clinicians to recommend that patients who have been diagnosed with this condition are involved in 
physical exercise at least twice every week (Petersen et al., 2018). Other reviews of clinical evidence 
are consistent with the idea that exercise can be effective as an adjunct therapy for particular 
neurodegenerative conditions, especially Parkinson’s disease and Alzheimer’s disease. Exercise done 
on a regular basis has also been linked to a lowered risk of developing neurodegenerative conditions. 
A huge body of emerging clinical evidence and preclinical evidence provides support to the 
employment of exercise therapy for both the prevention and treatment of the development addiction 











1.4.4 The effects of IGF-1 on the neuromuscular junction associated with sarcopenia 
 
The declining skeletal strength and mass which happens as a result of ageing, known as sarcopenia 
can be attributed to several factors, including a lack of balance between the synthesis of protein and 
its degradation, alterations in hormonal/metabolic status, and the levels of inflammatory mediators in 
circulation (Ascenzi et al, 2019). For this reason, the factors that lead to an increase in muscle mass 
while also boosting anabolic pathways may be useful in counteracting sarcopenia therapy. Among 
such the growth factor-1 (IGF-1) is associated with numerous skeletal muscle pathways.  
Insulin-like growth factor 1 is a pleiotropic growth factor that plays several roles, including 
fortification from oxidative stress, neurotrophic effect, preservation of muscle strength and mass, and 
advancement of motor neuron existence (Gonzalez-Freire et al., 2014.). Numerous studies have 
arrived at the conclusion that levels of circulating IGF-1 deteriorate with age. This deterioration may 
lead to motor unit denervation and neuromuscular junction degeneration (Messi & Delbono, 2003; 
Delbono, 2003). In keeping with this hypothesis, in mouse models, when muscle-specific IGF-1 is 
overexpressed, sarcopenia can be reversed (Musaro et al., 2001). This inhibits the decrease in type 
IIB and escalation of type IIA fibres which are linked to age (Messi & Delbono, 2003). It also results 
in enhanced nerve renewal through its action on axons, the NMJ, and Schwann cells. When IGF-1 is 
administered systemically, the result is a decrease in the death of motor neuron cells. It promotes the 
muscle re-innervation following injury in animals that are still young. This implies that declining 
levels of IGF-1 as individuals age could weaken the ability to repair and preserve NMJ’s integrity 
(Vergani et al., 1998). It is possible that IGF-1 sensitivity does not decrease as individual age, 
implying that IGF-1 may still have the capacity to facilitate rejuvenation after an injury to the nerve 
in individuals who are older. In mice, overexpression of IGF-1 may increase the NMJ size without 
extensive alteration in muscle fibre size, implying that the maintenance of a precise force in aged 
animals overexpressing IGF-1 in muscle is attained, partly, by improved motor neurons-muscle 
coupling (Payne et al., 2006).  
The problem of muscle wasting is that it can only be partly mitigated by making changes to the diet 
and engaging in physical exercise however, these are long-term strategies that do not usually solve 
the problem when a patient requires to be mobilised after being in a forced state of immobility, in 
which a short term pharmaceutical mediation could be the most viable solution. Whether targeted or 
sustained, the administration of insulin-like growth-1 (IGF-1) could be helpful for both normal 
growth, development, and skeletal growth of muscle. What makes IGF-1 unique is that it triggers 
both proliferation and differentiation of the cells in the muscle after the activation of its receptor and 
the following phosphorylation of the insulin receptor substrate-1 (IRS-1) and the downstream 
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signalling molecules. There are reports that both differentiation and proliferation include the 
phosphorylation and stimulation of extracellular signal-regulated Kinases 1/2 (ERK1/2), PI3K/Akt 
(Coolican et al., 1997), together with their downstream targets that have in previous cases been 




Figure 1.7: Signalling pathways associated with muscle growth and muscle disuse atrophy 
(Reilly and Franklin, 2006).  
 
 
According to Lai et al (1997) and Sorenson et al (2008), investigations are currently in progress on 
using IGF-1 as a possible solution for muscle wasting (Lai et al. 1997, and Sorenson et al., 2008). 
Coolican et al (1997) note that the reason behind the trials on IGF-1 as a treatment solution has to do 
with its effectiveness and capacity to promote both muscle survival and growth in cell culture in both 
human beings (Borasio et al. 1998) and animals (Svanberg et al. 2000). Apart from targeting this 
anabolic growth factor in stopping the wasting of muscle as a result of catabolic conditions (Borasio 
et al. 1998; Williams et al. 2008), contemporary applications have also been investigating how it can 
be applied to improve cardiac function in the context of chronic heart failure (Perkel et al. 2012). 
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Another area where it is also being applied is identified by Chernausek et al. (2007) as disorders of 
growth in children.  
Even though IGF-1 is seen as a possible solution to the challenge of muscle wastage, authors like 
Yakar et al. (2002) see some practical challenges such as the fact that it is low in bioavailability and 
its rate of clearance is rapid. Others such as Metzger et al. (2011) refer to the side effects which 
include the suppression of growth hormones (GH) and hypoglycaemia. Added to this Takahashi et al 
(2003) observes that the gene transfer therapy of IGF-1 in human beings is still not yet properly 
defined with regards to treating muscle wasting. Moreover the IGF-1 bioactivity is poor hence it has 
short half-live (Kempen et al., 2015). IGF-1 circulates bound to an IGF binding protein (IGFBP) in 
blood. The binding protein is responsible for the long plasma half-life of IGF. IGF-1 half-life is 
approximately 12 hours (Lammers et al., 1989; Ursø et al, 1999). This challenge is related to the 
potential for insertional mutagenesis and maintaining of therapeutic levels through methodical 


















1.5 Nanoparticles (NP) 
 
Nanotechnology is a multidisciplinary scientific endeavour which involves the development and use 
of materials, systems, or devices on the nanometer scale. Currently, the area of nanotechnology is 
undergoing changes on different fronts. It is expected that the technology will result in innovations 
and will also have a profound role to play in numerous biomedical applications, not just in the area 
of drug delivery but also in biomarkers, molecular imaging, and biosensors. Target-specific drug 
therapy and techniques to facilitate early diagnosis of pathologies are the main areas of study where 
nanotechnology is expected to have a huge role to play. In this review, several nanotechnology-based 
drug imaging and delivery approaches, and their economic impact on the biomedical and 
pharmaceutical industries are considered (Sahoo, 2003).  
Nanotechnology can be defined as the comprehension and regulation of matter which is generally 
within the 1–100 nm dimension range. Its application in the field of medicine, which is referred to 
nanomedicine, is concerned with the employment of specifically engineered materials, at this length 
scale, to create innovative diagnostic and therapeutic modalities (Zhang et al., 2008). Nanomaterials 
possess distinct physicochemical characteristics like ultra-small size, large surface area to mass ratio, 
and high reactivity. These differ from bulk materials of similar composition. These are the 
characteristics that can be taken advantage of to deal with some of the limitations which have been 
identified in standard diagnostic and therapeutic agents (Zhang et al., 2008).  
Often, NPs have a vital role to play as carriers, even though they also have the capacity to directly 
play the role of therapeutic agents. Based on conclusions from previous studies, NPs can be grouped 
into numerous types, even though it is not all types that can be used in combination with growth 
factors (GFs) (Kalantarian et al., 2018). Concerning the IGFs/NPs conjugation, they conducted an 
examination of some novel and classical models of exterior and interior patterns. The majority of the 
patterns were used effectively in the modulation of the release of drugs in a spatiotemporal way 
(Zhang et al., 2008; Kalantarian et al., 2018).  
Within the IGFs/NPs arrangement, other than the synergistic effects of NPs combined with growth 
factors, it has been noted that nanoparticles also exert specific effects. In the past, the focus was 
mainly given to stem cells and inductive growth factors in tissue engineering. However, several nano-
materials like perovskite nanoparticles, hydroxyapatite (HA), and Nano fibrin have also shown to 




1.5.0 Nanoparticles and Therapy 
          
Even though NPs/GFs applications are many, the diversity and specificity of GFs could best be 
represented in the advancement of the differentiation of progenitor cells or stem cells. Some of the 
cells that are most used in the NP/GF applications are identified by Kim et al. (2013): the adipose-
derived stem cells (ASCs), human mesenchymal stem cells (hMSCs), urine-derived stem cells 
(USCs), bone marrow stem cells (BMSCs).  
According to Kim et al. (2013) numerous GFs, including basic fibroblast growth factors (bFGF), bone 
morphogenic proteins (BMPs), and transforming growth factor b (TGF-b), can be added into PLGA 
nanosphere coated microspheres and trigger adipogenesis, osteogenesis, and chondrogenesis in 
hMSCs, respectively. In comparable studies, the human-derived dermal fibroblasts were transfected 
with TGF-b3, insulin-like growth factor (IGF)/bFGF, and BMP-2 genes coated on PLGA-NPs, and 
chondrogenesis, adipogenesis and osteogenesis were induced, respectively (Kurakhmaeva et al., 
2009). What can be inferred from the information above is that various growth factors can lead to 
varying effects. Hence, it can be argued that the selection of appropriate GFs based on what the 






Figure 1.8: NPs/GFs function and application. GFs and a section of NPs can impact signal 
transduction pathways. GFs can also interface with various sites across the body. This 
characteristic has a contribution to their wide range of functions in various processes such as stem 
cell differentiation, healing of chronic wounds, osteogenesis, anti-cancer effects, chondrogenesis, 
cardiac protection, angiogenesis, and neurogenesis (Nanoparticles combined with growth factors: 





















1.5.1 Nanoparticles and IGF-1 discharge 
 
Within both the nervous system and the peripheral nervous system (PNS), neural tissue repair can be 
promoted by NPs/GFs. In the CNS, the repairing of brain tissue is a more complicated process when 
compared to bone renewal. This is because the degree of tissue differentiation in the brain is higher, 
and there is also a presence of a blood-brain barrier (BBB). Some research paid attention to the use 
of NPs for the treatment of neurodegenerative disorders (Kurakhmaeva et al., 2009). The main focus 
of such studies has been determining in vivo and in vitro delivery methods. Based on a clear 
comprehension of the challenges linked to in vivo NP delivery, studies conducted in recent times 
have paid their attention to BBB and blood and brain circulation isolation by either chemical or 
physical means. In healthy organisms, the BBB is a requirement for ensuring that the brain is 
protected from the majority of pathogens and toxins. Unfortunately, it is this barrier that makes it 
impossible to deliver the majority of drugs in pathological settings; an arguable position 
(Kurakhmaeva et al., 2009). 
Standard systems of delivery like an intravenous injection of low-dose drugs do not have the 
capability to permeate BBB. Even though drugs administered in high doses can, to a certain degree, 
go past the BBB and enter the brain, they also have the potential to result in undesirable cytotoxicity 
(Pardridge & NeuroRx, 2005).   
It is good to note, however, that in the last few years, there has been a gradual exploration of improved 
delivery methods. An example of such methods is intranasal delivery which is a non-invasive 
technique for the treatment of numerous disorders/conditions of the CNS (Pardridge, & NeuroRx, 
2005). The leading limitations linked to intranasal delivery is that the nasal epithelium has limited 
capacity to absorb and the nasal cavity also has a short residence time (Pardridge & NeuroRx, 2005). 
To deal with the limitations, a few approaches have been embraced. Previously, it has been reported 
that NPs conjugated with Solanum tuberosum lectin (STL) can entrap bFGF, which has the capability 
to selectively bind to the nasal epithelial membrane in the treatment of Alzheimer's disease 
(Kurakhmaeva et al., 2009).  
Added to growing the nasal epithelium affinity, the other approach involves a further enhancement 
of the penetration via BBB. Because they are compatible with biomembranes, Gelatin-nanostructured 
lipid carriers (GNLs) that encapsulate bFGF (GNLs/bFGFs) can be delivered to the brain effectively. 
Hence,   GNLs/bFGFs have turned into an innovative carrier for conveyance via BBB. Based on their 
opinion, lipid nano-carriers present the best promise for applicable NPs because they have the 
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potential to penetrate the BBB through combining with the biological membrane, and they can also 
be functionally and structurally infused with other materials (Kurakhmaeva et al., 2009).  
It is not only in the brain that the repair of the CNS can occur but also in the spinal cord. For instance, 
scaffolds attained through the interface between fibrinogen and thrombin-conjugated g-Fe2O3 
magnetic NPs have been implemented to injuries of the spinal cord via the nasal olfactory mucosa 
cells (Kurakhmaeva et al., 2009). They also came to the realisation that the peripheral nerve's 
functional recovery after an injury usually needs numerous GFs; especially NGF, because of its 
synergistic effects. Self-assembled cubic lipid-based crystalline nanoparticles were developed by Bu 
et al. with the aim of boosting the internal ear bioavailability of bioactive NGF through a round 
membrane route. The NGF-loaded reservoirs substantially triggered the growth of neurons. 
Generally, studies on the implementation of IGFs/NPs still pay most of their attention to diseases of 
the brain (Kurakhmaeva et al., 2009).   
Since mesoporous silica was discovered in the later years of the 1970s, it has attracted a lot of 
attention. The reason for this attention can be attributed to their distinct properties like ordered pore 
structure, extremely high specific surface areas, and their potential fusion in a broad range of 
morphologies like discs, spheres, and powders. Mesoporous silica is different from traditional silica 
in that it displays remarkably ordered pores. This can be attributed to the nano-templating approach 
implemented during the material’s synthesis. In the last three decades, a broad range of mesoporous 
silica (SBA 15, SBA 16, MCM 41, MCM 48), with pore geometries and particles morphologies 
coming in a broad range, have been synthesised. The porous silica spheres present as spherical 
particles with porosity that is quasi ordered (Coleman et al., 2001).  
Current developments in the production of mesoporous silica, permitting manufacturing at large 
scale, has made it possible for them to transit from research-based in laboratories to more 
sophisticated implementation in driven studies. Currently, there is widespread employment of MS 
with tailorable and uniform pore dimensions with high surface areas in numerous applications. Such 
applications include the remediation of waste water, cleaning of indoor air, improvement of 
pervaporation membrane, catalysis, preparation of the bio-analytical sample, the capture of oxygen, 
delivery of drugs, and catalysis. MS also play the role of being templates that control the nanowires 
and quantum-confined nanoparticles’ aspect ratio. In current years, nanomedicine has developed at 
the forefront of nanotechnology, generating great expectations in the biomedical field. Researchers 
are using novel nanoparticles for both treatment purposes and diagnostic applications using imaging 
technology through drug delivery. Between all the available nanoparticles, inorganic mesoporous 
silica nanoparticles are the newcomers to the field, contributing with their unique and excellent 
properties (Manzano and Vallet‐Regí, 2020). 
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Nanoparticles and nano-mesoporous silicate particles are employed as potential drug delivery 
systems. This is attributed to their synthetic pore arrangement, large surface areas, and the fact that 
they are simple to chemically modify. In the biotechnology area, these particles are used broadly 
because of their distinct mesoporous arrangement (Lopez et al., 2006). Their structure allows for the 
absorption of drugs and proteins, because of their narrow and straight channels, large internal 
volumes, and high surface areas. Over a period of time, the absorbed proteins and drugs are diffused 
contingent on the chemical composition, the size, the morphology and size of particles, release 
medium, size of pores, and surface functionalization of the drugs (Tang et al., 2006). The factors 
controlling the release of drugs that happens over minutes, hours, or days include heat, chemicals, 
pH, magnetism, ultrasound, and light (Vallet-Ragi et al., 2004;  Vallet-Regi et al., 2001). Considering 
that nanoparticles employed in drug delivery are required to appropriate pore size, and a narrow 
structure and channel, Santa Barbara Amorphous (SBA) are considered to be appropriate for this 
study. SBA-15 is substantial mesoporous silica that has significant and limited properties of 
mesopores that are well organised. Its wall is thick and hydrothermally stable, has a huge surface 
area, and the volume of its pores is large (Rahmat et al., 2010). The pore size of SBA-15 is 7.2- 9.9 
nm. It also consists of pore sizes that are regularly ordered spheres (100 – 150 nm) and rods (700 – 
800 nm) respectively. The main application of SBA- 15 is in biorefinery production (Rahmat et al., 
2010).  
Kim et al (2011) discuss one developing application of nanotechnology medicine which deploys 
nanoparticles for the transmission of drugs, and other substances to specific types of cells and tissues. 
According to Yin et al. (2013), one of the reasons why nanoparticles are preferred when compared to 
standard methods of delivering drugs has to do with the fact that their exterior surfaces can be 
conjugated to proteins for example cytokines and antibodies so that they can be delivered to a specific 
location in the body. For in vivo application, porous silica nanoparticle has indicated considerable 







Figure 1.9: Parameters that govern the loading and release rate of drug molecules in silica-
based ordered mesoporous materials. Functionalization of mesoporous materials with functional 
alkoxysilanes (R is the organic group). https://royalsocietypublishing.org/doi/10.1098/rsta.2011.0258 
((Vallet-Regi et al., 2012). 
 
 
According to Vallet-Regi et al., 2007 and Vallet-Regi et al., 2012, mesoporous silica nanoparticles 
(MSNPs) are composed of channels that are ordered and packed close to each other, permitting the 
nanoparticles to play the role of a nanocontainer figure 1.9. The molecules adsorbed into the pores 
come out under constrained diffusion from the entrance of the pore. According to Al-Shanti & 
Aldahoodi (2006) nanoparticles can be used for drug delivery in slow release because they can be 
manipulated to have surface to volume ratios that are very high. Since they were discovered, different 
kinds of Mesoporous such as SBA-15, MCM-41, MCM-51 and MCM-48, have been developed. 
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However, for purposes of clinical applications, the SBA-15 is seen as the most suitable controlled 
drug delivery method (Izquierdo-Barba et al. 2009; Vavsari et al. 2015).  
The administering of IGF-1 inside loaded MSNPs does not only have the possibility of prolonging 
the accessibility of bioactive IGF-1; but also comes with the extra benefit of slow release on a 
continuous basis. The benefit of this it could be the delivery of doses of IGF-1 which are higher 
without the risk associated with marked hypoglycaemia (Cheetham et al. 1997).  
 
 





















1.6 Aims and Objectives 
The overarching aim of the PhD project was to develop a novel approach to manipulate NMJ 
formation and function using simplified bioengineered entirely NMJ platform.   This was achieved 
through chemical and biological objectives: 
 
Chemical objectives 
1. Fabricate of mesoporous silica nanoparticles (MSNPs) SBA-15 and MCM-41. 
2. Characterise MSNPs SBA-15. 
3. Optimise the non-toxic concentration of SBA-15. 
 
Biological objectives 
1. Investigate the effects of slow release of IGF-1 on muscle (drug release study). 
2. Generate and characterise human NMJ platform. 
3. Investigate the impact of slow release of IGF-1 on NMJ formation and function. 
4. Investigate the effects of slow release of IGF-1 on the bi-directional communications between 
















Chapter 2: Materials and Methods 
 
2.0 Materials  
 
All materials were purchased from Sigma Aldrich and used as received, unless otherwise noted. 
Tetraethoxysilane (TEOS), cetyltrimethylammonium bromide (CTAB), ethanol, methanol, 
hydrochloric acid (37%), sodium hydroxide, sodium chloride, potassium chloride, magnesium 
sulphate, calcium chloride, trimethylbenzene (TMB), human insulin, hydrocortisone, 
carboxymethylcellulose (medium viscosity), glutaraldehyde, and Pluronic P123 were all obtained 
from Sigma. All cell and tissue culture media and supplements were purchased as sterile. Heat-
inactivated (HI), foetal bovine serum (FBS), and HI new born calf serum (NCS) were purchased from 
Gibco (Paisley, Scotland); HI horse serum (HS) was from TCS Biosciences (Corby, England); 
penstrep (penicillin and streptomycin) and trypsin from Bio Whittaker (Wokingham, England); L-
glutamine from BDH (Poole, England), gelatine from Sigma (St Louis, MO, USA). Glassware, 
distilled water (dH2O) and phosphate buffered saline (PBS; Oxoid, Hampshire, England) were 
autoclaved prior to use. Sterile plasticware was purchased from Greiner Bio-one (Kremsmunster, 
Austria) unless otherwise stated. Recombinant human IGF-1 was obtained from Calbiochem 



















2.1.0 Synthesis of dye labelled Mesoporous Silica Nanoparticles (MCM-41, small pore size)  
 
Stöber methods, was used to fabricate the MCM-41.  N-cetyltrimethylammonium bromide (CTAB) 
1.0 g (2.7 x 10-3 mol) was dissolved in deionised water 480 ml. Sodium hydroxide 3.5 ml (2.0 M) 
was added to the solution and stirred vigorously at 80°C. Tetraethyl orthosilicate (TEOS) 5.0 ml (2.6 
x 10-3 mol) and fluorescein isothiocyanate FITC-APS was added dropwise to the solution containing 
CTAB. This mixture was stirred for 2 hours at 80°C, giving rise to white precipitates (MSNs). The 
round bottom flask from condenser was removed and the decanted equally into two 240 ml centrifuge 
bottles (Weighing was done to ensure equal distribution) and then centrifuged at 6000rpm for 15 
minutes.  The supernatant was then removed and stored in a large brown bottle or a clear bottle 
wrapped in foil. This product was filtered and then washed with deionized water and methanol. Next, 
the surfactant template (CTAB) needed to be removed. This was done by acid extraction. A 
suspension of 1.0 g of the product was in static condition left overnight at 50°C in methanol solution 
100 ml and concentrated HCl 1ml. The template removed solid product and was centrifuged and dried 






















Figure 2.0: Explain method 1, which is a synthesis of dye labelled Mesoporous Silica Nanoparticles 







2.1.1 Synthesis of dye labelled Mesoporous Silica Nanoparticles (MCM-41, large pore size) 
 
N-cetyltrimethylammonium bromide (CTAB) 1.0 g (2.7 x 10-3 mol) was dissolved in deionised water 
measuring 480 ml and sodium hydroxide measuring 3.5 ml (2.0 M). Mesitylene 7.0 ml (48.8 mmol) 
was then added to the solution and stirred vigorously at 80 °C for 2 hours. Tetraethyl orthosilicate 
(TEOS) 5.0 ml (2.6 x 10-3 mol) was added dropwise to the solution containing CTAB. This mixture 
was stirred for another 2 hours at 80°C, giving rise to white precipitates (MSNs). This product was 
centrifuged at 6000rpm for 15 minutes. Next, the surfactant template CTAB and mesitylene 
molecules were removed by acidic extraction. A suspension of 1.0 g of the product was in a static 
condition and left overnight at 50°C in methanol solution 100 ml with concentrated HCl 1ml. The 
template removed solid product and was centrifuged and dried at 60°C in the oven for 1-2 hours               




Figure 2.1: Explain method 2, which is a synthesis of dye labelled Mesoporous Silica Nanoparticles 











2.1.2 Synthesis of dye labelled Mesoporous Silica Nanoparticles (SBA-15, small pore size) 
 
SBA-15, with the average pore size of 9 nm, was prepared with a hydrothermal synthesis using 
Pluronic P123 (a PEG-PPG-PEG block copolymer, Aldrich) as a structure directing agent and 
tetraethyl orthosilicate (98% TEOS, Aldrich) as a silica precursor. First Pluronic P123 (2 g) was 
dissolved in a mixture of distilled water 50g and hydrochloric acid 12g (37% HCl, Aldrich) at 24 C 
under magnetic stirring. After 3 hours, the Pluronic P123 solution was placed in an oil bath at 24oC 
.TEOS 4.25g was added drop-wise under vigorous stirring and prepared dye 505 µl (FITC-APS 
(0.002 g) + Ethanol anhydrous instead of DMF) was added. After 10 min, the mixture was kept under 
static conditions at 39oC and left there for 20 hours. In the next day, the silica suspension was 
transferred into a Teflon-lined autoclave and placed in an oven for hydrothermal treatment at 100oC 
for 24 hours. A suspension of 2g of the product, in a static condition, was left overnight at 59°C in 
methanol solution 100 ml with concentrated HCl 1ml. The template removed solid product which 





Figure 2.2: Explain method 3, which is a Synthesis of dye labelled Mesoporous Silica Nanoparticles 








2.1.3 Synthesis of dye labelled Mesoporous Silica Nanoparticles (SBA-15, large pore size) 
 
Conventional mesoporous SBA-15 materials were synthesized using Pluronic P123 triblock 
copolymer as a template and TEOS as a silica source. In a typical synthesis, P123 1.0g was added to 
a mixture of HCl 7.50g (2M) and H2O 30g aqueous solution in a Teflon-lined container, which was 
stirred at 35oC. Then TEOS 2.10g and FITC-APS was added to this solution under vigorous stirring. 
The reactant composition was P123 : TEOS : HCl : H2O (Scheme 1: Schematic illustration of the two 
methods for the synthesis of large pore mesoporous silica nanoparticles and the coordinate bond based 
pH-responsive drug delivery system). The SBA-15 particles were selectively functionalized with 
amino groups on the mesoporous surface and quaternary ammonium groups on the particle surface 
via the post-synthesis and co condensation methods. The mixture was kept static at 35oC for 24 h, 
and then sealed in a polypropylene bottle at 100oC under static conditions for another 24 h. A 
suspension of 1.0g of the product was in static condition and left overnight at 50°C in methanol 
solution (100ml with concentrated HCl 1ml). The template removed the solid product which was 
centrifuged at 6000 rpm for 15 minutes and dried at 60°C in the oven for 1-2 hours (Zheng, Huang, 





















Figure 2.3: Explain method 4, which is a Synthesis of dye labelled Mesoporous Silica Nanoparticles 








2.1.4 Fabrication of the dye Fluorescein isothiocyanate (FITC) 
 
FITC-APS was prepared by placing fluorescein isothiocyanate (FITC, 0.002 g) into Eppendorf. This 
was followed by mixing anhydrous dimethyl formamide (DMF, 5 ml) with 3-amino propyl 
trimethoxy silane (APS, 50 µl). The next process involved taking 505 µl from the mixture solution of 
DMF with APS and adding it to the dye. The Eppendorf was then wrapped with foil, to prevent photo 













































2.1.5 Characterisation of the Mesoporous Silica Nanoparticles 
 
2.1.6 Electron microscopy 
 
2.1.7 SEM:  
Scanning electron microscopy was conducted using a FEI/Philips XL30 FEG ESEM. Samples were 
dried and ground before SEM analysis. SEM images were analysed using Gatan Digital Micrograph 
Version 3.6.5. It gives information about the sample structure and can produce very high-resolution 
images of a sample surface, revealing details less than 1 nm in size (Argast and Tennis, 2004). 
 
2.1.8 TEM:  
Samples were pre-treated by sonication and vortexing for 2 hours. Transmission electron microscopy 
was conducted using a JEOL JEM 200CX or a JEOL JEM 2010 electron microscope operated at an 
accelerating voltage of 200 kV. The powder was suspended in ethanol and placed directly on a 
carbon-coated copper grid (Hettler et al., 2016). 
 
2.1.9 Nitrogen adsorption 
Nitrogen gas physisorption isotherms were measured in a Micromeritics Flowsorb apparatus. Surface 
area calculations were carried out using the Brunauer-Emmett- Teller (BET) method. Pore size 
distributions were calculated using the KJS adjustment of the thermodynamic-based Barrett-Joyner-
Halenda (BJH) method (Li et al., 2021). 
 
 
2.1.10 Size and zeta potential measurements 
The particle size and zeta-potential measurement (surface charge) of the MSNs were measured using 
a Malvern Zetasizer NanoZS. Zeta-potential was calculated by Laser Doppler Electrophoresis (LDE) 
and size by dynamic light scattering (DLS). Samples were pre-treated by sonication and vortexing 





2.1.11 Thermogravimetric analysis 
The organic content on the different samples before and after protein adsorption was quantified by 
thermogravimetric analysis in a Mettler- Toledo TGA/SDTA851e apparatus (Wellisz et al., 2008). 
 
 
2.1.12 X-ray diffraction     
     
Powder X-ray diffraction data was obtained on a Philips X’pert diffractometer using Ni filtered Cu 
KR radiation with λ=1.54 Å. Samples were analysed from 0.3° to 70° 2θ. An endotoxin assay was 
conducted using the QCL-1000® test kit from Cambrex – samples were mixed with the LAL reagent 
and chromogenic substrate reagent over a short incubation period (16 minutes), and the absorbance 
was read at 408 nm. Using established protocols, which are already available within the chemistry 
division (Argast and Tennis, 2004). 
 
   
2.1.13 FTIR  
 
Spectra were obtained with a potassium bromide (KBr) disc of each mesoporous particle. This was 
performed upon a Thermo Scientific Nicolet 380 FT-IR spectrometer equipped with a Smart iTR 






















2.1.14 Immortalized human myoblast 
 
Our collaborating partners from the Institute of Myology made available the human myoblasts of 25 
years SkMC (Mamchaoui et al., 2011). For purposes of preserving the cells, 10% dimethyl sulfoxide  
(DMSO) and 90% foetal bovine serum (FBS) were used. The cells were then stored in at a density of 
1x106 cells in 1 ml on frozen vial. For the proliferation, the cells in the vial were defrosted before 
being moved into a conical tube of 9 ml growth media (GM) (Table2.0).   
 
 



































Growth media components Concentration 
Dulbecco’s Modified Eagle’s Media (DMEM) from Lonza (Nottingham, UK) 60% (v/v) 
Medium 199 with Earle’s BSS from Lonza (Nottingham, UK) 20% (v/v) 
Heat inactivated foetal bovine serum (FBS) from Gibo (Loughborough, UK) 20% (v/v) 
L-glutamine from Lonza (Nottingham, UK) 1% (v/v) 
Fetuin from foetal bovine serum from Sigma-Aldrich (Dorset, UK) 25µg/ml 
Recombinant human fibroblast growth factor-basic (FGFb) from Gibco 
(Loughborough, UK) 
0.5ng/ml 
Recombinant human epidermal growth factor (EGF) from Gibco (Loughborough, 
UK) 
5ng/ml 
Recombinant human hepatocyte growth factor (HGF) from Sino Biological Inc. 
(Suffolk, UK) 
2.5ng/ml 
Recombinant human insulin from Sigma-Aldrich (Dorset, UK) 5µg/ml 
Dexamethasone from Sigma-Aldrich (Dorset, UK) 0.2µg/ml 
Penicillin/Streptomycin (Sigma, UK) 1% (v/v) 
Plasmocin (InvivoGen, UK) 1:1000 (50 µl) 
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2.1.15 Human skeletal myoblast cultures 
 
In different flasks, the 25-year-old cells (C25) were plated. Each flask contained 10ml growth media 
(Table 2.0). The flasks with the C25 were kept at a temperatures of 37oC and 5% CO2 until the density 
of the cells was between 70% and 80% (the percentage of the covered area within the total area of 
view). Once the 70% to 80% of confluence was reached, Dulbecco’s Phosphate Buffered Saline 
(DPBS) (Lonza, Nottingham, UK) was used to wash the cells twice, when the GM had been taken 
out of the flask. This was followed by the application of the Gibco-obtained 2 ml of TrypLE™ 
Express Enzyme (Loughborough, UK) and incubated in a temperature of 37°C in 5% CO2 over 5 
minutes so that the cells could detach. Following this, the cell suspension was transferred into a 
conical 15 ml tube with 8 ml GM and centrifuged for 5 minutes at 1200xg. Using 5 ml GM, the pellet 




A cell count was achieved using a haemocytometer. The process involved 1:1 ratio, mixing a 20 µl 
Trypan blue stain (0.4%) and 20 µl of cell suspension solution, all obtained from Lonza (Nottingham, 
UK). A pipette was used to apply the cells into the haemocytometer chambers. Using a microscope 
light, the cell was counted in each chamber's four large corner squares (16 squares) (as illustrated by 
the blue colour in Figure2.5). The only cells that were counted were the ones which were visible. The 
visibility of the cells was achieved by the Trypan blue as it is a crucial stain that is removed from 
cells that are live. A hand tally counter (Figures 2.4-2.6) was used for counting the cells in all eight 
corner squares. Once the cells in each square had been counted, the next task involved the calculation 
of the cell concentration. This was achieved using the equation: average amount of live cells within 
1 large corner square x dilution element x conversion factor (104) = cell concentration per ml. A ratio 
of 1:1 was used. This leads to the dilution factor being equal to 2. A single large square’s volume 
equals 1mm2 with the conversion factor equalling 104.  On the other hand, the cell suspension layer 
equals 0.1mm; consequently 1mm2 x 0.1mm = 0.1cm x 0.1cm x 0.01cm =10-4cm3 = 10-4ml, according 









Figure 2.4: Schematic representation of the haemocytometer as visualised under a microscope; 






Figure 2.5: Shows one of the squares shown in blue in Figure 2.4. To ensure accuracy and 













2.1.17 IGF-1 loading and release 
DyLight 488 was used for IGF release. It is recommended by the manufacturer to mix DyLight with 
IGF in a 16-molar ratio. 1 mg of IGF was reconstituted in 1 ml distilled water. Thereafter, 100 µl 
(100µg) was taken from the 1 mg/mL IGF solution (7500 MW) and mixed with 13 μL of DyLight 
488 NHS Ester (10 mg/mL) and the solution was incubated for 1 hour. After 1 hour of dialysis, a tube 
was used to clean unbound DyLight. Subsequently, 113 µl of labelled IGF was mixed with 900 µl 
PBS (pH 7.2). Thereafter, 1 ml of labelled IGF was added to 1.5mg of MSNs and left for incubation 
for 4 hours. After this period the sample was spun down and the supernatant was removed so that the 
fluorescence can be measured. Then, 1 ml of fresh PBS (pH 7.2) was added to a nanoparticles (NPs) 
pellet, and the release study was started. The sample was regularly centrifuged over certain time 
periods, namely 2 hours, 4 hours, 8 hours, 16 hours, 24 hours, 48 hours and 72 hours. Next, the 
fluorescence of the supernatant was measured to estimate the release of the labelled IGF-488 from 
the MSN (Kempen et al. 2015). In addition to uploading study, ELISA was performed. Then, 0.75mg 
of nanoparticles was added to 1ml of PBS and mixed together for 15 minutes in the rotator. Thereafter, 
12.5μL of IGF-1 was added to the mix (NP+PBS+IGF). The substances were mixed together and 
placed in the rotator for 4hrs. After 4 hours, the mixture was centrifuged (speed 6000rpm for 5 
minutes) and the supernatant was discarded.  Thereafter, 5ml of DM was added to the nanoparticles 
and the solution was transferred to be added to SkMC (C25). 
 
 
2.1.18 Uploading IGF-1Study 
 
A total of 50µg (50 µl) of IGF was used: 25µg for uploading study and 25µg for standard curve (25µg 
dissolved in 1ml PBS). NPs (1.5mg) was dissolved in 1ml PBS with 25µg, rotated for 4hrs at room 
temperature with standard tube IGF uploading, 100 µl /well. 
Standard curve plotting: 25µg/ml, serial dilution (1:1) was applied as follow (6 tubes): 25µg; 12.5µg; 
6.25µg; 3.12µg; 1.56µg and 0.78 µg. 
BCA protein kit was used. Reagent A (50 part) mixed with reagent B (1 part), then BCA reagent and 









2.1.19 Cell treatment 
 
At a concentration of 1.5x105 cell/ml in GM, the C25 was seeded in a 0.5% gelatine pre-coated 12-
well plate. Over a period of 24 hours, the incubation of the cells was done in an environment with 
5% CO2 and a temperature of 37°C. This was followed by a process were DPBS was used to rinse 
the cells two times after the GM was extracted. After adding the differentiation media, DM (Table 
2.1), to each well, the cells were incubated in an environment of 5% CO2 and a temperature of 37°C 
for 96 hours. Contract microscopy was used for phenotypic differentiation for alignment, fusion, and 
elongation. The process of comparing the control’s differentiation parameters and for the various 
conditions in cell treatment was achieved using immunofluorescence microscopy.  
 
Confluence at specific intervals was measured using ImageJ software. This was achieved by adding 
together the whole myoblast area (MA). To complete this, the whole myoblast area over the total 
image x 100 was counted (Ricotti et al., 2011; Ren et al., 2008). For the assessment, five fields of 
view at a magnification of 10 times were selected. For each treatment, an aspect ratio was applied 
through dividing the length of the myotube by its width, for the differentiation parameter. This was 
in addition to the fusion index, a process involving taking the aggregate of the myotubes within a 
field and dividing it by the cumulative area of the field x 100. Table 2.2 presents the equations.   
 
 
2.1.20 Cell treatment with IGF 
 
Once the 0.5% gelatine was used for pre-coating the 12-well plate, at a concentration of 1.5x105  
cell/ml, the C25 was seeded in GM. This was followed by incubation in an environment of 5% CO2 
and a temperature of 37°C for 24 hours. This was followed by the process of using DPBS to rinse the 
cells twice after the GM had been removed. To each cell, differentiation media was introduced. The 
IGF-1 concentrations of the differentiation media in each cell were different. The cells were then 
incubated in an environment of 5% CO2 in temperatures of 37°C over 96 hours. The concentrations 
of IGF-1 used were 5 ng, 10 ng, 20 ng, 40 ng, 80 ng and 160 ng. In all studies, the incubation happened 
in an environment of 5% CO2, a temperature of 37°C, over a period of 96 hours. Varying 
concentrations were used with the aim of determining if they boosted differentiation and proliferation. 
Hence, for this study, the proliferation marker Ki67 was used together with MHC and DAPI. Red 
dots were used to denote that Ki67 marker. From each condition, five images were selected. From 
each image, the total of red dots was counted, and eventually, the average number was employed in 
statistical analysis (ANOVA), to identify noteworthy variances. For purposes of comparison, 
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differentiation parameters were applied to each condition. The same technique was employed for five 
images from five experiments, and the average number was employed for statistical analysis. 
 
2.1.21 Cell treatment with IGF-1 and nanoparticles 
 
Mesoporous silica nanoparticles (0.75mg + 1ml PBS) were used for cell treatment together with IGF-
1 after loading, and a release study 10 ng of IGF-1 was used; hence, for this concentration more 
differentiation was observed than proliferation. A pre-coated 0.5% gelatine 12-well plate was seeded 
with 1.5x105 cell/ml in GM for the human SkMC (C25). The treatment was then incubated in an 
environment of 5% CO2 at a temperature of 37°C for 24 hours. This was followed by the extraction 
of the GM and the rinsing of the cells twice using DPBS. To each well, DM was added with uploaded 
IGF-1 with MSNPs and then incubated in an environment with 5% CO2 and a temperature of 37°C. 
The IGF-1 size was 3 nm, and the pore size for SBA-15 was 9nm, a situation that permitted the upload 
of IGF-1. Using DAPI, Ki67, and MHC, together with immunohistochemistry, differentiation 
parameters were applied.  
  
Table 2.1: Differentiation media 
Differentiation media components Concentration 
Dulbecco’s Modified Eagle’s Media (DMEM) from Lonza (Nottingham, UK) 500 ml 
L-glutamine from Lonza (Nottingham, UK) 1% (v/v) 
Recombinant human insulin from Sigma-Aldrich (Dorset, UK) 10 µg/ml 
Penicillin/Streptomycin (Sigma, UK) 1% (v/v) 















Differentiation parameters Formula 
Aspect ratio (AR) (myotube length) / (myotube width) 
Fusion index (FI) (nuclei in each myotubes in a field) / (total nuclei of the field) (100) 
Myotube area (MA) (total area of myotubes in a field) / (total area of the field) (100) 
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2.1.22 Expansion of Neural progenitor cells (NPCs) 
  
The Neural progenitor cells (NPCs) used were derived from human embryonic stem cells (hESCs) 
and transfected with green fluorescent protein (GFP)-reporter lentivirus system, donated by the 
Skeletal Muscle Group at Manchester Metropolitan University (Abd Al Samid et al., 2018). NPCs, 
therefore, visually appeared green under a fluorescent microscope. A 1ml cryovial containing 0.5x106  
green fluorescent protein (GFP) transfected NPCs suspended in 90% fetal bovine serum (FBS) and 
10% (v/v) dimethyl sulfoxide (DMSO) was thawed and transferred onto a laminin coated T25 flask 
(prepared 72 hours earlier) and incubated at 37°C in a 5% CO2 environment. Prior to the transfer, 
NPCs were integrated with 4ml neural expansion media (NEM) to initiate NPC expansion (Table 
2.3). The NPC medium was renewed every 2 days for 6 days with 5ml NEM until a cell confluence 




Table 2.3: Neural Expansion Medium (NEM) 
NEM components Volume/concentration  
Dulbecco’s Modified Eagles Media (DMEM)- F12 (1:1) from Lonza (Nottingham, 
UK) 
48.5 ml 
MEM Non-essential amino acids (NEAA) (Life Technologies, UK) 0.5ml (1x) 
Penicillin/Streptomycin (Sigma, UK) (100x) 0.5 ml (1x) 
bFGF (R&D systems, UK) (100 µg/ml) 10 µl (20ng/ml) 
N2 supplement (Life Technologies, UK) (100x) 0.5 ml (1x) 
Heparin (Sigma, UK) (2mg/ml) 50 µl (2 µg/ml) 















2.1.23 Measurement of axonal growth in co-culture (nerve-muscle) 
 
The NPCs with a GFP-reporter lentivirus in the in vitro co-culture model were imaged under the 
fluorescent microscope (Leica CTR 6000), over the 7 days of culture with different treatments like 
NPs, IGF-1, IGF-1/NPs and DM only as control. The axonal length of the differentiating motor 
neurons were measured over 7 days in vitro using Image J (procedure illustrate in figure 2.7), assessed 
at X20 magnification (at least five random fields of view selected).  
 
 
Figure 2.7: Axonal length measurement of motor neurons using Image J software. Images were 
measured using fluorescent microscope (Leica CTR 6000), over the 7 days of culture with different 
treatments like NPs, IGF-1, IGF-1/NPs and DM only as control. The axonal length was measured 
using Image J software and using “analyse→tools→ROl manger” function tab and the same 
procedure was used for all the images. These were assessed at X20 magnification (at least five random 













Cells were washed two times with DPBS at 96 hours. At a temperature of 21°C, 4% paraformaldehyde 
was used to fix the cells for 10 minutes. Using DPBS, the fixed cells were washed two times. This 
was followed by the process of permeabilising the cells using a 1x perm/wash buffer (BD 
Biosciences, Oxford, UK). Soon after, the cells were incubated at a temperature of 21°C for 30 
minutes. The cells were then washed two times using DPBS for the final time. This was followed by 
adding a blocking solution of 0.2% Triton X-100 with 10% normal goat serum (GS) or horse serum 
(both obtained from Sigma-Aldrich (Dorset, UK)) before the cells were incubated for 60 minutes. 
Using DPBS, the cells were washed once more when the blocking solution had been removed. In the 
main antibody solution, there was 3% goat serum or horse serum with 0.05% Tween-20 (Sigma-
Aldrich, UK). Before being incubated at a temperature of 4°C for 24 hours, Ki67’s primary antibodies 
were added to the cells. Using DBPS, the primary antibodies were washed twice followed by 
incubation with matching secondary bodies after 24 hours. The incubation happened for one hour in 
an environment that also had 2 ng/ml 4′, 6-Diamidine-2′-phenylindole dihydrochloride (DAPI) from 
Sigma-Aldrich (Dorset, UK) and 5 μg/ml Anti-Myosin Heavy Chain Alexa Fluor® 488 from 
eBioscience (Hatfield, UK), at a temperature of 21°C. The Leica DMI6000 B inverted microscope 
obtained from Leica Microsystems (Milton Keynes, UK) was used for the confirmation of innervation 
for fluorescent microscopy. The qualification of the differentiation parameters was achieved through 


















2.1.25 Human Growth Factor Array 
 
In parallel experiments were conducted to compare the concentration of 40 human growth factors 
(Table 2.4). One ELISA-based microarray standard glass slide is spotted with 16 wells of identical 
growth factor antibody arrays (Human Growth Factor Antibody, Cambridge Bioscience, UK). Each 
well was spotted with different controls: positive control spot (a control for the amount of biotinylated 
antibody printed onto the array), negative control spot (buffer printed, to measure the baseline 
responses) and a blank spot (nothing printed, to measure the background response). Each antibody 
was arrayed in quadruplicate. The ELISA-based microarray analysis of the growth/neurotrophic 
factor concentration was used to determine whether the slow release of IGF-1 impacts the secretion 
of growth/neurotrophic factors in co-cultured conditions (untreated co-culture, co-culture with NPs, 
co-culture with IGF-1 and co-culture with IGF-1/NPs). Supernatant samples were collected from each 
condition for assessment using a human growth factor array kit on day 7, when spontaneous myotube 
contractions were first observed contracting in unison as a motor unit. Total protein concentrations 
was determined in all collected supernatant to ensure adding equal amount of the protein to 
microarray slide (0.5µg/µml).  Preparation of standards and reagents in the array kit were completed 
using manufacturer guidelines. Subsequently, 100 μl of sample diluent from the array kit was added 
to each well and incubated at 23°C for 30 minutes to block slides. The wells were then decanted and 
100 μl of standards, controls and supernatant samples were added to the individually assigned wells. 
The slides were sealed and incubated for 24 hours at 4°C on microplate shaker fixed to 500 rpm. 
Following incubation, the samples were decanted from the wells and the slides were washed 5 times 
for 5 minutes each time with 150 μl of 1X wash buffer 1, then washed 2 times for 5 minutes each 
time with 150 μl of 1X wash buffer 2. Next, 80 μl of detection antibody cocktail was added to each 
well and the slides incubated for 1.5 hours at 23°C. The detection antibody cocktail was aspirated 
from the wells and the wash steps with wash buffer 1 and wash buffer 2 were repeated once again. 
After washing slides, 80 μl of Cy3 equivalent dye-conjugated streptavidin was added to each well 
then sealed and incubated in darkness for 1 hour at 23°C. Following incubation, the wash steps were 
repeated once again. The slides were then separated from the well gaskets and placed into the 
provided slide washer/dryer tube. The tube was then filled with 30 mL of 1X wash buffer 1 to 
completely cover the slides and shaken gently for 15 minutes. The 1X wash buffer 1 was removed 
from the tube and 30 mL of 1X wash buffer 2 was added to completely cover the slides and gently 
shaken for 5 minutes. The slides were removed from the washer/dryer tube and dried with compressed 
air to remove residual buffer solution. Subsequently, the array was visualised with a GenePix 4000B 
laser scanner at 532nm wavelength. Raw data from the visualised array images was generated and 
processed with the GenePix Pro 4.1 Microarray Acquisition & Analysis Software, further statistical 
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Figure 2.8: An illustration of the process of enumerating the growth /neurotrophic factors in 
the supernatant of (untreated co-culture, co-culture with NPs, co-culture with IGF-1 and co-
culture with IGF-1/NPs). Using human growth /neutrophic factor microarray (adapted from 







Table 2.4: Descriptions of the human growth factors and neurotrophins quantified in aneural myotube 








2.1.26 Functional Assessment of Neuromuscular Junction Formation 
 
Co-cultures were functionally evaluated to validate the formation of NMJs via live phase contrast 
video analysis of myotube CF in response to agonist/antagonist treatments (Table 2.5). On Day 7, the 
co-cultured cell dishes were positioned onto an inverted microscope stage, which was enclosed by an 
incubation chamber to maintain atmospheric conditions of 37°C with 5% CO2. Following 5 minutes 
of live observation of uninterrupted spontaneous myotube contractile activity, the co-cultures were 
treated with cholinergic antagonists to block AChRs at the NMJ.  
 





L-Glutamic acid (L-Glut) 400 µM 
α-Bungarotoxin (α-BTX)  10 nM 
 
 
The co-cultures were also treated with the glutamatergic receptor agonists to stimulate glutamate 
receptor on the motor neurons (MNs). The specified concentrations where selected based on 
previously established studies (Guo et al., 2011; Borodinsky and Spitzer, 2007; Das et al., 2007). The 
myotube CF was measured 30 seconds before the application of the treatments to the cells, to establish 
a baseline spontaneous CF. Subsequently, agonist or antagonist treatments were added to the dishes 
at the centre of the field of view. Modulation of CF was measured immediately upon application of 
the treatment to the cells. Live measurement of CF in response to treatment were also conducted again 
after 10 minutes, 15 minutes, 20 minutes, 30 minutes, 45 minutes 1 hour and 1hour 30 minutes. 
Following 1 hour and 35 minutes after treatment, the cells were washed three times with 500 µL of 
DPBS then fresh untreated DM was added to the cells. The dishes were placed back onto the 
microscope stage in the incubation chamber and CF was immediately measured again following the 
washout and resupply of DM. The CF was measured once again at 2 hours and 24 hours after the 
initial treatments. Live video analysis was conducted at 24 frames per second with phase contrast 
microscopy using the DMI6000 B inverted microscope with an N Plan 10x/0.25na Ph1 objective. 






2.1.27 Statistical analysis 
Firstly, a normality test has been carried out using a Shapiro-Wilk test to determine if the data is 
normally distributed or not. If it’s normally distributed then there will be a bell curve 
(Gaussian distribution) this means that it’s parametric data and one-way ANOVA will be used. 
However, if the data is not-normally distributed data that means it’s non-parametric and Kruskal-
Wallis test will be used. Parametric tests are those that make assumptions about the parameters of the 
population distribution from which the sample is drawn. This is often the assumption that the 
population data is normally distributed. After that the GraphPad Prism software was employed in the 
analysis of results. The demonstration of the results is on the mean and standard deviation (±SD) of 
the mean. The Bonferroni's Multiple Comparison T-test and one way ANOVA were used for 
statistical analysis and the comparison of more than two means. At a level of 5% (P<0.05), the results 
were statistically significant. * denotes P<0.01, ** denotes P<0.001*** denotes P < 0.0001. The 
Bonferroni test is a type of multiple comparisons test used in statistical analysis. When performing 
a hypothesis test with multiple comparisons, eventually a result could occur that appears to 
demonstrate statistical significance in the dependent variable, even when there is none. Furthermore 
this statistical test is used to reduce the instance of a false positive. In addition, Bonferroni designed 
an adjustment to prevent data from incorrectly appearing to be statistically significant. The main 
limitation of Bonferroni correction is that it may lead analysts to mix actual true results (Hayes, 2020). 
Another analysis was used in this project which is the one-way analysis of variance (ANOVA) which 
is used to determine whether there are any statistically significant differences between the means of 
two or more independent groups and determining which of these groups differ from each other is 
important. In addition, a significant P value of this test refers to multiple comparison tests to identify 
the significant pairs (Mishra, et al., 2019) then in this test one continuous dependent variable and one 
categorical independent variable are used, where categorical variable has at least three categories. In 















Sometimes, because there is a lack of solubility and specification of drug molecules, patients remain 
with no option but to take drugs in high doses to get the required effects in disease treatment. In an 
attempt to deal with these challenges, several drug carriers are found in pharmaceuticals, which are 
employed in the delivery of therapeutic agents to a specific sit in the body (Bharti et al., 2015). A 
promising agent for dealing with the problems mentioned above is mesoporous silica materials, which 
have the ability to deliver effects in a way that is both controllable and sustainable. Specifically, 
mesoporous silica nanoparticles (MSNPs) are broadly employed as a delivery reagent since silica has 
some desirable chemical properties; it is biocompatible and thermally stable (Bharti et al., 2015). 
Silica's distinctive mesoporous construction enables drugs to be loaded effectively and eventually 
released in a controlled manner to the target site. It is possible to change the mesoporous properties 
such as the size of the pore, properties of the surface, porosity, and high drug loading. This ability 
depends on the preparation of the MSNPs. The active surface plays the role of facilitating 
functionalization to the changed surface and linked therapeutic molecules. MSNs are widely 
employed in the biomedical field in the areas of delivery of target drugs, diagnosis, cellular uptake, 
and bio-sensing. It is the aim of this review to deliver the prevailing knowledge about mesoporous 
nanoparticles that contain silica and how it is applied in different biomedical fields (Bharti et al., 
2015). In recent times, the combination of MSNs with liposomes has been reported, leading to unique 
nanocarriers denoted as “protocells” (Butler et al, 2016) and this nanosystem shows the robustness 
and high loading and controlled release capability of MSNs with the low toxicity and immunogenicity 
of liposomes. Protocells open up novel expectations in the drug delivery development due to their 
potential to tackle multiple challenges, such as stability, specificity and high loading capacity for 
diverse loads (Villegas et al, 2018). For example a liposome was used as a drug delivery vehicle for 
administration of nutrients and pharmaceutical drugs, for instance lipid nanoparticles in mRNA 
vaccines and DNA vaccines (Li et al, 2019).  
In the last ten or so years, several nanomaterials like mesoporous silica (Wang et al., 2015) have been 
used in the biomedical area for purposes of improving therapeutic results. In recent times, scholars 
have started to focus on exploring how stem cells are affected by biomaterials, in the process showing 
that the employment of biomaterials could present an effective alternative for c-kit-positive CSC 
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proliferation and migration. The mesoporous silica materials are among the biomaterials that have 
received the bulk of the attention as a drug release career for several biomedical uses. The reason 
behind this popularity has to do with its properties: the diameter of its pores, biocompatibility, and 
multifunctional surface features (Li et al., 2012). It is these features that place mesoporous silica 
materials among the effective careers for sustained IGF-1 discharge to lengthen the half-life (Yang et 
al., 2012; Chen et al., 2013).  
 
 
 3.0.1 Aims 
 
The initial aim of this study is to use nanotechnology, mesoporous silica nanoparticles (MSNPs) as a 
system for delivering drugs in a safe, regulated, and slow discharge of IGF-1, in a manner that will 
lengthen the bioavailability of IGF-1 (half-life of serum IGF-1) while boosting its effectiveness. On 
this basis, the specific aims of the study are listed below.  
 Fabricate mesoporous nanoparticles (MSNPs) 
 
 Characterise mesoporous nanoparticles (MSNPs) 
 
 Upload the IGF-1 into the mesoporous nanoparticles (MSNPs) 
 

















3.1.0 Fabricate mesoporous silica nanoparticles (MSNPs) 
With the aim of examining if it is possible to fabricate MSNPs (MCM-41 & SBA-15), a succession 
of initial experiments has been carried out. Experiments have also been done to determine the cellular 
uptake and cytotoxic influence of mesoporous particles on cells. The researcher also examined if the 
MSNPs' pore size was big enough to permit for loading, into the MSNPs, the IGF-1 affinity and IGF-
1. Considering that the cell surface is the area where the IGF-1 receptor is found, there is no need for 
MSNPs uptake. Hence, to facilitate my suggested project, the synthesis of MCM-41 & SBA-15 
monodispersed mesoporous silica particles was conducted using the normal surfactant templating 
technique (Kresge et al. 1992). Template molecule selection and reaction concentration conditions 
are the techniques employed in regulating the diameter and porosity. The application of configuration 
was done as soon as the particles were formed. This happened before acid extraction was used to 
remove the surfactant molecules, with the results being a well-organised and regular porous 
arrangement.     
MCM-41 MSNPs was fabricated and characterised carefully. This resulted in an even organisation 
of cylinder-shaped mesoporous, which create a pore system that is one dimensional (Reichinger, 
2007). It consists of a pore diameter that can be adjusted independently, a distribution of pores that is 
sharp, this means a pore size distribution can be calculated easily,  a big surface area measuring 
1199m2/g and a big pore volume measuring in the range of 2.6 and 3.8nm, as is represented in Figure 
3.7. It is easy to adjust the distribution of the pores (Silaghi et al., 2014). 
Hydrothermally, MCM-41 NPs did not show stability. This was the result of the high levels of silicate 
units cross-linking so that they could attain a pore diameter which is defined. In the synthesis solution, 
surfactants are employed for purposes of forming micelles. From these, stencils that assist in building 
up the mesoporous structure are produced.  Cetyltrimethylammonium bromide (CTAB) is used 
mostly for MCM-41.  
Following the adding of silica species which cover the rod, micelles that look like the rods are initially 
produced by the surfactant. These rod-like micelles then organise into hexagonal arrays. After this, 
acid extraction was used to remove the template with Cetyltrimethylammonium bromide (CTAB). 
To accomplish this, there is a need for an adequate heat for 24 hours. 
For this study, the synthesis of SBA-15 MSNPs took place as mentioned. The analysis of SEM 
indicated matching nanotube of SBA-15 MSNPs. Analysing the TEM showed that the SBA-15 
MSNPs size could be about 800 nm to 1µm with the straight channel pores organised into a highly 
organised hexagonal shape as is indicated in Figure 3.5 (a, b). An analysis of the nitrogen 
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adsorption/desorption isotherm’s sharp step shows clearly the well-arranged mesoporous structure of 
SBA-15 material. This is as a result of the nitrogen gas' capillary condensation/evaporation in the 
mesoporous at varying pressure levels. This depends on the size of the pore (in this case, 5-9 nm). Its 
surface area is also large (at 940 m2/g), as is depicted in Figure 3.7. 
     
3.1.1  Mesoporous silica nanoparticles (MSNPs) Characterisation 
Producing mesoporous nanoparticles was done with the aim of creating arrangements of different 
particle porosity and size. A synthesis of 19 samples was done. They were completely characterised 
in both techniques SBA-15 and MCM-4. Around six samples were employed in this study for the 
purpose of confirming biodegradability, cytotoxicity, and the correct NP size to be employed for the 
uploading and release study.   
From Table 3.0, below, can be seen the characteristics of the NPs: diameter, composition, porosity, 
and surface charge. With the aim of measuring the zeta potential and size, deionised water was used 
to re-centrifuge and dilute samples 1 to 7.         






3.1.2 Scanning Electron microscopy (SEM) and Transmission Electron microscopy (TEM) 
analysis 
 
3.1.3 Scanning Electron microscopy (SEM) 
With the aim of determining the morphology and size of the samples, SEM analysis was done. The 
figures presented below were examined in varying levels of magnification so that it could be 
confirmed that their shape was spherical and has sizes ranging between 200 and 300 nm.  
 
       
(a) SEM in 1µm scale, magnification x20.000                 (b) SEM in 1µm scale, magnification x20.000 
Figure 3.0 (a, b): SEM image of Sample 1 & 2 (MCM-41 technique). This analysis confirms the 














       
 (a) SEM in 10µm scale, magnification X1000                    (b) SEM in 5µm scale, magnification X3000   
 
 
(c) SEM in 1µm scale, magnification X10.000 
Figure 3.1 (a, b, c): Illustrates SEM images of Sample 6 (SBA-15). All images were captured in 
diverse magnifications and scales. They are rod-shaped, and their sizes ranged between 600 and 1µm.   
 
For the above images, the sample was taken after 48 hours of the reaction in a Teflon bottle. For the 
entire 48 hours, the sample was in a static condition. Between zero and 24 hours, the temperature was 
maintained at 35oC. Between 24 and 48 hours, the temperature was increased to 100oC. The product 
was then centrifuged and kept in methanol. Observing the sample shows a rod shape with sizes 
ranging from between 600 and 1 µm. For further analysis, the sample is diluted and preserved in 




       
 (a)  SEM in 2µm scale, magnification x10.00                (b) SEM in 1µm scale, magnification x10.000  
Figure 3.2 (a, b): SEM images of Sample 8 and 17 from SBA-15 technique following acid 
extraction. These images were captured in different magnifications and scales. They are rod-





















3.1.4 Transmission Electron microscopy (TEM) 
When the SEM analysis was complete, Transmission Electron Microscope (TEM), obtained from the 
University of Manchester’s specialist laboratory was used for the analysis and confirmation of the 
sample’s porosity and its surface area. When TEM analysis is done in varying magnification, the 
Mesoporous Nanoparticles (MNPs) can be seen, and the surface area, shape, and porosity of the 
sample is confirmed. This analysis has the capability to image resolutions that are higher as a result 
of the small de Broglie wavelength of electrons interacting with the specimen when it passes through. 
The images presented below are focused on mesoporous nanoparticles with a round shape and 
numerous pores.  
 
                                 
  (a) TEM in 200 nm scale, magnification x23000              (b) TEM in 50 nm scale, magnification x49000   
Figure 3.3 (a, b): TEM analysis for Sample 1 (MCM-41) and Sample 18 (MCM-41 with 
Mesitylene). Indicates that the samples’ surface area and porosity are good. They also confirm the 
shape of the samples. These images were captured in varying magnifications and scales.  
     
                             
Figure 3.4: Representative TEM image of myotubes incubated with MCM-41 for 7 days, 





          
   (a) TEM in 100 nm scale, magnification x30000             (b) TEM in 500 nm scale, magnification x11000 
Figure 3.5 (a, b): TEM images of Sample 6 (SBA-15, large size) and Sample 17 (SBA-15, small 
size). These images were captured in varying magnifications and scales. They illustrated an individual 
mesoporous nanoparticle at a higher resolution. It can be seen that they are rod hexagonal shaped, 
and the porosity with the surface area of the samples is confirmed. 
  
 
Figure 3.6: Representative TEM images of different sections of myotubes incubated with SBA-
15 for 7 days, which did not show internalisation of SBA-15 which is desirable for this study as IGF1 













3.1.5 Nitrogen adsorption 
The analysis of the nanoparticle was done through an evaluation of the surface area and pores by 
nitrogen gas desorption and adsorption. The significance of this is that it is not possible for the blocked 
pores in the template to be loaded with the drug. Analysis of the surface area makes it possible to 
calculate the pore’s area and the amounts they can absorb. In the graphs below, the adsorption of the 
sample/desorption from SBA-15 and MCM-41 techniques is indicated. In this study, the adsorption 
confirmed that the gas had attached into the nanoparticles’ surface. Simultaneously, the adsorption 
conducted an analysis of the gas discharge from the nanoparticles. For Sample 1(MCM-41), 
adsorption and desorption result was 1199 m2/g, and for Sample 6 (SBA-15) it was 940 m2 /g. For 
Sample 1 (MCM-41), the pore size was 2.6-3.8 nm, and for Sample 6 (SBA-15) it was 5-9.     
Figure 3.7: The graphs illustrate the surface area and the pore size distribution analysis of the 







3.1.6 Size and zeta potential measurements (by Dynamic Light Scattering (DLS) 
Figure 3.8 (a & b) below illustrate the zeta potential and size of Sample 2 (MCM-41). Water was used 
to dilute the sample. The high poyldispersion index (>0.7) shows particle aggregation. The average 
aggregate size is 256 nm. The zeta potential of Sample 2 is indicated in Graph B. In order for a 
colloidal solution to attain stability, the zeta potential has to be >+30 or <-30. For this sample, the 
zeta potential is -21, which shows a slight degree of particle instability. The light scattering result is 
confirmation of such particle instability.       
      
  (a) Sample 2(MCM-41), the size was 256 nm                           (b) Sample 2(MCM-41), the Zeta potential was -21mv 
Figure 3.8 (a, b): Shows the size and the zeta potential of Sample 2 (MCM-41). This is 














Figure 3.9 (a, b, c, and d) represents the results for Samples 6 and 8 (SBA-15). It shows that the size 
measured by DLS was in the region of 623 nm and 1681 nm. Methanol was used to dilute the samples. 
Nano-porous rods samples 6 and 8’s zeta potentials for graphs b and d were measured. The results 
were -27 mv and 8.2 mv.  
 
        




             
  (c) Sample 8 (SBA-15) the size was 1681 nm                               (d) Sample 8 (SBA-15) Zeta potential was 8.2 mV  
Figure 3.9 (a, b, c, d): Shows the size, zeta potential measured by DLS for Samples 6 and 8 from 
(SBA-15) method. (a) Sample 6 (SBA-15): Size was around 623 nm. (b) Sample 6(SBA-15): Zeta 
potential was -27 mv. (c) Sample 8 (SBA-15): Size was 1681 nm. (d) Sample 8 (SBA-15): Zeta 
potential was 8.2 mV. 
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3.1.7 X-ray diffraction and FTIR 
Using a potassium bromide (KBr) disc, the FTIR spectra of each mesoporous particle were obtained. 
This is a technique made in such a way that it is able to detect the template in the pores. With the aim 
of determining the proportion of the hydrogen, nitrogen, and carbon in each particle, the elemental 
analysis was done using CHN analyser (PE- 2400ll; Perkin Elmer). From Figure 3.10, below, of 
(SBA-15) sample, it can be seen that the template Pluronic P123 triblock copolymer has been 
removed.  
 
                  
Figure 3.10: FTIR analysis of (SBA-15) sample to confirm the removal of the Pluronic P123 
template. This method designed to detect the template within the pores. Elemental analysis was 
performed to determine the percentage of carbon, hydrogen and nitrogen on each particle using a 
CHN analyser (PE- 2400ll; Perkin Elmer). The graph shows that the template (Pluronic P123 triblock 










From 0.3° to 70° 2θ, an analysis of the X-ray diffraction samples was done. A test kit obtained from 
Cambrex was used for conducting an endotoxin assay. This was done by mixing samples with the 
chromogenic substrate reagent and LAL reagent over a 16-minute incubation, and 408 nm was the 
reading of the absorbance. Figure 3.11, below, representing the results for (SBA-15) sample, indicates 
that it is possible for X-rays diffraction to access the structural and morphological data of the 
nanomaterials to conform the holes or pores in the NPs.     
 
              
Figure 3.11: Shows that the X-rays diffraction of (SBA-15) sample. This method was used to 
confirm the holes and pores in the NPs sample.The graph of sample (SBA-15) shows that the X-rays 
diffraction can access the morphological and structural information of the nanomaterials to confirm 
that there are pores or holes in the NPs.     













3.1.8 Release study of IGF-1 loaded into MSNPs 
 
 3.1.9  IGF-1 3D Structure 
The Protein Homology/analogy Recognition Engine V 2.0 was used to determine the 3D dimension 
and structure of IGF-1, (Phyre2,http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index). With 
the aim of making sure that the IGF-1 will be captured inside the pores, the IGF-1’s affinity to MSNPs 
was evaluated and the MSNP’s pore sizes were measured (Basyuni et al., 2018). From the Phyre2 
engine analysis, it can be seen that the highest IGF-1 3D dimensions for X, Y, and Z are 3.3, 4.0, and 
3.4 nm respectively. From this data, the SAB-15 stability for our project is confirmed, not just based 
on the fact that the sizes of the pores are big enough to absorb the IGF-1 but because they also have 
a big surface area this permits adequate amounts of IGF-1 to be loaded. 
 
 
Figure 3.12: Phyre2 engine analysis for IGF-1 3-D dimensions. This indicates that the highest 3D 








The surface of the MSNPs is positively charged, permitting for the electrostatical adsorption of 
negatively charged IGF-1 (0-100µg/ml) into the nanoparticles’ pores. When the drug is loaded into 
the nanoparticles, controlled pore diffusion is used to regulate the release. So, the IGF-1 protein 
should be uploading for 4 hours with 72 hours required to determine the time course of the IGF-1 
release. At intervals (2hrs, 6hrs, 22hrs, 48hrs & 72hrs), the sample was centrifuged, and the 
supernatant’s fluorescence was measured with the aim of estimating the discharge of the labelled 
IGF-488 from the MSN.  
The following experiment was conducted three times. Nanoparticles measuring 1.5mg were added to 
PBS measuring 1ml, and a rotator was used to mix these together for 15 minutes. IGF-1 was then 
added together with 13 µl of DyLight 488 NHS Ester. After a four hours, when the labelled IGF-1 
was measured to determine the loaded quantity of IGF-1, it was noted that only 8.1µg of the labelled 
IGF-1 was inside the nanoparticles. Results also showed that the release was at 0.75µg after two 
hours. However, no release was noted at higher intervals (6hrs, 22hrs, 48hrs & 72hrs).       
Based on the reason above, we attempted to gradually reduce the concentration of IGF-1 so that it 
ended up being 22.5 µg/ml with only 2.6 µl of the dye added. From the results, it was noted that 
10.6µg/ml was uploaded after four hours. However, the discharge differs slightly between 2 and 72 
hours. Detailed results are presented in Table 3.1.  
 






















Uploading after 4hrs 377 373 375 11.9 
Release 2hrs 221 232 226 -0.00 
Release 6hrs 256 268 262 0.11 
Release 22hrs 287 275 281 0.17 
Release 48hrs 271 271 271 0.14 
Release 72hrs 268 263 265 0.12 
72 
 
The result for the past experiment showed that around 50 percent of the IGF-1 concentration was 
uploaded after four hours. It was noted that the discharge was slightly different from 2 to 72 hours. 
Therefore, nanoparticles measuring 0.75 mg were added to PBS measuring 1ml, and a rotator was 
used to mix them together for 15 minutes. Following this, 12.5μL of IGF-1 was incorporated into the 
mix (NP+PBS+IGF). After mixing them together, the substances were placed in a rotator for four 
hours. This was followed by centrifuging the mixture for five minutes at speeds of 6000rpm, and the 
supernatant was measured. The result showed that (10.7μg/ml), which is around 85 percent of IGF-1 
concertation was uploaded inside the NPs after 4 hours. A 100 hour period is used to determine the 
time course of the IGF-1 discharge. At intervals of 2hrs, 4 hrs, 8hrs, 25hrs, 50hrs and 75hrs, 100hrs 
the sample was centrifuged. This was followed by measuring the supernatant’s fluorescence so that 
the IGF-1 discharge from the MSNP could be estimated. The results of this experiment are presented 
in Figure 3.14. These results show that from zero to eight hours, the discharge of the IGF-1 loaded to 
the nanoparticles was at a rate of 10-15 ng/ml. From 25 hours and above, an increase in the discharge 
to 48 ng/ml was noted. A further increase was recorded in 100 hours: 60 ng/ml.        
 









Concentration µg /ml 
A 0 0 0 0 
B 316 319 318 0.625 
C 561 613 587 1.25 
D 107 106 106 2.5 
E 198 190 194 5 
F 346 330 338 10 








Figure 3.14: Shows the loaded IGF-1 release profile. From zero to eight hours, the release was 
between 10 and 15 ng/ml from the MSNP. After 25 hours, the release of IGF-1 increased to 48 ng/ml 








Concentration µg/ml   
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3.1.10 MSNPs cytotoxicity and Biodegradation 
It is important that MSNPs that will be employed as a drug delivery system (DDS) show that they 
have very low or no proliferative or cytotoxic effects on the cells that are targeted. It is for this reason 
that in initial essays, we scrutinised the MSNPs' impact on cell proliferation and apoptosis. Results 
showed that cells that were cultured with MSNPs, MCM-41 and SBA-15, indicated matching levels 
of death and S-phase entry to untreated controls. Before the nanoparticles are used in tissue culture, 
clinical environment, or animal models, it is important to determine cytotoxicity. From the flow 
cytometry analysis, it was noted that the data between untreated and treated SBA-15 cells was non-
significant after three days in culture. SBA-15 treated cells with varying concentrations of SBA-15 
MSNPs (200 µg, 400 µg and 800 µg) produced 12%, 10%, and 9% dead cells respectively. From the 
untreated cells, 10 percent of dead cells were recorded, which matches the results of the cells that 
were treated.      
 
Figure 3.15: Shows cells cultured with MSNPs (MCM-41 and SBA-15). These cells revealed 














3.1.11 Analysing SEM to confirm NPs biodegradability 
 
To evaluate biodegradation, SBA-15 MSNPs and MCM-41 was cultured only in DM for 14 days. 
From the results, it was indicated that there is a limited degree of biodegradation, irrespective of the 
concentration of NPs.   
 
   
 (a) Sample1 MCM-41 after the first week of incubation       (b) Sample 6 SBA-15 after the first week of incubation 
Figure 3.16 (a, b): Illustrates the biodegradability following Week 1 of incubation with DM.  
 
               
(a) Sample 1 MCM-41 after the second week of incubation     (b) Sample 6 SBA-15 after the second week of incubation 









Figure 3.18 (a, b, c), below, shows the SEM analysis of Sample 6 (SBA-15). The images indicate 
the biodegradability following three months of incubation with methanol/water in varying 
temperatures. This is an exercise aimed at conforming the optimal condition to keep our NPs for 
extended periods. The results show a slight difference. However, it can be concluded that the best 
conditions can be obtained by keeping the sample in menthol at room temperature.   
   
         
     (a) Kept with methanol in -20C               (b) kept with water at -20C                    (c) kept with methanol at RT 
Figure 3.18 (a, b, c): Illustrates SEM analysis of Sample 6 (SBA-15) biodegradability after three 
months incubation with methanol/water in varying temperatures to confirm the optimal condition to 



















In this chapter, a definition of the stability and toxicity of MSNPs was completed and confirmed that, 
the SBA-15 mesoporous silica nanoparticles are better at retaining IGF-1. Over the past years, 
MSNPs and skeletal muscle have been managed separately. However, it has been gradually realised 
that the use of nanotechnology as a novel method of delivering drugs is required. This is the idea that 
was applied in this study which examines how the proliferation skeletal muscle stem cell is affected 
by MSNPs (Mamaeva et al., 2013). The use of this method is driven by the aim of this research which 
is to obtain a comprehension of the effects MSNPs on the myoblast proliferation of the human skeletal 
muscle. The eventual objective behind these efforts is to develop a system for the treatment of skeletal 
muscle cell using IGF-1. It also aims to grow IGF-1 bioactivity periods through a safe and effective 
delivery mechanism that uses MSNPs to reduce the wasting of skeletal muscle and other linked 
conditions.  
With regards to cytotoxicity, the nanoparticles shape and size, together with MSNPs concentrations, 
have a vital role to play. There is confirmation that a decrease in the size of particles corresponds with 
an increase in cytotoxic effects (Pasold et al., 2015). An analysis of available research shows that 
there are not many studies focusing on the effect of nanoparticles formed from numerous sources of 
cell proliferation and function. The studies become even fewer when one considers the effect of 
nanoparticle size and shape on cellular proliferation and function. Conclusions have shown that 
nanoparticles and cells collaboration could be a result of the shape of particles. In this regard, it has 
been noted that nanoparticles that have an aspect ratio that is minor influence proliferation and 
function to a lesser measure, a situation that is opposite to the nanoparticles that have an aspect ratio 
which is bigger (Huang et al., 2010). The reason behind the scenario discussed in the above paragraph 
is that the nanoparticles employed in this research are rod-shaped, and those MSNPs have been seen 
to be easily absorbed through the endocytosis. This is a situation that differs when one looks at 
alternative nanoparticles with shapes that are different. It is likely that this will have an impact on the 
cell’s viability and function in addition to their proliferation (Gupta & Gupta, 2005). Even though 
nanoparticles that are spherical in shape are not likely to be easily endocytosed by cells, they still can 
have an effect on the proliferation and function of cells through circulating in the blood for extended 
periods as a lesser level when comparison is made to nanoparticles that are rod-shaped (Huang et al., 
2010). As a result, it has been noted that nanoparticles that are spherical in shape tend to be more 
biocompatible and deliver more appropriate delivery of blood when working together with 




It has been shown that the size of MSNP impacts the proliferation of cells (Huang et al., 2010). The 
development of cellular signalling is altered in connection with the size of nanoparticles. It is for this 
reason that a size range of between 2 and 200 nm could affect the SkMC proliferation and viability. 
Nevertheless, the most noticeable impacts are emphasised in the size range of MSNP between 40 and 
50 nm (Jiang et al., 2008). Other research has come to the conclusion that for a nanoparticle size of 
50 nm, there is a confirmed cells uptake which leads to cell function distribution and repressed 
proliferation (Lu et al., 2009). When the oxide nanoparticle pore size is large (for instance, 200nm), 
the impact on cell proliferation is low because this lessens cellular uptake. On the other hand, when 
the size of the pores is smaller (for instance 50nm), there could be a constraint in the growth of lung 
fibroblast cells, a situation which decreases the viability of such cells. In lung fibroblast cells, size 
showed the biggest effect, constraining the growth of cells and lessening their viability (Limbach et 
al., 2005). From the data, it can also be noted that the MSNP pore construction has an effect on cell 
proliferation. For instance, the supreme interface with SkMC was noted in the absorbent construction 
in that it is long-term controlled, a situation that upset proliferation and prompted apoptosis (Lin & 
Haynes, 2010).  
The use of MSNPs in the treatment of cells in relation to injury, wasting, and other disorders like 
cancer is vital because they can function as a way of delivering drugs that is safe. This makes it 
possible to deliver anti-cancer drugs that are toxic, like doxorubicin (DOX). (Zhu et al., 2011; 
Kempen et al., 2015). It has been concluded from studies that DOX shows fluorescence, while the 
presence of apoptosis is noted in situations where nanoparticles deliver DOX to the site of the tumour 
(Lee et al., 2011). Added to this, it has been shown by some studies that nanotechnology could be a 
useful solution in therapy because it could have the capacity to convey other molecules like protein, 
antibodies, peptides, and plasmids (Lim et al., 2012). 
Nanoparticles could be valuable when it comes to delivering drugs based on DNA. Hence, such drugs 
tend to have a short-half life, which means that cells do not freely embrace them as a result of their 
negative charge. Added to this, they have reduced nuclear access, together with their levels of 
translation and transcription. This situation results from intracellular degradation following cellular 
uptake (Mamaeva et al., 2013). The role of nanoparticles is to maintain the required particles which 
are important for the delivery of genes. At the present moment, the delivery of genes depends on viral 
vector use (Kempen et al., 2015). There is now knowledge to the effect that plasmids are not just 
uploaded into SBA-15’s mesopores. However, research conclusions have shown nanoparticles 
enclosed with the common gene transfection agent polyethyleneimine (PEI) and produced a cationic 
surface to which the DNA and siRNA concepts were enclosed (Xia et al., 2009). The hosts are minute 
membrane-resistant proteins which are delivered into cells inside a transmembrane carrier which is 
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efficient and has huge pores (Slowing, Trewyn & Lin, 2007). Hence, macromolecules can be 
delivered through nanoparticle-based methods in addition to small drug molecules (Slowing et al., 
2008).      
      
 
3.3 Conclusions 
From the results presented in this study, a decision was made to use SBA-15 mesoporous silica 
nanoparticles for my project because they have a big pore size and surface area which permits 
adequate amounts of IGF-1 easily. It can be inferred that the SBA-15 can be employed for purposes 
of controlling the discharge of IGF-1 in new systems of delivery, which is used to boost IGF-1 
bioactivity. With the development of nanotechnology applications in the medical field, it is vital to 



























The human insulin-like growth factor-1 (IGF-1) gene introduces numerous, assorted mRNA 
transcripts via an amalgamation of several transcription instigation sites, alternative splicing, and 
distinct polyadenylation signals. Such IGF-1 mRNA transcripts provide coding for numerous 
isoforms of the original peptide of IGF-1 (IGF-1Ea, IGF-1Eb and IGF-1Ec or MGF in human skeletal 
muscle) that also experience alteration following translation. Focus in the effect of IGF-1 isoforms 
and differential expressing in the regulation of the hypertrophy and regeneration of muscle fibre 
following damage and mechanical overloading has been growing. One of the eye-catching 
developments in the framework of the IGF-1 autocrine/paracrine actions is the identifying a locally 
expressed, loading- or damage-sensitive IGF-1 isoform in skeletal muscle (Philippou A et al., 2007).  
The idea is that the competing procedures of cellular proliferation and differentiation, together with 
the escalation in the synthesis of protein needed for hypertrophic adaptation or repair of damaged 
muscle are controlled by differential expression and by specific roles played by IGF-1 isoforms 
(Philippou et al., 2007). 
The loss of skeletal muscle as a result of ageing, ischemia, degeneration of motor neurons, heart 
failure, and cancer is a grave condition which has no effective cure at the moment however exercise 
and nutritional intervention could help for instance, modern research recommends that substantial 
physical exercise offers an outstanding motivation concerning the re-establishment of SkMC, and 
exercise has also been documented that growth factors show more significantly diverse expressions 
of proliferation throughout the following muscle repair and subsequent hypertrophy than normal 
(Armakolas et al., 2016). IGF-1 has an important role to play in the maintenance and repair of the 
muscle (Song YH, et al., 2013). From pre-clinical studies, it has been concluded that IGF-1 has the 
effect of boosting muscle strength and mass, lessening degradation, and constraining the protracted 
and extreme inflammatory process which results from toxin injury. It has been shown to have the 
effect of boosting satellite cells’ proliferation potential (Song YH, et al., 2013). Also, IGF-1 has 
proved to be a robust neurotrophic factor, redeeming neurons from apoptosis and facilitating neuronal 
myelination and growth. Added to this, IGF-1’s signalling pathway plays a profound role in the 
expansion of cancer. Hence, efforts to prompt this pathway for the purposes of therapy are currently 
progressing. A comprehension of the instruction and function of IGF-1 structure is going to be vital 
for both basic and clinical applications (Bentov & Werner, 2013). This is an issue that can be resolved 
by the selection of suitable peptides of isoforms, and then creating targeted delivery methods (Song 




This study aims to use IGF-1 to create a treatment solution for the skeletal muscle cell. It will also 
seek to expand IGF-1 bioactivity duration through a safe and effective system for delivering drugs 
through nanotechnology to proficiently distribute IGF-1 to skeletal muscle cells with the aim of 
lessening skeletal muscle wasting and other conditions linked to it. This aim will be realised through 
the following objectives.      
1. Optimising the concentration of IGF-1 to be employed in skeletal muscle cell culture to 
maintain cell viability and growth  
2. Examining the properties of IGF-1 with MSNPs on the proliferation of skeletal muscle, its 

























4.1.0 Impact of IGF-1 on skeletal muscle myoblasts (C25) 
For a period of 24 hours, C25 was grown in a plate with six wells at a density of 1.5x105 cell/ml. DM 
was used to treat the cells after 24 hours. A comparison of the IGF-1 concentrations that follow 
compared with DM treatment only: 10 ng, 20 ng, 40 ng, 80 ng and 160 ng (this concentration was 
doubled each time to see the effect of IGF-1 on the cells and the significant difference between them). 
The treatment using DM only was used as a negative control so that the impact of IGF-1 on 
differentiation and proliferation could be validated. At a period of 96 hours following IGF-1 and DM 
cell treatment, morphological studies were done. The aim was to see if the IGF-1 had an influence on 
the C25 myoblast differentiation or proliferation. The images of the cell treatments where taken at 96 
hours using a live cell imaging system microscope (Leica DM I6000 B). A magnification x20 and 
scale of 100 µm was used in capturing all images. For all the treatment schedules, the morphological 
differentiation and proliferation were evaluated across microscopic fields (in each microscopic view). 
C25, which was treated with DM only, showed myotubes with normal differentiation (Figure 4.0A). 
Relative to the myoblast proliferation, the myotube formation was dominant at 96 hours. In those 
cells were 10 ng IGF-1 was the treatment (Figure 4.0B), the results indicated myotubes that dominated 
the observed fields. On this basis, it could be said that the presence of differentiation decreases 
proliferation. The proliferation ratio was highlighted using the proliferation marker Ki67. It is 
concluded that this mark was low in instances where the concentration of IGF-1 was also low.  
The second concentration used for IGF-1 was 20 ng and the results, just like 10 ng IGF-1, indicated 
that large differentiation myotubes dominated the microscopic fields, while the Ki67 marker was 
seldom detected (Figure 4.0C). For IGF-1 40 ng, the same results were observed with regards to 
proliferation and differentiation. In this instance, low Ki67 was noted for differentiated myotubes 
(Figure 4.0D). With the aim of measuring the substantial variation in myotube differentiation between 
various IGF-1 concentrations, the myotube area, fusion index, and aspect ratio were quantified. The 
experiments were repeated several times and five images were used for each treatment to calculate 
the averages for myotube area, fusion index and aspect ratio. From these calculations, substantial 
differences were noted in the area of myotubes at 96 hours between the negative control and IGF-1 
in low concentrations in C25 cell treatment (control= 53% vs. 10 ng IGF-1= 77.4% (p =9.96), and 20 
ng IGF-1 = 75.2%). Nonetheless, it is noted that at 40 ng IGF-1, the value of the myotube area what 
marginally lower (at 56.2%). A substantial variance was noted (p = 0.31) (Figure 4.3). Added to this, 
there were significant differences for various concentrations when one looks at the fusion index as 
presented in percentage. In this case, the negative controls value was 71.6% while the 10 ng IGF-
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1fusion index was 82.4% with a substantial variance to the control (p = 0.006). For 20 ng IGF-1, the 
value was 80.6% and no significant difference was noted (p = 0.007) (Figure 4.4). An analysis of the 
aspect ratio at 96 hours indicates a slight difference. In that case, 3 represents the negative control. 
For 10 ng IGF-1, the value was 4.6 (p = 0.01), 20 ng IGF-1 had a value of 4 (p = 0.14), and 40 ng 
IGF-1was 2.4 (p = 0.02) (Figure 4.5). 
   
When the concentration of IGF-1 was high, it was observed that proliferation happened without 
differentiation. While proliferation was noted when concentrations of IGF-1 were 80 ng and 160 ng, 
extremely small or no amounts of myotubes were identified. However, it was noted that there was 
cell growth. As can be seen in the images, the marker of proliferation, Ki67, was noted more in 
instances when concentrations were higher in the presence of proliferation (Figure 4.1). With the aim 
of measuring the growth of cells, fusion index, myotube area, and aspect ratio where quantified. The 
results showed that there were substantial variances in myotube differentiation when compared to the 
negative control. When IGF-1 concentrations were high, significant differences were presented by 
myotube area in contrast with the negative control. From the results, it can be noted that the myotube 
area, when the treatment area is 80 ng IGF-1, stands at 20.2% (p = 9.50E-05). For area 160 ng IGF-
1 (p = 0.0001), the value is 17.4% (Figure 4.3). There were significant differences noted in the fusion 
index measurement: 80 ng IGF-1 delivered a result of 34.8% (p = 2.75E-05) and 160 ng IGF-1 brings 
up a fusion index of 32.2% (p = 0.0008) (Figure 4.4). For the aspect ratio, significant differences were 
also observed:  80 ng IGF-1 showed a result of 0.8 (p = 0.005) and 160 ng IGF-1 was 0.9 (p = 0.0041) 
(Figure 4.5).  
 
    






     
Figure 4.0: Representing low concentration IGF-1 cell treatment. From the images, it can be seen 
that the differentiation of C25 in DM occurred at 96 hours; (A) C25 differentiated in DM (negative 
control); (B) C25 treated with 10 ng IGF-1; (C) C25 treated with 20 ng IGF-1; and (D) C25 treated 
with 40 ng IGF-1. MHC, Ki67, and DAPI were employed for the purpose of staining all images. The 
proliferation marker is indicated using the pink arrow while the MHC-stained myotube is shown using 
the blue arrows, with numerous nuclei inside stained with DAPI (blue). A magnification x20, n=5 
and scale of 100 µm scale was used when capturing all the images.  
 
     
Figure 4.1: Illustrates treatment of cells with IGF-1 in high concentration. From the images, 
results for high IGF-1 concentration and DM-treated C25. Image A shows results for 80 ng IGF-1-
treated C25 and B shows the results for 160 ng IGF-1-treated C25. MHC, Ki67, and DAPI are used 
for staining the images. The proliferation marker Ki67 is indicated by the pink arrows (red dots), 
while the MHC-stained myotube size is indicated by the blue arrows and the DAPI-stained nuclei 










4.1.1 Impact of IGF-1 and MSNPs on skeletal muscle myoblasts (C25) 
 
When the cells were treated with 0.75 mg/ml SBA-15 (MSNPs), it can be seen that the nanoparticle 
did penetrate the myotube. Nonetheless, it is also noted that there were no substantial differences 
observed with regard to differentiation. It is for this reason that large and clear myotubes can be seen 
(Figure 4.2A), with the quantity of the red dots (Ki67) being small. When compared to the negative 
control, it can be noted that the myotube area percentage was a little higher at 54% (p = 1.73). At 
71.2%, the fusion index was a little lower, showing no significant difference (p = 0.83). An aspect 
ratio of 2.8 (p = 0.74) was also slightly lower (Figure 4.5).  
 
Nonetheless, 0.75 mg/ml MSNPs and 10 ng IGF-1 was used to treat the cells; a higher level of 
differentiation could be seen (Figure 4.2B). For each condition, the fusion index, myotube area, and 
aspect ratio were calculated (Figures 4.3 -4.5). The results show distinct significant differences 
between the cells treated with IGF+ NP in low concentration and the control. The calculations indicate 
that the myotube area is higher than it is in the negative control. A proportion of 83.4% (p =0.0001) 
represents the myotube area, a significant difference. At 95.4% (p = 0.0002), it can be noted that the 
fusion index was also high. An aspect ratio of 5.6 is also higher than the negative controller with 
significant value (p = 0.006). Immunofluorescent images captured using primary antibody Ki67 with 
Texas Red®-X staining and DAPI nuclear counterstain, Alexa Fluor-488-MyHC were employed for 
the purpose of measuring the myotube area, fusion index, and aspect ratio.   
 
     
Figure 4.2: Illustrates treatment of cells with IGF-1 and MSNPs (SBA-15). Image A shows 0.75 
mg/ml MSNPs (SBA-15)-treated C25 at 96 hours. Image B shows MSNPs (SBA-15) and 10 ng IGF-
1-treated C25. MHC, Ki67, and DAPI are used for staining both images. The proliferation marker 
Ki67 is indicated by the pink arrows (red dots), while the MHC-stained myotube size is indicated by 
the blue arrows and the DAPI-stained nuclei (blue). A magnification of x20, n=5 and a scale of 100 






Figure 4.3: Presents a graph showing the myotube area as demonstrated in percentages in the 
cell treatment area for each condition with negative control included. For each condition a One-
way ANOVA and Bonferroni's Multiple Comparison Test was performed. The graph shows that there 
is a significant difference between cells treated for each condition however, in this graph it compares 
and highlights the significant differences between cells treated with 10ng IGF-1 and cells treated with 
NPs +10ng IGf-1 only, which is (** denotes P<0.001).The calculation of the myotube area is done 







































Figure 4.4: Illustrates the fusion index which is presented in percentages in the cell treatment 
for each condition, with the negative control included (DM only). Error bars are shown to 
represent ± SD. For each condition, a One-way ANOVA and Bonferroni's Multiple Comparison Test 
was performed.The graph shows that there is a significant difference between cells treated for each 
condition however, in this graph it compares and highlights the significant differences between cells 
treated with 10ng IGF-1 and cells treated with NPs+10ng IGf-1 only, which is (** denotes 
P<0.001).The computation of the fusion index was done as follows: (total number of the nuclei in 






































Figure 4.5: Graph representing the aspect ratio for each cell treatment condition, including 
negative control (DM only). Error bars are shown to represent ± SD. For each condition, a One-way 
ANOVA and Bonferroni's Multiple Comparison Test was performed. The graph shows that there is 
a significant difference between cells treated for each condition however, in this graph it compares 
and highlights the significant differences between cells treated with 10ng IGF-1 and cells treated with 
NPs +10ng IGf-1 only, which is (** denotes P<0.001). The calculation of the aspect ratio was done 
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4.1.2 Ki67 proliferation marker  
The ratio of proliferation to differentiation is highlighted using the proliferation marker Ki67. The 
computation of the Ki67 numbers was obtained for each condition from the five images. This made 
it possible to compute the average quantity of Ki67 markers for each cell treatment. Hence, the 
significant difference was obtained using the T-test, and the standard deviation was computed for the 
purpose of attaining the significant differences. As can be seen in Figure 4.6, the average number for 
the negative controller is 2. For 10 ng IGF-1, the average number is 1.4, with no significant difference 
when compared to the negative control (p = 0.2). When 20 ng IGF-1 is used as the treatment, 1.8 
becomes the average, and no significant differences were observed. The number for 40 ng IGF-1 was 
a little bit higher at 3 (p = 0.14).  With regards to higher IGF-1 concentrations, significant differences 
can be noted as levels of proliferation were higher, and differentiation was lower. When treatment 
was done with 80 ng IGF-1, the average number was 11.4 (p = 0.0005). The average number 
dramatically escalated with 160 ng IGF-1 21.25 (p = 0.001). For this level of treatment, almost the 
whole field contained proliferated cells. For C25 treated only with 0.75 mg/ml SBA-15, the average 
number was 2.4, and there was a significant difference when compared to the control (p = 0.0037). 
For the cells treated with 10 ng IGF-1 and 0.75 mg/ml SBA-15, the observed average number was 1 
(p = 0.034), considering that almost no Ki67 marker was observed because of the big dominance of 








Figure 4.6: Presents the Ki67 markers. In the graph, each cell treatment condition, including the 
negative control (DM) is presented. Error bars are shown to represent ± SD. For each condition 
performed, the One-way ANOVA and Bonferroni's Multiple Comparison Test was performed. The 
graph shows that there is a significant difference between cells treated for each condition however, 
in this graph it compares and highlights the significant differences between cells treated with 10ng 



















In this chapter, optimising the concentration of IGF-1 was employed in skeletal muscle cell cultures 
to maintain cell viability and growth, as well as the impact of IGF-1 on differentiation and 
proliferation is validated at a period of 96 hours following IGF-1 and DM cell treatment, 
morphological studies. Notwithstanding the fact that there are several studies emphasising the role 
played by IGF-1 in the process of muscle repair, numerous studies have shown that there is a link in 
the differentiation process by activating the adipogenic and osteogenic genes expression pattern in 
mesenchymal stem cells. As human mesenchymal stem cells (hMSCs) are organised by IGF-1, there 
is a reduction of the expression of osteogenic genes and an increase in adipogenic genes. This is a 
process that allows for the adipogenic differentiation while inhibiting osteogenic differentiation, a 
situation linked directly with the healing of wounds. From studies, it has also been concluded that 
IGF-1 in neochondrogenesis facilitating the differentiation of rabbit MSCs regarding chondrocytes in 
the application of the PI3 K/AKT (Armakolas et al., 2016). As a result of the transforming growth 
factor 3 (TGF-3), in the hMSCs, chondrogenesis is triggered. Contemporary studies advise that IGF-
1 has the ability to act in synergy with TGFβ-3 enclosed in silk fibroin scaffolds to embolden 
chondrogenic differentiation and chemotactic homing of hMSCs (Armakolas et al., 2016).  
Depending on the concentration, there is a significant increase in TGFβ-3 (up to 2 times), in 
combination with IGF-1. It has also been observed that aggressive discharge of TGFβ-3 and enlarged 
collagen II facilitate the chondrogenesis of hMSCs. On the other hand, silk fibroin scaffolds with 
IGF-1 and TGFβ-3 made use of more CD29+/CD44+ cells and showed more extracellular matrix 
resembling cartilage and lower levels of fibrillary collagen in connection with TGFβ-3 adapted 
scaffolds. The research proposes that the IGF-1 concentration motivation is linked to the SkMC re-
establishment. It has also been recognised that there is a link between hypertrophy and the 
proliferation expression (Armakolas et al., 2016; Tong et al., 2015; Jing et al., 2018).  
The results produced by this study indicate that SkMC is significantly impacted by low concentration 
of IGF-1. Between the low concentration IGF-1 in C25 cell treatment and the negative control, there 
were significant differences noted in myotube area. In the meantime, with regards to myotube 
proliferation, myotube development was dominant. Results for 10 ng IGF-1 treated cells (Figure 
4.0B) produced differentiated myotubes that had significant differences with regard to fusion index, 
myotube area, and aspect ratio with the C25 negative control. It is also illustrated by the IGF-1 release 
analysis that this was the most suitable concentration to be employed with regards to nanotechnology. 
Hence, it is seen as the most appropriate method for uploading nanoparticles. Notwithstanding the 
fact that 20 ng is not advisable for use in nanoparticle treatment, it indicated big differentiated 
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myotubes dominating the microscope fields while the Ki67 marker was hardly detected (Figure 4.0C). 
The same results were shown by IGF-1 40 ng with regards to proliferation and differentiation. 
Nonetheless, there were some significant differences noted. On this basis, it is not advisable to use 
IGF-1 40 ng in studies involving nanotechnology (Figure 4.0D). From the statistical analysis, it can 
be noted that there is no significant difference between IGF-1 concentrations of 10 ng and 20 ng. 
However, there are slightly lower significant differences with the IGF-1 40 ng concentration.  
It has been recognised that IGF-1 overexpresses skeletal muscle cells at high concentrations. This is 
because proliferation seems to occur when there is no differentiation. This study analysed two IGF-1 
high concentrations (80 ng and 160 ng). Both these concentrations indicated high proliferation. As a 
result of the absence of differentiation, myotubes were seldom observed. As can be seen from the 
images, the proliferation marker Ki67 was more noticeable when proliferation was higher, and 
proliferation was present (red dots) (Figure 4.1). As a result of the effect it has on cell expression, 
IGF-1 plays an important role in cancer where it has been linked to the facilitation of proliferation 
and an escalation of metastatic capacity in numerous cancers. In contexts of overexpression, IGF-1R 
or the insulin receptor's isoform A prompt some reaction. However, cancer cell proliferation is 
inhibited by their downregulation. IGF-1’s oncogenic properties connection with cancer results in the 
development of antibodies when compared to IGF-1R and IGF-1, even though the effect is 
insufficient. This is due to the activation of downstream pathways (to a considerably more minor 
degree than IGF-1) when the anti-IGF-1R antibody binds to IGF-1R. For that role, targeting some 
main effects of the IGF-1R is considered based on their results in cancer when used together with 
anti-IGF-1R antibody or on its own (Armakolas et al., 2016).  
The contributory role of other factors like the IGF-1Ec isoform has been proposed, more recent 
studies, to have a link to precancerous or cancerous conditions. It has been suggested that there is a 
link between IGF-1Ec expression and stage and grade in cancer. For instance, IGF-1Ec 
overexpression is connected to human prostate cancer (PCa) tissues and in prostatic intraepithelial 
neoplasia (PIN). Nonetheless, normal prostate tissue and prostatic epithelial cells have not been seen 
to have IGF-1Ec. Besides, unlike IGF-1, the exogenous controlling of artificial Pec, IGF-1Ec COO-
terminal comprising the last 24 amino acids, which is lacking in IGF-1 that is mature, inspires PCa 
cell growth and triggers ERK1/2 phosphorylation without unsettling Akt phosphorylation.  
Once INSR or IGF-1R is stopped, the result of PEc on PCa is maintained. This implies that the Ec 
peptide technique is implemented across GF-1R, INSR and IGF-1R/INSR hybrid receptors 
independent use. From reports on genetic overexpression, it can be noted that IGF-1 does have an 
effect on making muscle regeneration simpler after injury. This observation approves it as a molecule 
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with potential for use in the treatment of muscle injuries. On the other hand, IGF-1’s short half-life is 
approximately 12 hours (Lammers et al., 1989) however, it was found to be 10–30 minutes in (Pan 
and Kastin , 2000; Hammers et al., 2012) together with potentially harmful systematic possession has 
lessened the beneficial presentation of the molecules. It was the aim of this report to appraise the 
curative potential of the delivery of IGF-1 in an environment that is safe and regulated, making use 
of appropriate IGF-1 concentration and a nanotechnology platform being used for drug delivery when 
treating skeletal muscle (Hammers et al., 2011). For this study, only 0.75 mg SBA-15 (MSNPs) was 
used for the treatment. The results indicated that nanoparticle was absorbed in the myotube. However, 
the presence of big clear myotubes indicated that there were no big differences noted with regards to 
differentiation (Figure 4.2A). This is indicated by the low quantity of red dots (Ki67). Considering 
the fact that a nanoparticle does not have the capability to deliver vital significant differences for cell 
treatment, it is important that IGF-1 plays the role of the cell treatment for muscle wasting and muscle 
injury. However, introducing IGF-1 is aimed at raising or facilitating chondrogenic differentiation 
since IGF-1 is a growth factor and has been employed to facilitate the link between chondrocytes to 
extracellular matrix proteins. It also controls prechondrocytes proliferation.  
IGF-1 is an important contributor in preserving the reliability of cartilage and matrix production. 
However, when IGF-1 is overexpressed, it can trigger differentiation and hypertrophic mineralisation. 
It is on this basis that an organised and safe delivery of biomolecules across the process of recovery 
is important if adverse results are to be prevented. As is the case with other growth factors, IGF-1 has 
a short half-life. This implies the importance of closely managing them as opposed to systematically. 
For this study, it has been shown that the introduction of low concentrations of IGF-1 (10 ng), together 
with drug delivery SBA-15 at a concentration of 0.75 mg results in the upgrading of local, and 
constant delivery of IGF-1 to skeletal muscle cells. To achieve a long-term and organised local 
stimulation of cells when applied medically, MSNPs, together with growth factors, are employed in 
the delivery (Pasold et al., 2015).  
For this experiment, huge differentiated myotubes were observed in morphological studies in addition 
to observation of myotubes in shorter time with this large size. For this study, the nanoparticles used 
were kept outside the SkMC (C25) cell membrane for targeting drug distribution to the cell 
membrane. Nonetheless, this study has shown that it is possible to adopt nanoparticles into the cells 
through endocytosis, and cell movement variations, resulting in reduced proliferation (Huang et al., 
2010). A similar set of results to those of the experiment was produced in a study by Tsukahara and 
Haniu (2011). The results showed that IGF-1 and nanoparticles facilitated skeletal muscle myoblast 
differentiation while simultaneously inhibiting myogenic proliferation (Chen et al., 2012; Tsukahara 
& Haniu, 2011). The regulatory factors myogenin and MyoD regulate the transformation from 
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proliferating satellite cells to differentiated skeletal muscle cells (Yamane et al., 2000). An analysis 
of mesoporous silica-collagen hybrid nanoparticles cultured with skeletal muscle cells indicates an 
up-regulation in the expression of myogenin and MyoD, leading to augmented skeletal muscle cells 
differentiation into terminally differentiated myotubes that do not have the capacity to return to the 




From the results presented in this study, it can be noted that the optimal IGF-1 concentration that 
induce myoblasts differentiation for use with MSNPs is 10 ng. It is at this level that differentiation is 
boosted and proliferation reduced. When SBA-15 was introduced, differentiation was noted at 10 ng, 
20 ng, and 40 ng. On the other hand, it has been noted from the study that high IGF-1 concentrations 
result in reduced differentiation as proliferation escalates. In high concentrations, Ki67 markers (red 
dots) were observed. This implies that Ki67 plays the role of a proliferation marker. For a drug 
delivery system that is efficient, it is a requirement that the MSNPs are biocompatible, possess 
skeletal muscle tissue specificity, and the release of the drug molecules if they are released are in a 



















Chapter 5: Generation, Characterisation and Functional assessments of 




The neuromuscular junction (NMJ) is a dedicated site that connects a motor neuron’s axon’s terminal 
to skeletal muscle. As the structure that makes it possible for a neuron to transmit a chemical or 
electrical signal to another neuron, the integrity of the NMJ is vital for moving the motor neuron 
signals which trigger the contraction of the skeletal muscle. The majority of diseases and the ageing 
of the skeletal muscle can be connected to the impairment in NMJ function and the connected wasting 
of the muscle (Liu & Chakkalakal, 2018). Neuromuscular Junctions also play the role of being a 
platform for the skeletal muscle and nerves to interact. It contains a presynaptic motor neuron 
terminal, a postsynaptic motor endplate, and a synaptic cleft. The structure for the formation and 
maintenance of NMJs relies on the back and forth molecular interface between the motor neuron and 
muscle (Zahavi et al., 2015).Co-dependent tissues motor neurons and skeletal muscle rely on each 
other for successful transmission/stimulation and trophic support (Delbono, 2003). Motor neurons 
and skeletal muscles synthesize IGF-1 (Delbono, 2003). The resulting IGF-1 signalling plays an 
important role in the formation of the neuromuscular junction as shown by Caroni and Becker (1992). 
Neuromuscular junctions become active as they form while at the same time motor neurons stop the 
production of GAPs (Caroni and Becker, 1992), which correlate highly with the skeletal muscle 
decreased production of maturational IGF-1. IGF-1 levels decrease as people age considering there 
is concomitant endplate loss and existing motor endplates decreased innervations (Messi and 
Delbono, 2003), which may make the transmission of impulses problematic. Age-related changes can 
be reversed successfully with overexpression of IGF-1 in skeletal muscles. The process can also 
sustain neuromuscular junction complexity successfully the required innervation and subsequent 
transmission of signal impulses (Messi and Delbono, 2003).  
NMJ importance in NM disease has been shown in many studies on amyotrophic lateral sclerosis 
(ALS). Most research has shown that NMJ is one of the earliest yet detectable signs of the condition. 
There have been observations that NMJ insults are closely linked to the disease progression rather 
than the death or loss of MNs (Murray et al., 2008; Fischer et al., 2004; Gould et al., 2006). The 
degeneration of NMJ has been an important aspect in studying NM diseases that have not been 
thought of such as diabetes that is associated with many types of peripheral neuropathy as one of the 
commonest NM complications (Bril, 2014). Methods to study NMJs degeneration’s contribution to 
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the aetiology of NM disease are non-existent.  Most of the in vivo models that have been developed 
to study NM disease are animal models that are limited as they cannot replicate diseases in human 
beings adequately (van der Worp et al., 2010). In vitro models have a similar challenge as they use 
cells derived from animals (Haase, 2006; Prather et al., 2013). In addition, in vitro human SkMC 
monolayers NM models do not provide functional innervations necessary for the formation of NMJ 
and advanced muscle differentiation (Suuronen et al., 2004; Ashby et al., 1993; Wilson and Harris, 
1993). The pathogenesis of NM disease can be enhanced by techniques that can successfully 
manipulate NMJs. Such methods must consider the importance of SkMC innervations and formation 
of NMJs in differentiation, maturation, and function of SkM. Such techniques may provide an 
important platform for testing potential NM disease therapies in human beings.   
Mouse, rat, primary human myoblasts, human induced pluripotent stem cells (hiPSCs)-derived cells, 
human embryonic cells, and cross-species systems muscle co-culture models have been proposed as 
some of the best solutions to this challenge (Umbach et al., 2012; Arnold et al., 2012; Demestre et 
al., 2015; Guo et al., 2014; Harper et al., 2004). These proposed systems have the major challenge of 
inadequate experimental reproducibility due to the intricate culture system that needs neutrophiric 
and growth factors. Common culture media additions include animal serum, foetal calf serum, or 
foetal bovine serum (FBS) because they include y-globin and strong promoting driver (Ferruzza et 
al., 2012). However, there are serious ethical and scientific concerns for use of serum but it remains 
an important supplement of cell culture media (Brunner et al., 2010).  In addition, there are technical 
disadvantages as the resident molecules increase the chances of contamination (Hadwe, 2009). At the 
same time, there are concerns that the serum collection process in animals makes them suffer, which 
raises ethical issues about their use (Riebeing et al., 2011). The concerns have made some researchers 
desist from using the approach. The division has had a negative impact as the number of studies is 
much less characterised by lower reproducibility.   
These ethical concerns have led to the development of alternative chemical components for 
mammalian cell lines and primary cultures. Manufacturers must determine the appropriate medium 
formation, which is usually time consuming (Brunner et al., 2010). The serum used in classically 
established nerve-muscle co-culture systems (Giller et al., 1973; Nelson et al., 1993; Li et al., 2001; 
Daniels et al., 2000; Dutton et al., 1995) has indeterminate variables that arise because of the serum 
composition variation that leads to lower experimental reproducibility that may affect the 
experimental treatments on the system. These conditions make the addition of serum to a co-culture 
for the generation of NMJs in vitro impractical. Moreover, there are suggestions that serum in co-




Recently, our research group developed a novel entirely human NMJ platform using hESCs-derived 
neural progenitor cells (NPCs)-transfected with green fluorescent protein (GFP) and human myoblast. 
The aim of the current chapter was to use GFP transfected-NPCs (previously generated in our lab) 
and myoblasts to replicate Abd Al-Samid’s model (Abd Al-Samid’s et al., 2018), which was 
characterised using specific differentiation markers for motor neurons and myoblasts. To further 
verify that this NMJ model behaving physiological and muscle contraction is motor neuron-driven, 
NMJ model was manipulated using pharmacological drugs to pre- and post-synaptic NMJ agonist 






















5.1 Results  
 
5.1.0 Neural progenitors cells (NPCs) Expansion 
Recently established an in vitro human co-culture (nerve-muscle) model in a serum-free/neural 
growth factor-free defined medium (Abd Al Samid et al., 2018). The model develops functional NMJs 
rapidly to elicit muscle contraction. The model is established using human embryonic stem cells 
(hESCs, shef3) derived NPCs and immortalised human myoblasts engineered. Neural progenitor cells 
(NPCs) derived from hESC differentiate into motor neuron in the co-culture myoblasts and are also 
named NPC passage 1(P1) that can be stored in liquid nitrogen to allow future studies. The cells can 
be passaged from P1 to P10 depending on the gestation period taken. Passage P1 or P2 being used 
extensively in many experiments throughout my PhD studies. They are usually removed from the 
liquid nitrogen a week before they can be used in a study. During this week, NPCs were cultured in 
laminin coated T25 flask with NEM media to induce proliferation to ensure that enough number of 
NPCs for the experiments were obtained. The cells that remained were cryopreserved in a 1 mL 90% 
fetal bovine serum (FBS) suspension and 10% Dimethyl sulfoxide (DMSO) (NPC P2). One cryovial 
taken from the liquid nitrogen was cultured in laminin coated T25 flask that included NEW media to 
start the proliferation process (Figure 5.0).  Following the expansion of NPCs which are committed 
cells for motor neuron differentiation, their neural linage differentiation was confirmed using the 
Nestin-antibody specific marker for NPCs (Figure 5.1A). Some of the NPCs were transferred together 
with GFP-reporter lentivirus system (Figure 5.2). This step was followed by incubation of human 
myoblasts with GM in a period of 24 hours at 37°C within a 5% CO2 environment in 6-well plates. 
Thereafter, there was a replacement of muscle differentiation media (co-culture media). The 
concentration of NPCs was 25 x 103/ml, which was incubated for up to 7 days at 37°C within 5% 
CO2. After myogenic differentiation was initiated, the characteristics of functional motor units began 
to develop. This included myotube formation and axonal sprouting from the NPCs which 











Figure 5.0: Neural progenitors cells (NPCs) Expansion. Neural progenitor cells expanding in 
suspension in NEM media, NPCs were observed at a Microscope Leica DMI6000B live. Image A 




                  
Figure 5.1: Representative images for neural progenitor cells identification. Image (A) 
immunohistochemistry staining for NPCs, using Nestin antibody (red) and DAPI for nucleus staining 
(blue). Scale bar =100µM. Image (B) representative of the MN and NMJ formation in co-culture 









5.1.1 Morphology characterisation of the established NMJ platform  
There was morphological co-culture assessment in day 1, 3, 5, and 7 after NPCs were plated with 
myoblasts using immunohistochemistry as shown in figure 5.2. Phalloidin (red), and nuclei with 
DAPI (blue), and NCPs transfected with GFP (green) were used to stain the myotubes. The fusion of 
myotubes was little after 24 hours as they showed multi and mono-nucleated myocytes' 
characteristics, which was an indication that differentiation was at the initial stage while NPCs did 
not show any differentiation signs such as neurite growth (Figure 5.2 day 1). The successful 
differentiation of NPCs leads to the sprouting of neurites and expansion over myotubes and myocytes 
in which more fusion was observed, which shows that there was multinucleated myotube formation 
(Figure 5.2 day 3). Obvious myocytes-to-myotube differentiation started and expansion of neurite 
growth expanded further in day five as shown in (Figure 5.2 day 5). Further expansion of neurite 
growth and progressive maturation of myotubes were observed in day seven (Figure 5.2 day 7). The 
neuronal axon terminals started having visible connections with the myotubes (Figure 5.2 day 7) 
while the first spontaneous contractions in individual myotubes were observed on the seventh day. 
These factors are an indication that immortalised human myoblasts were fully differentiated and 































Figure 5.2: A representative images for the developing of NMJ model using NPCs-GFP and 
human myoblasts. This figure illustrates the differentiation of NCPs into mature motor neurons (left 
panel) and myoblasts into advanced differentiated myotubes (middle panel) and overlay (right panel) 
from day 1, 3, 5 and 7. The myotubes were stained for actin with phalloidin (red), differentiated motor 








5.1.2 Axonal growth measurements  
Images were captured on days 1, 3, 5, and 7 to assess neurite growth in the co-culture (see section 
2.1.23).  NPC neurite elongation of the axonal length was measured using the Leica microscope 
micro-meter option. The neurite outgrowth increased from (32±3µM) in day one to (91±9µM) in day 
seven, which underscores that there was high motor neuron differentiation.   
 
 
Figure 5.3: Neurite outgrowth in co-culture. This graph shows the axonal length in co-culture from 
day 1 to 7. Leica microscope measurement tool was used to assess the axon outgrowth, which 

















5.1.3 Spontaneous Muscle contraction 
 
Early contractions that do not have any external stimuli were observed in myotubes on the seventh 
day after the co-culture of NPCs with C25. Co-cultures with robust motor neuron differentiation 
innervated with the myoblasts to produce advanced and differentiated myotubes that had a form of 
contractile function when the atmospheric conditions were at 37°C with a 5% CO2. (Figure 5.4) 
Functional motor units’ characteristics developed after the initiation of myogenic differentiation. 
Some of the observations included myotube formation and axonal sprouting from the NPCs that lead 
to the formation of NMJs on the myotubes. Myotubes got spontaneous muscle contractions after the 
seven days without exogenous chemical and electrical stimuli (Figure 5.4). The force of the 
contractions made some myotubes to detach from the culture plate, which created large spaces in the 
co-culture. The myotubes cultured did not detach from the culture plate as they did not contract. These 
findings suggest that myotubes’ contractions are single motor units that receive stimulation bursts 
from MNs. There were also some innervations points on myotubes in this stage. The distinction was 
the higher spontaneous contractile activity in myotubes co-cultured with motor neurons.    
 
 
Figure 5.4: Phase contrast video micrograph of immortalised human myotube contractions at 
Day 7. Demonstrative video 1 of NPCs co-cultured in DM showing spontaneous contracting in serum, 






5.1.4 Characterisation of NMJ co-cultures 
Assessment of motor neuron formation was completed on the seventh day using the βIII-tubulin 
motor neuron differentiation marker.  Mature motor neurones have axons terminating on myotubes 
as shown in Fig. 5.5. The formation of cholinergic motor neurons was confirmed using 
acetyltransferase antibodies (ChAT, a key enzyme for acetylcholine biosynthesis), which is shown in 
green in Fig. 5.6 (Young et al., 2003). The two images (Fig. 5.5 & 5.6) show mature differentiated 
myotubes with the nuclei in the periphery.  
NMJs usually have acetylcholine receptor (AChR) clusters along myotubes that were assessed using 
alpha-bungarotoxin (α-BTX) staining and can be identified as the red clusters as shown in Fig. 5.5 & 
5.6. Motor neuron axons serve the myotubes with nerves that lead to the formation of NMJ as marked 
with α-BTX (red) (Young et al., 2003). Spontaneous myotube contractile activity was confirmed on 
the seventh day. 
  
 
Figure 5.5: Characterisation of functional neuromuscular junction formation on Day 7. A 
representative image showing an individual motor neuron axon terminal interacting with an 
acetylcholine receptor cluster in culture. The co-cultures were stained for β-III-tubulin (green), α-








Figure 5.6: Characterisation of motor neuron formation on Day 7. A representative image 
showing the co-cultures were stained with ChAT (green), α-bungarotoxin (BTX) (red) and DAPI 
















5.1.5 Functional Assessment of NMJs with α-Bungarotoxin (α-BTX)  
 
Myotube contraction cessation can be shown with the reversible and irreversible AChR inhibitors 
application such as bungarotoxin (Umbach et al.,2012; Guo et al., 2011). This study’s experiments 
were done with C25 co-cultures to study the NMJs functional responses to biochemical intervention. 
The objective was to determine whether NMJs generated in vitro in the co-culture reflected the SkM 
paralysis observed in vivo. A dilution of 1:400 α-BTX (10nM) was added to the co-culture 
(Santhanam et al., 2018) to ensure the induction of postsynaptic AChRs permanent blockade. The 
most appropriate time to conduct it was the seventh day when peak spontaneous contraction 
frequency (CF) could be observed.  The baseline CF was measured 30 seconds prior to the application 
of α-BTX, which showed that there were no significant differences in baselines CF between the 
positive (0.711 Hz ± 0.024) and negative controls (0.720 Hz ± 0.025), (P =0.42) before the treatment. 
Contraction of the myotubes stopped in the control and α-BTX-treated myotubes after the addition of 
treated and untreated diluent to the cultured cells. CF in the control decreased to 0.477 Hz ± 0.011 
after fifteen minutes but there was no contraction of myotubes in co-cultures treated with α-BTX. 
The contraction in the untreated control was at 0.438 Hz ± 0.018 while no contraction was observed 
in the α-BTX after twenty minutes. The contractions in the control increased to 0.572 Hz ± 0.015 
after 30 minutes but there was no activity in the α-BTX treated co-cultures. Further contraction 
occurred after 45 minutes (0.705 Hz ±0.014) and an hour 0.900 Hz ±0.014 in the controls while there 
were no contraction observations in the α-BTX treated cells. Control and BTX co-cultures were 
washed after which there was an addition of fresh DM at 1 hour and 35minutes which led to the 
cessation of contractions in the two. The two concentrations had similar contractions after 30 minutes 
with a baseline 30 minutes after washout (2 hours after the initial application of treatment) frequency 
of 0.633 Hz ± 0.008. A similar observation was made 24 hours after treatment with CF in the control 
being 0.606 Hz ± 0.12. There were no observations of contractile activity in the α-BTX treated co-









Figure 5.7: Assessment of the functional effects of 1:400 of 10nM α-Bungarotoxin (α-BTX) on 
co-cultured myotubes. A line graph comparing the contraction frequency (CF) of myotubes treated 
with α-BTX and untreated controls (There were no significant differences between them). The graph 
shows that the contractions had stopped completely in the myotubes treated with α-BTX and also 
stopped in the controls and α-BTX-treated myotubes at the time 0 and after wash at 1.35h. Data is 














5.1.6 Functional Assessment of MNJs with L-Glutamic Acid 
Past nerve-muscle co-culture models used in the application of excitatory neurotransmitters such as 
L-glutamate to stimulate MNs that result in contraction of myotubes have been used to demonstrate 
NMJs functional assessment. The experiment that followed aimed to show the impact of presynaptic 
agonist stimulation on MNs. The excitatory neurotransmitter glutamate, in the form of 400 µM L-
glutamic acid (Smith et al., 2013) was used to assess the impact of L-Glut on the CF of co-cultured 
myotubes in the co-cultures (Figure 5.8). The CF baselines measurements were recorded 30 seconds 
before L-Glut application to the positive controls and untreated diluents to the negative controls in 
which there were no significant differences (0.749 Hz ± 0.003 vs 0.756 Hz ± 0.003, P = 0.148 ). The 
addition of treatment solutions to the culture leads to the cessation of contraction immediately after. 
The measurement of CF after 15 minutes after treatment application shows that the myotubes in the 
L-Glut treated cultures have a CF 0.106 Hz ± 0.003 (P < 0.0001), which was much higher compared 
to the controls (0.069 Hz ± 0.004).  L-Glut treated co-cultures had a significantly higher CF of 1.463 
Hz ± 0.033 compared to the control’s 0.141 Hz ± 0.004. The CF of the myotubes was 0.780 Hz ± 
0.014 in the controls after 30 minutes, which was an indication that it was the baseline. At the same 
time, the myotubes in the L-Glut treated cultures contracted at 2.305 Hz ± 0.033 with P < 0.0001, 
which is 1.5 Hz more than in the controls. The myotubes in the L-Glut co-culture had a CF of 0.690 
Hz ± 0.018 while the controls had a CF of 0.700 Hz ± 0.014 after 45 minutes following treatment. 
The two cultures had CFs of (0.711 Hz ± 0.017 vs 0.775 Hz ± 0.004, P = 0.002) after one hour and 
(0.760 Hz ± 0.004 vs 0.803 Hz ± 0.006, P < 0.0001) after one and half hours.  Washout and 
replacement of the DM after 1.35 hours after the first treatment led to the stoppage of the contractions 
in the two cultures. The two cultures had similar contractions 30 minutes after the washout (0.691 Hz 
± 0.010 vs 0.735 Hz ± 0.005, P = 0.001) when compared to the baseline. The control and L-Glut 
treated cultures had similar CF of (0.750 Hz ± 0.004 vs 0.702 Hz ± 0.006), which was indicative of 





Figure 5.8: Assessment of the functional effects of 400 µM L-glutamic acid on co-cultured 
myotubes. A line graph comparing the contraction frequency of myotubes treated with L-glutamic 
acid and untreated controls.The graph shows that the contractions have significantly increased in the 
myotubes treated with the L-glutamic acid comparing with the controls. The contraction of the 
myotubes stopped in the controls and treated myotubes with L-glutamic acid at the time 0 and after 
wash at 1.35h. Data is presented as a mean, error bars signify ± SD.  n = 10 independent experiments. 














In this chapter, the generation, characterisation and functional assessments of neuromuscular junction 
were confirmed that in addition, the modulation of myotube contractile activity using the NMJs 
manipulation with presynaptic MN agonists and postsynaptic AChR antagonists was successful. 
Studying operational motor units is important in understanding the pathophysiological characteristics 
of NMJ disorders are common in major neurological diseases and older age. Recently, our research 
group developed a novel entirely human NMJ platform using hESCs-derived neural progenitor cells 
(NPCs)-transfected with green fluorescent protein (GFP) and human myoblast. The aim of the current 
chapter was to use GFP trafeceted-NPCs (previously generated in our lab) and myoblasts to replicate 
Abd Al-Samid’s model (Abd Al Samid et al., 2018), which was characterised using specific 
differentiation markers for motor neurons and myoblasts. The importance of understanding the 
behaviour of neurons in human beings is underscored by the rejection of animal models. The explants 
and SkMCs cellular interaction would be better stipulated by replicating in vivo interactions (Zhang 
et al., 2015). Although some animal models could show similar physiological changes that lead to 
disease in human beings, they are avoided. In vitro human cell and tissue cultures would be much 
better in the analysis of physiological changes that can lead to the formation of disease. In addition, 
such studies are more relevant, cost effective, and faster compared to animal models that involve 
more stages that increase costs and time needed to achieve the desired results.   
The use of the established functional nerve-muscle co-culture showed that there were muscle 
contractions after some time. Spontaneous differentiation of NPC nerve cells was in serum free 
media. The normal process involves platting NPCs on matrigel (50µl/cm2) to achieve orient terminal 
neural stem cell differentiation that can be observed in a period of four weeks. However, 
differentiation functional nerve muscle co-cultured as shown by Jasdeep occurred much faster with 
no additional regulation factors (Saini et al., 2019). Another similar human-based study with in vitro 
muscle co-culture had at least ten regulator factors, some of which included B27 and insulin growth 
factor (Guo et al., 2011) but there is a need for further categorisation and optimisation. The NPCs 
used in the study were from hESCs that differentiate in the order neuroepithelial stem cells, neural 
stem cells, and into NPCs. Neuroepithelial stem cells can differentiate into neurons, oligodendrocytes, 
and astrocytes. Confirming the NPCs stem cells was done using the nestin antibody, which is a 
specific marker for NPCs.  
After the first contractions, the co-cultures were monitored every day and maintained with regular 
media changes to ensure that innervation and myotube maturation continued to achieve the desired 
level. The number of contraction per minute and an increase in the number of contracting myotube 
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was used to determine contraction frequency (CF). Large networks characterised by myotubes 
contracting in a systematic manner were observed by the seventh co-culture day (Figure 5.4). These 
findings suggest that myotube contractions were stimulated by MNs as a single motor unit. The co-
culture system has more benefits in studying NM and muscle wasting disorders compared to 
traditional myoblast monoculture models. Moreover, the large nerve networks provide a better 
platform to determine what happens during disease development and progression. However, 
aneurally cultured human myotubes did not contract spontaneously in culture. On the contrary, 
innervated myotubes in the co-culture system showed contractile functionality stimulated 
endogenously (Feher, 2017). 
The second objective of the experiment was to the physiological behaviour of NMJ and confirm that 
the spontaneous contractile activity of the myotubes was facilitated by MN signalling through NMJ. 
Therefore, NMJ assessment was done by analysing the myotube CF modulation while using agonist 
and antagonist pharmacological interventions that act on presynaptic MNs (L-Glut) or 
postsynaptically (α-BTX) on AChRs at the NMJ.  The addition of α-BTX ion the co-cultures led to 
the immediate and permanent ceasure of spontaneous myotube contractions. Therefore, AChRs 
binding at NMJ motor endplate (MEP) with α-BTX inhibits Ach from binding with the postsynaptic 
receptors, which leads to the paralysis in the co-cultured innervated myotubes. There was indefinite 
immobilisation of myotube spontaneous activity despite being washed out and reverted to normal 
culture conditions after exposure to α-BTX. It was demonstrated that NMJs generated in the study’s 
in vitro co-culture system was physiologically irreversible to competitive antagonist at the AChRs in 
vivo mammalian NMJ (Domet et al., 1995). Some studies have shown that receptors involved in 
muscle fiber membrane potential regulation through the nitric oxide synthase system (Urazaev et al., 
1995), rather than signalling at the NMJ despite glutamate receptor detection in mammalian NMJs. 
It was shown that myotube contraction frequency increased significantly when there was 
implementation neuron-specific excitatory neurotransmitter L-Glut in the investigation of stimulation 
of associated neurons in co-cultures. MN impact stimulation with L-Glut on myotube CF was 
observed immediately, which made myotube contractions to increase significantly (P < 0.0001) 
between 15 and 20 minutes while there was a greater increase of 1.5 Hz after 30 minutes. The 
myotubes CF returned to normal in 45 minutes after the stimulation of MN with L-Glut.  It is expected 
that SkMC membranes in mammals are stimulated through AChRs, which shows that there is a 
successful enhancement of myotube contractions in the co-cultures with the introduction of L-Glut, 
which is possibly achieved because of the increased Ach release from the MN cultured into the 
synaptic NMJs cleft.      
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5.3 Conclusion  
In summary, entirely human NMJ was replicated in which myoblasts differentiated into myotubes 
while NPCs differentiated into MN sprouted axons and branched to form multiple NMJ innervation 
sites on the myotubes. It was also determined that spontaneous myotube contractions in the co-
cultures were indeed driven by MN signalling through NMJs which was verified by responding 



















Chapter 6: Investigating the effects of slow release IGF-1 (IGF-1/NPs) on NMJ 





Previous chapters have shown how novel complete human nerve-muscle co-culture devoid of serum 
and trophic was established to induce spontaneous contractile activity in myotubes that have 
differentiated. The system’s formation of neuromuscular junctions (NMJs) was underscored by the 
co-localisation of the axons and acetylcholine receptor (AChR) clusters. This chapter investigates the 
effects of IGF-1/NPs on the NMJ model formation and function. The study is guided by the 
researcher’s findings that insulin-like growth factor 1 (IGF-1) can lead to the maturation and 
maintenance of neurons (Lewis et al, 1993). Another important finding was that some neurological 
disorders such as stroke may arise due to impaired IGF-1 signalling pathway (Lewis et al, 1993). 
IGF-1 action was mediated by type 1 IGF receptor (IGF-1R) binding proteins that regulate the 
bioavailability of the IGFs.  
IGF-1 therapy has shown varying therapeutic outcomes in the treatment of motor neuron diseases 
such as amyotrophic lateral sclerosis, neuropathy, and peripheral nerve injury (Caroni and Becker, 
1992). Functional repair of adult human beings central nervous system (CNS) is one of the major 
challenges in modern medicine. CNS traumatic injuries and neurodegenerative diseases usually lead 
to irreversible cognitive and/or motor functions loss as underscored by permanent disabilities (Dupraz 
et al., 2013). The main requirement to re-establish neural connections is the regeneration of the axonal 
and dendritic neurons to enhance normal CNS operations. The process through which axonal 
regeneration occurs is one of the major mechanisms of CNS development (Cui, 2006).    
 IGF-1 has an additional function of preventing choline acetyltransferase activity loss in embryonic 
spinal cord cultures and reducing programmed motor neurons death in vivo after spinal transaction or 
axotomy or normal development (Iwasaki and Ikeda, 1999). IGF-1 increased neuromuscular 
junctions’ numbers and maintains the normal muscle morphology.  However, positive nerve 
regeneration necessitates the local application of IGF-1, which is thought to be influenced by IGF-1 
acting on Schwann cells in the treatment of nerve injuries (Iwasaki and Ikeda, 1999). Motor axons 
develop muscle targets that are important in the development of neuromuscular junctions (NMJs). 
The changes that occur during the maturation of incipient synapses at the nerve-muscle contact sites 
include clustering of acetylcholine receptors (AChRs) in the postsynaptic muscle membrane and 
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synaptic vesicles that store and release ACh accumulate within the presynaptic nerve terminal (Sanes 
and Lichtman, 2001).  The changes at the two sites unsure that there is reliable synaptic transmission 
ate the NMJ and start the interaction with a muscle targets prevent the advancement of axon to trigger 























The aim of this study is to examine how slow release of IGF-1 (IGF-1/NPs) affects NMJ formation 
and function. The human immortalized myoblasts and human embryonic stem cells (hESCs)-derived 
neural progenitor cells (NPCs) were used to study its concept to enhance NMJ model development 


























6.1.0 The effects of slow release IGF-1 on NMJ function (myotube contractions) 
In the last chapter, NPCs were co-cultured with human immortalized myoblasts for 7 days in co-
culture media (Figure 6.0) approved and used as a control. Therefore, the following experiments were 
performed to confirm the effects of slow release IGF-1 on NMJ function (myotube Contractions) for 
7 days in co-culture media with adding NPs only (Figure 6.1), IGF-1 only (Figure 6.2), and slow 
release of IGF-1(IGF1/ NPs) (Figure 6.3). After the initiation of myogenic differentiation, functional 
motor units started to develop, including axonal sprouting from the NPCs formed along myotubes on 
NMJ and myotube formation. Myotubes were characterised by spontaneous muscle contractions 




Figure 6.0: Phase contrast video1 micrograph of young immortalised human myotube 
contractions at Day 7. Illustrative video 1 of co-cultured in DM only spontaneously contracting as 







Figure 6.1: Phase contrast video 2 micrograph of human immortalised myotube contractions 
at Day 7. Illustrative video 2 of co-cultured treated with NPs spontaneously contracting as a network, 




Figure 6.2: Phase contrast video 3 micrograph of human immortalised myotube contractions 
at Day 7. Illustrative video 3 of co-cultured treated with IGF-1 spontaneously contracting as a 






Figure 6.3: Phase contrast video 4 micrograph of human immortalised myotube contractions 
at Day 7. Illustrative video 4 of co-cultured treated with IGF-1/NPs spontaneously contracting as a 





















6.1.1 Contraction Frequency  
To ensure optimal innervation of co-cultured myotubes, the efficiency of NPCs to induce contractions 
in the co-culture system with DM only was used as a control to compare against myotubes co-cultured 
with NPs only, IGF-1 only and IGF-1/NPs. Optimal innervation of myotubes was quantified by 
analysing Contraction Frequency (CF) every 24 hours post co-culture for 7 days, using live phase 
contrast microscopy to assess 20 random fields of view at x10 magnification. The results revealed no 
observable myotube contractions in either DM (control), NPs, IGF-1 or IGF-1/NPs co-cultured with 
myoblast after the first 48 hours. Following 6 days of co-culture, initiation of myotube contractions 
were observable in the DM, NPs, IGF-1 and IGF-1/NPs co-cultures, contracting at a frequency of  
DM (0.55 Hz ± 0.18), NPs (0.58 Hz ±0.20), IGF (0.69 Hz ± 0.28) and  IGF/NPs (0.74 Hz ± 0.37). On 
day 7 the contractions were slightly higher in each condition for DM (0.59 Hz ±0.19), NPs (0.64 Hz 
± 0.23), IGF-1 (0.81 Hz ± 0.33) however the contractions were witnessed and increased CF further 
in slow release IGF-1 co-culture (0.96 Hz ± 0.47), which was significant (P < 0.0001) (Figure 6.4). 












Figure 6.4: Contraction frequency of myotubes co-cultured with different co-culture conditions 
over 7 days. A line graph comparing the onset of myotube contractions and contraction frequency in 
young immortalised human myoblasts co-cultured with neural progenitors cells in differentiation 
media only (green line), NPs only (black line), IGF-1 only (red line) and IGF-1/NPs (blue line) 
suspension over 7 days.The contraction frequency started from day 6. Data presented as a mean, error 

















6.1.2 Effects of IGF-1/NPs on motor neuron differentiation and axonal length 
During embryonic development, motor axons grow to their muscle targets and establish 
neuromuscular junctions (NMJs) (Sanes and Lichtman, 2001). Investigations conducted in the future 
using this model could detect the main factors discharged from the muscle and nerve to coordinate 
axonal sprouting, localisation, and maintenance of NMJ (Jensen et al., 2009). Although One-Way 
ANOVA statistical text was used to analyse the data below, the main comparison focused on IGF-1 
vs IGF-1/NPs. Therefore, the axonal length of differentiated motor neurons in vitro nerve-muscle co-
culture treated with NPs, IGF-1 and IGF-1/NPs were measured over 7 days using Image J (see section 
2.1.23 in the method and Figure 2.7). The degree of differentiation of motor neurons with regards to 
IGF-1 (12.5μg/ml) treatment, NPs (0.75 mg/ml) and IGF/NPs (12.5μg/ml + 0.75mg/ml) and DM as 
a control were stipulated using the measured axonal length (µM) at 24hr intervals. In the first set of 
analysis, the axonal length calculated on the first day was relatively different when compared to the 
differentiation measure obtained within 24 hours, which showed that there was no statistical 
significance. However, the axonal length of differentiated motor neurons was measured by using 
Bonferroni's multiple comparisons test  at each time point over the 7 days of co-culture for all 
treatments. The results showed that the axonal length was increasing over 7 days in all treatment but 
the highest axonal length with a greatest significant difference was in the co-culture with IGF-1/NPs 
added (P <0.0001), (Figures 6.5 – 6.12). 
 
On the contrary, the axonal length calculated on day-7 showed high variance with remarkable increase 
of axonal length indicated by the white arrows in Figure (6.5, 6.7, 6.9 and 6.11). All treatments 
showed significant differences from day 1 to day 7, but the IGF-1/NPs showed the highest axonal 
length (228.6M± 61.53) in day 7 when compared to the IGF-1 only and other treatments such as 
NPs and DM only. Lastly, the axonal length of differentiated motor neurons was measured at each 
treatment over the 7 days of co-culture.  The result showed that the axonal length was increasing over 
the 7 day co- culture period with a greatest significant difference in DM adding IGF-1/NPs compared 
to other treatments. The mean for IGF-1/NPs was (228.6M ± 61.53) compared to the control DM 
where the mean was (82.84M ± 13.98), the NPs mean was (90.20M ± 11.88) and when compared 
to the IGF-1 only, the mean was (158.8M ±41.59). The IGF-1/NPs presented significant difference 
with P value <0.0001 (Figure 6.13), which underscores co-cultured IGF-1/NPs are more effectual 




Figure 6.5: Shows the axonal growth in human myoblast co-cultured nerve cells for DM only 
at day 1 and 7. The image on the left displays the axonal growth at day one of culture. The image on 
the right displays the axonal growth at day seven of culture. Images were captured at x20 




Figure 6.6: Quantitative analysis of axonal length in human myoblast co-cultured in DM over 
7 days. This graph shows comparing the onset of axonal length in young immortalised human 
myoblasts co-cultured with neural progenitors cells in differentiation media only suspension over 7 
days. Data presented as a mean, error bars signify ± SD.  n = 4 independent experiments. 
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Figure 6.7: Shows the axonal growth in human myoblast co-cultured nerve cells for DM treated 
with NPs at day 1 and 7. The image on the left displays the axonal growth at day one of culture. The 
image on the right displays the axonal growth at day seven of culture. Images were captured at x20 




Figure 6.8: Quantitative analysis of axonal length in human myoblast co-cultured treated with 
NPs over 7 days. This graph shows comparing the onset of axonal length in young immortalised 
human myoblasts co-cultured with neural progenitors cells in differentiation media after treated with 





Figure 6.9: Shows the axonal growth in human myoblast co-cultured nerve cells for DM treated 
with IGF-1 at day 1 and 7. The image on the left displays the axonal growth at day one of culture. 
The image on the right displays the axonal growth at day seven of culture. Images were captured at 





Figure 6.10: Quantitative analysis of axonal length in human myoblast co-cultured treated with 
IGF-1 only over 7 days. This graph shows comparing the onset of axonal length in young 
immortalised human myoblasts co-cultured with neural progenitors cells in differentiation media after 





Figure 6.11: Shows the axonal growth in human myoblast co-cultured nerve cells for DM 
treated with IGF-1/NPs at day 1 and 7. The image on the left displays the axonal growth at day one 
of culture. The image on the right displays the axonal growth at day seven of culture. Images were 




Figure 6.12: Quantitative analysis of axonal length in human myoblast co-cultured treated with 
IGF-1/NPs over 7 days. This graph shows comparing the onset of axonal length in young 
immortalised human myoblasts co-cultured with neural progenitors cells in differentiation media after 
treated with IGF-1/NPs suspension over 7 days. Data presented as a mean, error bars signify ± SD.   







Figure 6.13: Quantitative analysis of axonal length comparisons between different co-culture 
conditions. This graph shows comparing the onset of axonal length in young immortalised human 
myoblasts co-cultured with neural progenitors cells in differentiation media after treated with NPs, 
IGF-1 and IGF-1/NPs suspension over 7 days. Data presented as a mean, error bars signify ± SD.       















The main finding of the generation, characterisation and functional assessments of neuromuscular 
junction (NMJ) platform study was consistent with the in vitro NMJ model discussed in the previous 
chapter. Therfore, the effects of slow release IGF-1 on NMJ formation and function were analysed, 
characterised and confirmed in this chapter. NPCs co-cultured with human immortalised C25 showed 
that cholinergic MNs co-localisation with differentiated myotubes that enhanced NMJs and myotubes 
interactions. Monitoring of the co-cultures was done every 24 hours after the first contractions were 
witnessed followed by maintenance with media regularly to enhance further innervation and 
maturation of myotubes. Co-cultures treated with slow release IGF-1 (IGF-1/NPs) showed higher 
myotube contraction frequency as defined by more contractions per minute and the higher number of 
myotubes. The myotubes were contracting systematically as large networks by the seventh co-culture 
day in figures 6.0, 6.1, 6.2 and 6.3), which affirmed that myotube contractions functioned as a single 
motor unit with MNs stimulation bursts. The IGF-1/NPs co-culture model has much more benefits 
compared to traditional myoblast monocultures in researching NM and muscle wasting disorders. The 
culture system’s innervated myotube showed signs of endogenously stimulated contractile 
functionality (Feher, 2017). The study showed contraction frequency in myotubes co-cultured control 
DM only, adding NPs, IGF-1, and IGF-1/NPs individually in a period of seven days. A line graph has 
compared onset of myotube contractions and contraction frequency in a co-culture of young 
immortalised human myoblasts and neural progenitor cells while adding NPs, IGF-1, and IGF-1/NPs 
in a period of seven days.  Initiation of myotube contractions was observed in all treatment cultures 
by the sixth day of co-culture but was slightly higher in different conditions. More contractions and 
CF increased significantly by the seventh day in IGF-1/NPs, which confirms that co-culture treated 
with slow release IGF-1(IGF-1/NPs) are much more enhanced compared to the IGF-1 due to its 
involvement in maturation and maintenance of neurons. IGF-1 signalling pathway has been 
determined to have an impact in the development of some neurological diseases such as stroke (Lewis 
et al, 1993). Motor axons usually grow muscle targets and establish neuromuscular junctions (NMJs) 
(Sanes and Lichtman, 2001). The future application of this model could help in detecting main factors 
discharged from nerves and muscles to coordinate axonal sprouting, maintenance of NMJ, and 
localisation (Jensen et al., 2009).            
The use of the term “sprouting” has been controversial. Ramon and Cajal (1928) referred “The 
innervation of the peripheral stump of cut nerves (occurs) through the growth, across the scar, of 
nerve sprouts arising in the central stump.” On the other hand, Liu and Chambers (1958) used 
“sprouting” to refer to growth that arises from an undamaged axon and maintains the growth of the 
central projections of intact dorsal root ganglion axons after adjoining roots injury. Repair neuron 
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programs are usually available for a short period after an injury and only remain effective if axons 
injured are provided a growth opportunity (Boyd and Gordon, 2003). Delayed reconstruction makes 
the growth associated genes to downregulate in which case the neurons die or become atrophic. The 
delay also leads to the impairment of the Schwann cell ability that usually supports regeneration 
(Sulaiman et al., 2002) and deterioration of denervated muscles (Boyd and Gordon, 2003). The axonal 
length of differentiated motor neurons in vitro nerve-muscle co-culture with human myoblast C25 
treated with IGF-1, NPs, and IGF-1/NPs and measured in a seven day period. The measurement was 
completed using axonal length (M) every day. The study found that the IGF-1/NPs had the highest 
axonal length and significant differences especially in the seventh day when compared to IGF-1 and 
other treatments. Although it had more effect on neuromuscular junctions, which confirms that they 
are more effective compared to IGF-1 and other treatments, the finding provides support to the 
bidirectional communication between the nerves and muscles that supports the formation of NMJ 
(Zahavi et al., 2015). The process is further enhanced by neural growth factors such as neurotrophic 
factors obtained from the brain and discharged by the muscle to ensure the formation, growth, and 
maturation of NMJ (Henderson et al., 1993; Funakoshi et al., 1995), which will be evaluated in the 
next chapter (7).         
 
6.3 Conclusion  
The data for this study demonstrated significant effects in morphology as observed in human 
immortalised myoblast co-cultured with NPCs over 7 days and especially in NMJs contraction and 
the axonal length of co-cultured motor neurons following treatment with IGF-1/NPs. The potent 
effect of the slow release of IGF-1 on the proliferation, differentiation, and survival of neurons make 












Chapter 7: Investigating the effects of Slow Release of IGF-1 on Bi-directional 





Growth factors and neurotrophin occurring endogenously play an important role in the development, 
function, plasticity, survival, and death of neurons in vivo (Oppenheim 1991; Reichardt 2006). 
However, exogenous growth/neurotropic factors introduction in alternative nerve-muscle co-cultures 
(Guo et al., 2011; Guo et al., 2014; Das et al., 2007; Puttonen et al., 2015; Rumsey et al., 2009)  can 
have a negative impact on drug screening and testing (Dugger et al., 2018). Therefore, there has been 
extensive research on the role of growth or neurotrophic factors play in the development and function 
of the nervous system. Some studies have indicated that the two play an important role in some cell 
populations such as SkMCs that has a perceived role in the expression of some growth factors, 
neurotrophins and cytokines. The finding indicates that SkMCs play an important role in neurotrophic 
signalling during formation, development, and innervation (Griesbeck et al., 1995; Gonzalez et al., 
1999 ; Chevrel et al., 2006). IGF-1 is a possible trophic factor or a molecule that enhance the survival 
of cells for motor neurons and muscle fibers (Florini et al., 1996). Skeletal muscle IGF-1 has a target-
derived neurotrophic impact on the survival of embryonic motor neurones (Neff et al., 1993) and 
innervation in muscles of aged animals (Messi & Delbono, 2003). Overexpression of IGF-1 improves 
motor neurone re-innervation in skeletal muscles after nerve injury (Rabinovsky et al., 2003). Further, 
the administration of IGF-1 improves re-innervation after nerve injury and hinders the death of motor 
neurone cell (Sjoberg & Kanje, 1989; Kanje et al., 1989; Li et al., 1994). The treatment of muscle 
mass and function loss as people age may be achieved using this system. Overexpression of IGF-1 
reduces muscle loss associated with older age (Barton-Davis et al. 1998; Musaro et al. 2001). The 
process also plays an important role in maintaining skeletal muscle-specific force (Gonzalez ´ et al. 
2003; Renganathan et al., 1998) and innervation of fibre in older mice.  Higher levels of IGF-1 have 
target-derived trophic effects on mature muscle innervation and maintenance of neuromuscular 
junction’s morphological integrity (Messi & Delbono, 2003; Barton-Davis et al., 1998). IGF-1 also 
regulates the genes involved in BDNF neurogenesis expression (Carro, 2001). IGF-1 binding proteins 
(IGFBPs) may improve or compromise IGF-1 activity depending on the cellular context (Murphy, 
1998). IGFBPs during brain development studies (Green et al., 1994; Bondy and Lee, 1993) indicate 
that the proteins play a role in NSCs. Neutrophin-4 (NT-4) and Neutrophin-4 (NT-5) null mice studies 
have clear muscle development and function defects, which shows that NT-4/5 play a role in the 
differentiation of SkM fibre (Carrasco and English , 2003). Neurotrophin-3 (NT-3) has been 
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important in muscle spindles formation (Ernfors et al., 1994) and pathologies of dystrophic muscles 
common in altered nerve growth factor (NGF) (Capsoni et al., 2000). Studies on the expression of 
brain-derived neurotrophic factor (BDNF) have indicated that there are many physiological and 
pathological conditions that have an impact on SkMC expression of BDNF (Chevrel et al., 2006). 
Research with human subjects living with multiple sclerosis has shown that circulating BDNF can 
increase as individuals engage in more physical exercises (Ferris et al., 2007;Vega et al., 2006; Gold 
et al., 2003). It has also been shown that exercising at least two hours using equipment such as the 
ergometer bicycle has been used to induce BDNF mRNA production in SkM (Matthews et al., 2010). 
SkM neurotrophin concentrations are compromised in denervated SkMCs. Decreased expression of 
NT-3 and NGF mRNA and increased expression of BDNF mRNA in muscle had been revealed in 
studies involving diabetic mice (Fernyhough, Diemel, Hardy, et al., 1995; Ihara et al., 1996; 
Fernyhough, Diemel, Brewster, et al., 1995; Fernyhough et al., 1998; Fernyhough et al., 1996). 
Overexpression of glial cell line derived niurotrophic factor (GDNF) is SkM is characterised by hyper 
innervation NMJs because of the increased MN sprouting (Nguyen et al., 1998). Some studies have 
shown that GNDF can maintain cholinergic MNs during the aging process (Ulfhake et al., 2000) and 
ensure transient expression of GDNF at NMJs during embryonic myogenesis as seen in vivo. GDNF 
expression also increases denervated human SkM (Lie and Weis, 1998)      
 
The human neural stem cells (NSCs) secrete IGF-1 that prolongs the lifespan of animals they are 
transplanted into by protecting dysfunctional motor neurons in amyotrophic lateral sclerosis models 
(Xu et al., 2006; Brain, 2007; Lu et al., 2003; Yan et al., 2004; Crigler et al., 2006). IGF-1 activates 
multiple downstream signal transduction pathways such as the transcription and epigenetic regulators 
that play a role in the regulation of expression genes during the neurogenesis process after binding to 
membrane receptors (Ming et al., 2011). Phosphatidylinositol 3-kinase (PI3K/Akt) and mitogen 
activated protein kinase/extracellular signal-regulated kinase (MEK/ERK) mediate these signalling 
pathways. The mechanisms allow sustainable neuron survival due to the good environment they 
provide (Pfrieger, 2009) for the proliferation and survival and differentiation of NSCs into motor 
neurons.  NSCs secrete NT-3, GDNF, BDNF, and NGF that increase neuron survival in vitro and in 
vivo models (Glia, 2009; Park et al., 2008; Lu et al., 2003; Yan et al., 2004). Experiments in the 
previous chapter investigated the effects of slow release of IGF-1 on the functionality of NMJs in in 
vitro co-culture model. Myotube contractile activity successful modulation through the slow release 
of IGF-1 is an indication that in vitro NMJ system is physiologically consistent with the in vivo 







NMJ’s interact with complex cytokines arrays and growth factors secreted by muscle and motor 
neurons to promote differentiation and the formation of NMJ and dictate their functions. This co-
culture model is probably the first that involves the neural growth factors. Therefore, all the factors 
required for NMJ formation and maturation, myoblast and motor neurons differentiation were 
endogenously secreted in the co-cultures. Considering IGF-1 signalling pathways are important in 
neurogenesis and myogenesis regulation, the aim of the chapter is to evaluate the way in which slow 
release of IGF-1 affect the bi-directional communication that occurs between the muscle and the 
motor neuron as well as the co-culture microenvironment (endogenously secretion of neurotrophic 
factors such as BDNF, GDNF, IGF-1 and NT‐3) in the process of NMJ formation. The hypothesis of 
the present study is that the growth factors that play an important role in enhancing the formation of 
NMJ are produced and secreted in co-culture cells as slow release IGF-1 avails a favourable 
regenerative microenvironment that can allow the formation of NMJ as well as the differentiation of 






























7.1.0 Quantification of endogenously secreted Growth and Neurotrophic Factors 
 
An ELISA-based microarray analysis of the growth/neurotrophic factor concentration followed by 
one way ANOVA statistical test was performed to determine whether the slow release of IGF-1 
impacts the secretion of growth/neurotrophic factors in co-cultured conditions (co-culture only, co-
culture with IGF-1, co- culture with NPs, and co- culture with IGF-1/NPs). Although the ANOVA 
test was conducted, the simplicity view of comparing NMJ treated with IGF-1 to those treated with 
IGF-1/NPs was undertaken as shown in the table below. Table 7.0 shows the quantified concentration 
of 40 growth/neurotrophic factors on the seventh day. The results indicate that four factors were 
significantly different (P<0.05) in varying co-culture conditions. BDNF, GDNF, IGF-1, and NT-3 
(Figure 7.1) concentrations were very high in co-cultures that had been treated with IGF-1/NPs 



































Table 7.0: ELISA-based microarray analysis of growth and neurotrophic factor in supernatant  
















AR 4.03 ± 5.27 1.61 ± 1.87 0.4 0.26 0.987 
BDNF 43.4 ± 7.8 91.8 ± 18. 3 2.1 0.02* 0.976 
bFGF 16.7 ± 7.5 5.7 ± 0.2 0.3 0.21 0.943 
BMP-4 5.35 ± 3.6 12.9 ± 4.75 2.4 0.09 0.961 
BMP-5 214.8 ± 244.6 400.3 ± 60.3 1.9 0.65 0.996 
BMP-7 1.9 ± 2.76 3.7 ± 3.1 1.9 0.77 0.994 
b-NGF 0.4 ± 0.5 0.24 ± 0.29 0.6 0.48 0.991 
EGF R 39.2 ± 1.6 39.5 ± 1.08 1.0 0.8 0.995 
EG-VEGF 0.3 ± 0.28 0.9 ± 0.56 3.0 0.35 0.986 
FGF-4 13.65 ± 7.6 35 ± 15.49 2.6 0.68 0.997 
FGF-7 1.53 ± .19 0 0 0.9 0.996 
GDF-15 228.3 ± 6.9 260.5 ± 8.71 1.1 0.12 0.999 
GDNF 4.7 ± 1.02 7.51 ± 8.7 1.6 0.02* 0.996 
GH 1.63 ± 0.95 5.81 ± 0.28 3.6 0.08 0.994 
HB-EGF 0.38 ± 0.15 1.0 ± 0.14 2.6 0.15 0.971 
HGF 68.25 ± 2.8 90.85 ± 33.2 1.3 0.79 0.991 
IGFBP-1 2.73 ± 0.4 2.6 ± 0.98 1.0 0.9 0.997 
IGFBP-2 1590.2 ± 765 1891 ± 945.01 1.2 0.11 0.999 
IGFBP-3 911 ± 1480 1014 ± 783 1.1 0.23 0.988 
IGFBP-4 1296 ± 319 1191 ± 11 0 0.54 0.999 
IGFBP-6 1331.6 ± 161.6 948.9 ± 149.9 0.7 0.45 0.987 
IGF-1 84 ± 8.4 1848 ± 424.82 22.0 0.002** 0.975 
Insulin 6438 ± 205 4796 ± 254 0 0.09 0.989 
MCSF R 2.33 ± 1.58 4.21 ± 2.2 1.8 0.98 0.991 
NGF R 144.1 ± 8.12 131.8 ± 0.91 0.9 0.38 0.987 
NT-3 1.4 ± .2 2.5 ± 0.4 1.8 0.0016** 0.997 
NT-4 2.8 ± 0.5 3.4 ± 0.62 0 0.9 0.999 
OPG 772 ± 37.7 852.7 ± 113.1 1.1 0.8 0.996 
PDGF-AA 818 ± 812.7 828 ± 613.4 1.0 0.91 0.996 
PlGF 137.3 ± 13 171.8 ± 29.89 1.3 0.07 0.987 
SCF 1.3 ± 0.2 1.28 ± 0.7 1.0 0.99 0.996 
SCF R 2.2 ± 0.2 1.66 ± 1.12 0.8 0.47 0.998 
TGFa 0 0.01 ± 0.04 0 0.51 0.889 
TGFb1 98.63 ± 197.3 15.71 ± 44.44 0.2 0.26 0.984 
TGFb3 0.3 ± 0.6 0.21 ± 0.46 0.7 0.78 0.979 
VEGF 60 ± 154.7 91.1 ± 105.9 1.5 0.8 0.963 
VEGF R2 4.78 ± 6.74 1.96 ± 3.51 0.4 0.35 0.999 
VEGF R3 4 ± 4.67 1.66 ± 1.92 0.4 0.23 0.991 












































Figure 7.1: Trophic factor quantification and comparison between different co-culture 
conditions. The above Figures illustrate comparisons in the levels of the trophic factors between 
different co-culture treatments. Data is presented as a mean concentration of the trophic factor in each 
condition with error bars signifying ± SD.  n=3 and represents the independent experiments/sample 
types from which the supernatant was collected. Four factors were significantly different, the BDNF 










In this chapter it’s determined and confirmed that the slow release of IGF-1 impacts the secretion of 
growth/neurotrophic factors in co-cultured conditions (co-culture only, co-culture with IGF-1, co- 
culture with NPs, and co- culture with IGF-1/NPs). The important IGF-1 growth factor plays a role 
in the regulation of muscle regeneration and neurogenesis. ELISA-based arrays was used in the quest 
to understand the way in which slow release IGF impacts the microenvironment that has soluble 
growth factors as well as differentiation factors and communication between muscle and motor 
neurons enhanced. The results were based on the comparison of quantitative measurement of 40 
human growth factors and neutrophils produced endogenously in NMJ culture treated with IGF-1 in 
vitro and endogenously produced factors treated with IGF-1/NPs co-cultured myotubes. Microarray 
experiments were used to determine the growth factors’ concentration to confirm that NMJs 
formation and development in co-culture systems were because of endogenous regulation of some 
growth or neurotrophic factors. The concentration of some of the factors like BDNF, GDNF, IGF-1, 
and NT-3 used in NMJ formation, MN maintenance, and myotube development was higher in IGF-
1/NPs treated co-cultures compared to the IGF-1 only.   
Motor neurons and skeletal muscles depend on each other for trophic support and synaptic stimulation 
and transmission (Aging Cell, 2003). IGF-1 (Aging Cell, 2003; LeRoith, 2008) and its receptors 
(Bedlack and Hardiman, 2009; Anastácio, 2006) are expressed by skeletal muscles and motor 
neurons, which underscores that the two cells communicate. Caroni and Becker (J Neurosci., 1992) 
found that IGF-1 plays a role in the formation of neuromuscular junction. Motor neurons usually stop 
the production of GAPs after the formation and action of the neuromuscular junctions (J Neurosci, 
1992).  
Data from the ELISA-based microarray indicated that BDNF levels increase significantly with slow 
release IGF-1 when compared to IGF-1 only (Figure 7.1A). IGF-1 that is involved in the expression 
of BDNF (McCusker et al., 2006) also enhances the regulation of BDNF-related neurogenesis 
(Pareja-Galeano et al., 2013).  The injection of IGF-1 has the same effect as exercise-induced BDNF 
expression in the hippocampus that is later accumulated in brain cells (Pareja-Galeano et al., 2013). 
Studies that have focused on the role of BDNF in NMJs development have shown that SkM-derived 
BDNF plays a role in SkM innervation, MN survival, and the transmission of NMJ (Zhang and Poo, 
2002; Yan et al., 1993). During embryonic development in vivo, high levels of BDNF are expressed 
by myoblasts and are gradually down regulated after NMJ and SkM fibre maturation (Griesbeck et 
al., 1995). Upregulation of BDNF led to synaptogenesis inhibition in the development of NMJs in 
vitro. These findings show that regulation of BDNF concentration endogenously in the presence of 
slow release IGF-1 co-culture system is instrumental in the formation and development of NMJs in 
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vivo. On the other hand, the inclusion of nerve exogenous BDNF in nerve-muscle co-culture systems 
(Das et al., 2010; Rumsey et al., 2010; Das et al., 2007; Guo et al., 2017; Guo et al., 2011; Guo et al., 
2014; Puttonen et al., 2015; Vilmont et al., 2016; Smith et al., 2016) may not lead to robust formation 
of NMJ expected in vitro because of the unsuitable exogenous BDNF concentrations that prevent the 
maturation of NMJs (Song and Jin, 2015) . 
 
IGF-1 slow release (IGF-1/NPs) increases GDNF levels unlike the cases in which a co-culture model 
is treated with IGF-1 only (Figure 7.1B). GDNF possibly provides postnatal motor neurons with 
neurotrophic or survival factors. A postnatal rat spinal cord slice model was used to evaluate whether 
there is interaction of IGF-1 and GDNF to increase the survival rate of motor neuron, the trophic 
effect on the activity of choline acetyltransferase (ChAT), and the possible impact they have on 
neurite growth (Bilak, 2001). The results show that there is a possibility that IGF-1 interact with 
GDNF to prevent chronic glutamate-mediated toxicity of the rat motor neurons while increasing their 
ChAT activity. It is important to note that IGF-1 does not enhance neurite growth in the model under 
study. These findings suggest that IGF-1 and GDNF interact and increase the chances of survival for 
the motor neuron.     
 
This chapter’s data shows that IGF-1 levels increased significantly in models in which the slow 
release of exogenous IGF-1 had been treated with IGF-1/NPs but such levels were not attained in 
cases in which treatment was done with IGF-1 only (Figure 7.1C). IGF-1 growth factor is thought to 
be an anabolic hormone that enhances growth throughout the human body and induces hypertrophic 
effects on SkM as it has been documented in muscle and animal cell culture models (Velloso, 2008). 
Muscle specific IGF-1 expression stabilises NMJs and enhances the survival of motor neurons 
(Dobrowolny et al., 2005). The injection of IGF-1 into SkM leads to the degeneration of MNs and 
NMJs that subsequently prevents age-related decline in mice (Payne et al., 2006). The concentration 
of IGFBP -1, -3, -4, -6 insulin-like growth factor binding proteins evaluated during microarray 
experiments with IGF-1 were higher in the co-cultures. The main function of IGFBPs is to serve as 
membrane transporter protein for IGF-1 as almost all IGF-1 bind to at least one of the seven members 
IGFBP Superfamily (Hwa et al., 1999). IGFBP-3 binds to ~80% of IGF-1 in circulation, which makes 
it the most common protein (Adachi et al., 2017). In addition, IGFBP was the most common in co-
cultures and monocultures compared to the other IGFBPs in the microarray experiment. Studies show 
that IGFBPs has an impact by increasing the bioavailability of IGFs in circulation (Stewart et al., 
1993). The upregulation of IGFBPs and IGF-1 confirms that ESCs and SkMCs in the co-culture 
system provides a favourable environment for the maturation of MN, differentiation of myofibres, 
and robust formation of NMJ in vivo formation.       
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The data in figure 7.1D show that there was a significant increase in NT-3 levels in co-culture systems 
treated with IGF-1/NPs compared to those treated with IGF-1 only. Studies on the effect of post 
traumatic IGF-1 administration on NT-3 in a focal unilateral penetrating brain injury showed that 
IGF-1 prevents the injury-induced changes in NT-3 and increases its concentration, which 
underscores that it can be used in repair and protective processes (Kazanis et al., 2004). The 
concentration of NT-3 also increased in the co-culture as compared to aneural myotube cultures. NT-
3 also modulates synaptic function for the development and maintenance of NMJ presynaptic and 
postsynaptic apparatus ( Belluardo et al., 2001; Gonzalez et al., 1999). Research on the early postnatal 
NMJ development and MN system deficient in mice models showed reduced somal size but the αMNs 
number were unaltered (Woolley et al., 1999). Additional research showed that there was less MEPs 
innervation by MNTs as well as a lower number of SkM fibres in NT-3 deficient mice at birth. The 
step that follows is a catastrophic postnatal loss of MNTs through postnatal development by the 
seventh day and full denervation of the muscles of the hindlimb that have no observable NMJ in the 
entire SkM endplate zones (Woolley et al., 2005). Further, haploinsufficiency-induced reductions in 
NT-3 in mice is characterised by MNT maturation, lower synaptic vesicle recycling, and reduced 
fibre diameter of SkM (Sheard et al., 2010). These findings may explain the data observed in the 
previous chapter which showed enhanced NMJ formation and function in co-culture treated with 
IGF/NPs compared to other treatments. 
            
 
7.3 Conclusion 
The report is an analysis of 40 human growth factors and neurotrophins concentration in vitro NMJ 
system. The higher concentrations of four factors involved in the development of MN, SkM and NMJ 
in a co-culture system with slow release IGF-1 were measured and showed that in terms of the higher 
concentrations of those four factors indicated, the NMJ platform observed in vitro behaved 










Chapter 8: General Discussion & Conclusions 
 
8.0 Discussion 
IGF-1 may have some impact on the proliferation, differentiation, and survival of muscle and neurons, 
which makes it a potential solution to diseases associated with the wasting of muscle conditions 
(Horst-Sikorska et al., 2013), ageing neuronal death and axonal damage, and MN diseases (Vincent 
et al., 2004). There have been attempts to apply IGF-1 in treatment of various conditions but only a 
few have included phase III human trials other than studies involving Amyotrophic Lateral Sclerosis 
(ALS). Injection of IGF-1 in ALS patients did not have any effects on them (Sorenson et al., 2008). 
Howe et al (2009) states that the negative impact may be because of low bioavailability of IGF-1 in 
brain parenchyma. Methods used to deliver IGF-1 have limited success due to the rapid depletion of 
local concentration, potency, bioavailability, and tissue response. The use of biodegradable polymeric 
systems leads to a localized and sustained growth factor that could address these challenges. IGF-1 
is not enough to reverse muscle atrophy in all motor neuron degenerative diseases.       
The main aim of this project was to develop a novel and simplified nerve-muscle co-culture with the 
addition of slow-release IGF-1 (IGF-1/NPs) system capable of generating functional in vitro NMJs, 
without the use of serum, growth, and/or neurotrophic factors. It provides a defined platform to 
investigate disease and disorders of the NM system through the examination of NMJ formation and 
functionality. In this report, a physical human motor unit platform produced by immortalised skeletal 
myoblasts and NPCs obtained from hESCs is described. Several objectives are behind the 
establishment of this unique platform. The fulfilment of this aim was first addressed through the 
optimisation size and shape of NPs. Therefore the first objective was to fabricate and characterise 
mesoporous nanoparticles (MSNPs). Experiments have also been done to determine the cellular 
uptake and cytotoxic influence of mesoporous particles on cells. As well as examining if the MSNPs' 
(MCM-41 and SBA-15) pore size was big enough to permit for loading IGF-1 into the MSNPs. 
Hence, to facilitate our suggested project, 19 samples of MCM-41 & SBA-15 monodispersed 
mesoporous silica particles were synthesised and conducted using the normal surfactant templating 
technique (Kresge et al. 1992). In Table 3.0, the characteristics of the NPs diameter, composition, 
porosity, and surface charge. Template molecule selection and reaction concentration conditions are 
the techniques employed in regulating the diameter and porosity. The application of configuration 
was done as soon as the particles were formed. This happened before acid extraction was used to 
remove the surfactant molecules, with the results being a well-organised and regular porous 
arrangement. With regards to cytotoxicity, the nanoparticles shape and size, together with MSNPs 
concentrations, have a vital role to play. There is confirmation that a decrease in the size of particles 
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corresponds with an increase in cytotoxic effects (Pasold et al., 2015). The eventual objective behind 
these efforts is to develop a system for the treatment of skeletal muscle cell using IGF-1. It also aims 
to increase IGF-1 bioactivity periods through a safe and effective delivery mechanism that uses 
MSNPs to reduce the wasting of skeletal muscle and other linked conditions. The second objective 
was to upload the IGF-1 in the mesoporous nanoparticles (MSNPs).Therefore the IGF-1 structure 
(3D structure) was studied first .The Protein Homology/analogy Recognition Engine V 2.0 was used 
to determine the 3D dimension and structure of IGF-1.With the aim of making sure that the IGF-1 
will be captured inside the pores of NPs, the IGF-1’s affinity to MSNPs was evaluated and the 
MSNP’s pore sizes were measured. From the Phyre2 engine analysis, it can be seen that the highest 
IGF-1 3D dimensions for X, Y, and Z are 3.3nm, 4.0nm, and 3.4nm respectively ( From this data and 
the information mentioned above, the two types of mesoporous silica particles were synthesised and 
fully characterised (MCM-41 and SBA-15) and then decided to use the SBA-15 stability for this 
project (which has been confirmed) because they have no cytotoxic effects on the cells and because 
the pore size of SBA-15 (5-9 nm) is big enough to absorb and fit the IGF-1 easily (3D dimention are: 
3.3nm, 4.0nm, 3.4nm). In addition, they also have a big surface area which permits adequate amounts 
of IGF-1 to be loaded when its compared to MCM-41. 
The following objective was to optimise the concentration of  IGF-1 to be employed in skeletal muscle 
cell culture to maintain cell viability and growth while also examining the properties of IGF-1 with 
MSNPs (SBA-15) on the proliferation of skeletal muscle, its existence, differentiation, and 
metabolism. For a period of 24 hours, C25 was grown in a plate with six wells at a density of 1.5x105 
cell/ml. Differentiation media (DM) was used to treat the cells after 24 hours. A comparison of the 
IGF-1 concentrations that followed were compared with control DM only: 10 ng, 20 ng, 40 ng, 80 ng 
and 160 ng. The treatment using DM only was used as a negative control so that the impact of IGF-1 
on differentiation and proliferation could be validated. At a period of 96 hours following IGF-1 and 
DM cell treatment, morphological studies were completed. Using DAPI, Ki67 (proliferation marker), 
and MHC (differentiation marker), together with immunohistochemistry, differentiation parameters 
were applied. The aim was to find out if the IGF-1 had an influence on the C25 myoblast 
differentiation or proliferation. The results confirmed that the optimal IGF-1 concentration for use 
with MSNPs is 10 ng. It is at this level that differentiation is boosted and proliferation reduced. When 
IGF-1/SBA-15 was introduced, differentiation was noted at 10 ng, 20 ng, and 40 ng. On the other 
hand, it has been noted from the study that high IGF-1 concentrations result in reduced differentiation 
as proliferation escalates. In high concentrations, Ki67 markers (red dots refer to the figure 4.1) were 
observed. This implies that Ki67 plays the role of a proliferation marker. For a drug delivery system 
that is efficient, it is a requirement that the MSNPs are biocompatible, possess skeletal muscle tissue 
specificity, and the release of the drug molecules are released in a controlled fashion. This will ensure 
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a concentration for IGF-1 (12.5μg/ml) and NPs (0.75mg) is effective. The next objective was to 
investigate the IGF-1 release from MSNPs (drug release study). The experiment was conducted three 
times and the concentration of IGF-1 used in these experiments was (12.5μg/ml) and the SBA-15 was 
(0.75 mg). The results of the experiments showed that around 85 percent of the IGF-1 concentration 
was uploaded inside the NPs after four hours. A 100 hour period is used to determine the time course 
of the IGF-1 discharge. At intervals of 2hrs, 4hrs, 8hrs, 25hrs, 50hrs and 75hrs and 100hrs, the sample 
was centrifuged. This was followed by measuring the supernatant’s fluorescence so that the IGF-1 
discharge from the MSNPs could be estimated. The result showed that from zero to eight hours, the 
discharge of the IGF-1 loaded to the nanoparticles was at a rate of 10-15 ng/ml. From 25 hours and 
above, an increase in the discharge to 48 ng/ml was noted. A further increase was recorded in 100 
hours: 60 ng/ml. This outcome will establish and confirm the optimal concentration of IGF-1 is 
(12.5μg/ml) and SBA-15 is (0.75 mg), this refers to the drug release figure (3.14). As well as 
confirming that MSNPs can be used to boost IGF-1 bioactivity it can also be inferred that the SBA-
15 mesoporous silica nanoparticles can be employed for purposes of controlling the discharge of  
IGF-1 in new systems of delivery. Moreover to be used in the treatment of muscle cells in relation to 
injury, wasting, ageing and other wasting disorders associated with diseases like diabetes and cancer 
which is vital because they can function as a way of delivering drugs that is safe. We recently 
established an in vitro human co-culture (nerve-muscle) model in a serum-free/neural growth factor-
free defined medium (Abd Al Samid et al., 2018). The model develops functional NMJs rapidly to 
elicit muscle contraction. Neural progenitor cells (NPCs) from hESC differentiate into motor neuron 
in the co-culture myoblasts and are also named NPC passage 1(P1) that can be stored in liquid 
nitrogen to allow future studies. The objective was to conduct the generation and characterisation of 
the system with the aim of verifying the incidence of physiological NMJ formation. Before 
performing the co-culture characterisation, there were experiments done with the aim of determining 
the best time point, which would indicate that NMJ formation has reached maturity (Figure 5.5). For 
purposes of determining the mature formation of NMJ, peak contraction frequency was employed. 
The peak was observed to be seven days following the co-culture. Using antibodies for ChAT, the 
characterisation and identification, in the system, of Cholinergic MNs was done, revealing the 
interface between the systems myotubes and MNs. Such a significant finding is a reflection of NMJ 
noted in vivo ChAT are needed for the correct development and function of MN (Brandon et al., 2003; 
Misgeld et al., 2002). The assessment of motor neuron formation was done on the seventh day using 
the βIII-tubulin motor neuron differentiation marker.  Mature motor neurones have axons terminating 
on myotubes as shown in Figure 5.5. The formation of cholinergic motor neurons was confirmed 
using acetyltransferase antibodies (ChAT, a key enzyme for acetylcholine biosynthesis), which is 
shown in green in Figure 5.6 (Young et al., 2003). NMJs usually have acetylcholine receptor (AChR) 
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clusters along myotubes that were assessed using alpha-bungarotoxin (α-BTX) staining and can be 
identified as the red clusters.  Motor neuron axons serve the myotubes with nerves that lead to the 
formation of NMJ as marked with α-BTX (red) (Young et al., 2003). The skeletal muscle and neuron 
co-cultures were able to mature with no serum or neural growth factors cocktails being added. Within 
a period as short as six to seven days, the formation of myotube started being apparent, and the 
spontaneous myotube contractions were documented (Figure 5.4). When compared to previous 
studies where the myotube contractions and NMJ formation took 14 days (Vilmont et al., 2016), and 
sometimes as long as 20 to 25 days (Das et al., 2010) this can be considered quick. Studying 
operational motor units is important in understanding the pathophysiological characteristics of NMJ 
disorders common in major neurological diseases and older age.  
Human cultures can be used to increase the chances of success in clinical practice. Most of the past 
cell culture models used cross-species cell types (Arnold et al., 2012; Guo et al., 2010) and had to be 
done with some growth factors (Demestre et al., 2015; Guo et al., 2011; Das et al., 2010; Guo et al., 
2010). The present model deviated from these conventional methods and no adverse effects were 
observed. Therefore, all the necessary factors that promote nerve axonal spouting and NMJ formation 
in myotubes were availed to muscles and nerve cells. The interpretation of toxicity and 
pharmacological studies can be enhanced by the elimination of serum, the anonymous factor that may 
impact reproducibility (Rumsey et al., 2009). To confirm the physiological behaviour of NMJ and 
the spontaneous contractile activity of the myotubes by MN signalling through NMJ the NMJ 
assessment was completed by analysing the myotube CF modulation while using agonist and 
antagonist pharmacological interventions that act on presynaptic MNs (L-Glut) or postsynaptically 
(α-BTX) on AChRs at the NMJ. The results show that there is a successful enhancement of myotube 
contractions in the co-cultures with the introduction of L-Glut, which is possibly achieved because of 
the increased Ach release from the MN cultured into the synaptic NMJs cleft. In summary, entirely 
human NMJ was replicated in which myoblasts differentiated into myotubes while NPCs 
differentiated into MN sprouted axons and branched to form multiple NMJ innervation sites on the 
myotubes. It was also determined that spontaneous myotube contractions in the co-cultures were 
indeed driven by MN signalling through NMJs which was verified by responding physiologically in 
an appropriate manner to the drugs used in this study. 
Consequently, the objective that followed was investigating the effects of IGF-1/NPs on NMJ model 
formation and function. In other studies it has been found that some neurological disorders such as 
stroke may arise due to impaired IGF-1 signalling pathway (Lewis et al, 1993). To ensure optimal 
innervation of co-cultured myotubes, the efficiency of NPCs to induce contractions in the co-culture 
system with DM only (Figure 6.0) approved and used as a control. Therefore, the experiments were 
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performed to confirm the effects of slow release IGF-1 on NMJ function (myotube contractions) for 
7 days in co-culture media with adding NPs only (Figure 6.1), IGF-1 only (Figure 6.2), and slow 
release of IGF-1(IGF1/ NPs) (Figure 6.3). After the initiation of myogenic differentiation, functional 
motor units started to develop, including axonal sprouting from the NPCs formed along myotubes on 
NMJ and myotube formation. Myotubes were characterised by spontaneous muscle contractions 
without any exogenous chemical and electrical stimuli starting the seventh day. As well as the optimal 
innervation of myotubes was quantified by analysing Contraction Frequency (CF) every 24 hours 
post co-culture for 7 days, using live phase contrast microscopy to assess 20 random fields. The 
results revealed on day 7 that the contractions were slightly higher in each condition, however the 
contractions were witnessed and increased CF further in slow release IGF-1 co-culture, which was 
significant (P < 0.0001) (Figure 6.4). The findings confirmed co-cultured IGF-1/NPs are more 
efficient than the IGF-1 only and other conditions. A number of studies have showed that during 
development, motor neurons respond to IGF-1 with increased neurite outgrowth in vitro and in vivo 
models (Kissileff, and Van Itallie, 1982; Mulholland, 1992; Kimpinski, and Mearow, 2001). In 
addition the axonal length of differentiated motor neurons in vitro was measured at each treatment 
over the 7 days of co-culture.  The result showed that the axonal length was increasing over the 7 day 
co- culture period with the greatest significant difference in DM adding IGF-1/NPs compared to other 
treatments. The mean for IGF-1/NPs was (228.6M ± 61.53) compared to IGF-1 only, where the 
mean was (158.8M ±41.59). The IGF-1/NPs presented significant difference <0.0001 (Figure 6.13), 
which underscores co-cultured IGF-1/NPs are more effectual than the IGF-1 only and other 
treatments. The potent effect of the slow release of IGF-1 on the proliferation, differentiation, and 
survival of neurons make it good for studying treatment strategies for studies on axonal damage, 
demyelination, and neuronal death (Lewis et al, 1993). 
The process is further enhanced by neural growth factors such as neurotrophic factors obtained from 
the brain and discharged by the muscle to ensure the formation, growth, and maturation of NMJ 
(Henderson et al., 1993; Funakoshi et al., 1995). Therefore the last objective was to study the  NMJ 
interact with complex cytokines arrays and growth factors secreted by muscle and motor neurons to 
promote differentiation and the formation of NMJ and dictate their functions. This co-culture model 
is probably the first that involves the neural growth factors. Hence, all the factors required for NMJ 
formation and maturation, myoblast and motor neurons differentiation were endogenously secreted. 
Considering IGF-1 signalling pathways are important in neurogenesis and myogenesis regulation, the 
aim was to evaluate the way in which slow release of IGF-1 affect the bi-directional communication 
that occurs between the muscle and the motor neuron as well as the co-culture microenvironment 
(endogenously secretion of neurotrophic factors such as BDNF, GDNF, NT‐3 and IGF-1) in the 
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process of NMJ formation. The ELISA-based microarray analysis of the growth/neurotrophic factor 
concentration followed by one way ANOVA statistical test was performed to determine whether the 
slow release of IGF-1 impacts the secretion of growth/neurotrophic factors in co-cultured conditions 
(co-culture only, co-culture with IGF-1, co- culture with NPs, and co- culture with IGF-1/NPs). Table 
7.0 shows the quantified concentration of 40 growth/neurotrophic factors on the seventh day. The 
results indicate that four factors were significantly different (P<0.05) in varying co-culture conditions. 
BDNF, GDNF, IGF-1, and NT-3 (Figure 7.1) concentrations were very high in co-cultures that had 
been treated with IGF-1/NPs compared to those that had been treated with IGF-1 only. The data from 
the ELISA-based microarray indicated that BDNF levels increase significantly with IGF-1/NPs when 
compared to IGF-1 only (Figure 7.1A). IGF-1 that is involved in the expression of BDNF (McCusker 
et al., 2006) also enhances the regulation of BDNF-related neurogenesis (Pareja-Galeano et al., 
2013).The regulation of BDNF concentration endogenously in the presence of slow release IGF-1 co-
culture system is instrumental in the formation and development of NMJs in vivo (Pareja-Galeano et 
al., 2013). IGF-1 slow release increases GDNF levels unlike the cases in which a co-culture model is 
treated with IGF-1 only (Figure 7.1B). GDNF possibly provides postnatal motor neurons with 
neurotrophic or survival factors. The results show that there is a possibility that IGF-1 interact with 
GDNF to prevent chronic glutamate-mediated toxicity of the rat motor neurons while increasing their 
ChAT activity. These findings suggest that IGF-1 and GDNF interact and increase the chances of 
survival for the motor neuron. The data in this study shows that IGF-1 levels increased significantly 
in models in which the slow release of exogenous IGF-1 had been treated with IGF-1/NPs but such 
levels were not attained in cases in which treatment was completed with IGF-1 only (Figure 7.1C). 
These findings suggest that IGF-1 and GDNF interact and increase the chances of survival for the 
motor neuron. Muscle specific IGF-1 expression stabilises NMJs and enhances the survival of motor 
neurons (Dobrowolny et al., 2005). The injection of IGF-1 into SkM leads to the degeneration of 
MNs and NMJs that subsequently prevents age-related decline in mice (Payne et al., 2006). The 
upregulation of IGFBPs and IGF-1 confirms that SCEs and SkMCs in the co-culture system provides 
a favourable environment for the maturation of MN, differentiation of myofibres, and robust 
formation of NMJ in vivo formation. The data in (Figure 7.1D) show that there was a significant 
increase in NT-3 levels in co-culture systems treated with IGF-1/NPs compared to those treated with 
IGF-1 only. Studies on the effect of post traumatic IGF-1 administration on NT-3 in a focal unilateral 
penetrating brain injury showed that IGF-1 prevents the injury-induced changes in NT-3 and increases 




Limitations & Future Directions: Despite the findings from this project, many concepts of 
nanotechnology in SkMCs treatments are still not completely understood and need further research. 
For an efficient drug delivery system, the MSNPs need to be biocompatible, have skeletal muscle 
tissue specificity and controlled release of the drug molecules to achieve an effective local 
concentration. After this, further research into the effects of MSNPs on human immortalised skeletal 
myoblasts (C25) proliferation and differentiation is necessary to further advance nanotechnology 
research towards a clinical stage for the development of a new drug delivery system for the treatment 
of skeletal muscle wasting. Future work could include studying the different cell treatments over a 
longer period of time as the experiment applied in this study was over 96 hours in monoculture and 
over 7 days in co-cultures. Other suggestions could be further examination of gene expression 
analysis in 3D constructs culture with and without motor neurons. This could be assisting in the 
development of 3D culture platforms for the study of diseases such as amyotrophic lateral sclerosis 
(ALS) (Richard and Maragakis, 2015). More research is still needed to elucidate SkMCs treatment 
with IGF-1 and nanoparticles in co-culture of human skeletal myoblasts and NPCs proliferation and 
differentiation, for better understanding of these drug delivery nanotechnology helps in cell treatment 
development and improvement of nanotechnology which can be translated into the clinical field. The 
additional tests that can be done in regard to this include immunohistochemical markers such as 
reverse transcriptase polymerase chain reaction (PCR), to identify motor-neuron specific markers 
(homebox) after RNA isolation and also for further studies to determine how motor neurons can be 
used to identify NMJs (Alves et al., 2015; Yi et al., 2018) and a triple co-culture method could be 
used to investigate the effect of these different cells on myoblast proliferation and differentiation. 
Results from this project fit with data from previous studies and confirm that the impact of results 
from this study can help in the future nanomedicine field. As the possibility of nanotechnology 
applications in medicine develops, it is significant to instantaneously distinguish and advance 
contributions useful to public health. A widespread range of modernisations in nanomedicine stand 
to influence nearly every medical specialty and expose novel ways to advance the quality and extend 
the duration of life. These improvements can be measured at both individual and population levels. 
Investigations determined by reformers through regulations such as engineering, biology, medicine, 
and public health should collaborate to accomplish greatest possible impression in health for 
individuals and populations. In addition, lack of knowledge concerning the potential health and safety 
associations of exposure to engineered nanomaterials must be continuously addressed and 
aggressively researched. Active and communally dependable research will drive nanomedicine as it 





In this project, 19 samples of MSNPs were completely synthesised and characterised with both 
techniques, the SBA-15 and MCM-41 to confirm the biodegradability, cytotoxicity and the correct 
NPs size to be employed for the uploading and release study. From the results presented in this study, 
a decision was made to use SBA-15 mesoporous silica nanoparticles for my project because they 
have a big pore size and surface area which permits adequate amounts of IGF-1 easily. It can be 
employed for purposes of controlling the discharge of IGF-1 in new systems of delivery, which is 
used to boost IGF-1 bioactivity. With the development of nanotechnology applications in the medical 
field, it is vital to directly separate and advance contributions useful to public health. As well as the 
results presented in this study, it also suggests that the best concentration of IGF-1 to be used with 
MSNPs is 10 ng, whereby differentiation is enhanced and proliferation is reduced. Differentiation 
was observed at 10 ng, 20 ng and 40 ng when SBA-15 was added. On the other hand, the study 
showed that a high concentration of IGF-1 reduces differentiation as proliferation is increased. Ki67 
markers (red dots) were demonstrated clearly at high concentrations, thus Ki67 works as a 
proliferation marker. In addition, this project detailed the human immortalised myoblasts that were 
co-cultured with human embryonic stem cells (hESCs)-derived neural progenitor cells (NPCs). It was 
done in seven days in DM only as a control and by adding treatments such as NPs, IGF-1 and slow 
release of IGF-1 (IGF-1/NPs). The co-culture system does not have serum, growth, and neurotrophic 
factors yet they generate contractile myotubes, which is an indication that they have advanced 
differentiation that leads to the formation of NMJs that are functional and appropriate as is the case 
with in vivo conditions. Moreover the slow release of IGF-1 enhanced the bi-directional 
communications between motor neurons and muscle cells through the elevation of endogenously 
secreted essential neural growth factors providing a regenerative role for NMJ formation and 
function. The in vitro co-culture system can provide a platform for advanced research on the 
physiology of the skeletal muscle system and the formation and development of NMJ. The outcome 
of this project may provide a breakthrough approach to enable research in designing new therapeutic 
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